KR20220010411A - Dosage Regimen For Preventing Or Treating COVID-19 - Google Patents

Abstract

The present application relates to a method for preventing or treating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) by administering a monoclonal antibody having neutralizing activity against SARS-CoV-2. According to the present invention, the method for preventing or treating, composition, kit or use enable the SARS-CoV-2 infection (COVID-19) to be prevented or treated, by administering a composition of a monoclonal antibody having neutralizing activity against the SARS-CoV-2.

Description

Dosage Regimen For Preventing Or Treating COVID-19

The present application relates to a method of preventing or treating SARS-coronavirus infection (COVID-19) by administering a monoclonal antibody having neutralizing activity against SARS-coronavirus-2.

Coronaviruses are single-stranded ribonucleic acid viruses that can cause life-threatening diseases in humans and animals. SARS-coronavirus-2 was first discovered in December 2019 when an outbreak of atypical viral pneumonia of unknown etiology occurred in the People's Republic of China (hereinafter "China"). Although most of the initial infections outside China were travel-related (eg, travel from an infected area in China to another country), human-to-human transmission in other countries also occurred rapidly. The World Health Organization (WHO) has named the disease caused by SARS-Covid-19 as COVID-19.

Most people get mild (40%) or moderate (40%) sickness when infected with SARS-CoV-2. However, about 15% of infected people develop serious diseases that require oxygen supply, and 5% have multiple organ failures such as respiratory failure, acute respiratory distress syndrome, sepsis and septic shock, thromboembolism and/or acute kidney or heart failure. They suffer from serious diseases with the same complications. Older age, smoking, diabetes, hypertension, heart disease, chronic lung disease, and non-communicable underlying diseases such as cancer have been reported as risk factors for these serious diseases and mortality.

SARS-coronavirus-2 infection has also been associated with psychiatric and neurological symptoms, including delirium or encephalopathy, agitation, ischemic and hemorrhagic stroke, meningoencephalitis, disorders of smell or taste, anxiety, depression and sleep disturbances. In most cases, neurological symptoms are reported without respiratory symptoms. Cases of Guillain-Barrι syndrome and meningoencephalitis have also been reported in patients infected with SARS-CoV-2. Clinical symptoms of SARS-coronavirus-2 infection were generally reported mildly in children compared to adults, and a relatively small number of confirmed cases in infants were reported. However, recently, cases related to SARS-coronavirus-2 infection in children and adolescents and multisystem inflammatory syndrome have also been reported (WHO Guidelines, 2020).

The invasion of the coronavirus into the host cell is an important factor in determining the infectivity and pathogenesis of the virus, and therefore it is also a major target of host immune surveillance and therapeutic strategies. As established so far, it is known that SARS-coronavirus-2 binds to epithelial or endothelial cells through the receptor of angiotensin-converting enzyme 2 (ACE2) (Varga et al., Lancet . 2020 May 2;395:1417-18). SARS-coronavirus-2 infection begins when the virus binds to angiotensin-converting enzyme inhibitor 2 through receptor binding protein (RBD) of the spike protein that mediates virus invasion into target cells. Because viruses mutate, their pathogenicity and infectivity will change over time, and there is a diversity of major infection-mediated surface proteins. A new study finds that there are two viruses in SARS-coronavirus-2, the most prevalent and the more aggressive type L (70%) and the less aggressive type S (30%) (Tang et al., National Science Review . 2020;0:1-12). In addition, it is said that the symptoms and results of infection vary from person to person. These findings suggest that immediate and comprehensive urgent research and robust assay validation should combine genomic data, charting, and clinical symptoms to enable disease understanding, risk assessment, and screening, and to support public health policy and more. strongly suggest.

On March 11, 2020, the World Health Organization (WHO) declared a pandemic, with more than 118,000 cases of SARS-coronavirus-2 infection in 114 countries and 4,291 deaths. Currently, there are no approved monoclonal antibody therapies available to treat coronaviruses such as SARS-coronavirus-2, and the rapid development of such therapies is urgent.

Accordingly, the present applicant has developed a pharmaceutical formulation comprising a monoclonal antibody that binds to SARS-coronavirus-2 and consequently prevents infection of SARS-coronavirus-2.

The problem to be solved by the present invention is to prevent or treat SARS-coronavirus infection (COVID-19), comprising administering to a patient a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof to provide a way

In addition, another object to be solved by the present invention is to provide a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof.

In addition, another problem to be solved by the present invention is (a) a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; and (b) instructions for administering the composition for treatment of a patient with coronavirus infection (COVID-19).

In addition, another problem to be solved by the present invention is in the preparation of a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) administered to a patient, anti-SARS-coronavirus-2 antibody or antigen binding thereof To provide the use of a composition comprising fragments.

The present invention provides a method of preventing or treating SARS-coronavirus infection (COVID-19), comprising administering to the patient a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof, to the patient It provides a method of administering a composition comprising the antibody or antigen-binding fragment thereof at a dose of 1 to 120 mg/kg.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 5 to 100 mg/kg may be administered to a patient.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 10-80 mg/kg may be administered to a patient.

In one embodiment of the invention, the antibody is administered at a dose of 20 to 80 mg/kg, 40 to 80 mg/kg, 20 to 40 mg/kg, 10 to 40 mg/kg, or 10 to 20 mg/kg to the patient, or A composition comprising an antigen-binding fragment thereof may be administered.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 10 mg/kg, 20 mg/kg, 40 mg/kg, or 80 mg/kg may be administered to a patient.

In one embodiment of the present invention, the composition comprising the antibody or antigen-binding fragment thereof may be administered intravenously or subcutaneously, but is not limited thereto.

In one embodiment of the present invention, the composition comprising the antibody or antigen-binding fragment thereof may be administered once or several times. In one embodiment, the composition comprising the antibody or antigen-binding fragment thereof may be administered more than once. Here, when one or more administration is performed, the administration cycle may vary depending on the condition of the patient and the diagnosis and prescription of the doctor. In one embodiment, the composition comprising the antibody or antigen-binding fragment thereof may be administered once (single time).

In one embodiment of the present invention, the antibody or antigen-binding fragment thereof may be any one antibody or antigen-binding fragment thereof selected from the group consisting of the antibodies or antigen-binding fragments thereof shown in Table 1 below. In Table 1 below, No. means the number of each antibody or antigen-binding fragment thereof.

In the present invention, the CDRs of the variable region were determined by a conventional method according to the system devised by Kabat et al. (Kabat et al., Sequences of Proteins of Immunological Interest (5th), National Institutes of Health, Bethesda, MD. (1991)]). Although the Kabat method was used for CDR numbering used in the present invention, binding molecules comprising CDRs determined according to other methods such as the IMGT method, Chothia method, and AbM method are also included in the present invention.

In one embodiment of the present invention, the antibody or antigen-binding fragment thereof may be any one antibody or antigen-binding fragment thereof selected from the group consisting of the antibodies or antigen-binding fragments thereof shown in Table 2 below. In Table 2 below, No. means the number of each antibody or antigen-binding fragment thereof.

In one embodiment of the present invention, the antibody or antigen-binding fragment thereof comprises a light chain variable region comprising a CDR1 region of SEQ ID NO: 829, a CDR2 region of SEQ ID NO: 830, and a CDR3 region of SEQ ID NO: 831; and an antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a CDR1 region of SEQ ID NO: 832, a CDR2 region of SEQ ID NO: 833, and a CDR3 region of SEQ ID NO: 834. In the present invention, the antibody or antigen-binding fragment thereof of the above sequence is referred to as a CT-P59 or CT-P59 antibody, and are used interchangeably.

In one embodiment of the present invention, the antibody or antigen-binding fragment thereof comprises a light chain variable region of the polypeptide sequence of SEQ ID NO: 2017; and a heavy chain variable region of the polypeptide sequence of SEQ ID NO: 2018. In the present invention, the antibody or antigen-binding fragment thereof of the above sequence is referred to as a CT-P59 or CT-P59 antibody, and are used interchangeably.

In one embodiment of the present invention, the composition comprising the antibody or antigen-binding fragment thereof is SARS-coronavirus-2 activity inhibitory drug, antiviral agent, SARS-Plasma of a person recovered from coronavirus-2 infection, anti-TNFα (tumor necrosis factor-α) may be administered in combination with an antibody or a mixture of any one or more thereof.

In one embodiment of the present invention, the SARS-coronavirus-2 activity inhibitory drug may be a binding molecule that binds to the SARS-coronavirus-2 surface spike protein (S protein). In one embodiment, the SARS-coronavirus-2 binding molecule binding to the spike protein (S protein) on the surface is a) different from the antibody or antigen-binding fragment thereof of the present invention - SARS-coronavirus-2 an antibody or antigen-binding fragment thereof; b) a recombinant protein of angiotensin-converting enzyme 2 (ACE2), a fragment thereof, or a variant thereof; And c) may be any one or more selected from the group consisting of a recombinant neuropilin-1, a protein, a fragment thereof, or a variant thereof. In one embodiment, the b) angiotensin-converting enzyme inhibitor 2 (Angiotensin-converting enzyme 2, ACE2) recombinant protein, a fragment thereof, or a variant thereof; Alternatively, c) a recombinant protein of neuropilin-1, a protein, a fragment thereof, or a variant thereof may be a fusion protein fused to an Fc region of an antibody.

In one embodiment of the present invention, the antiviral agent may be remdesivir, chloroquine, hydroxychloroquine, or a mixture of any one or more thereof.

In one embodiment of the present invention, the anti-TNFα antibody may be infliximab, adalimumab, cetorizumab pegol, golimumab, or a mixture of any one or more thereof.

In one embodiment of the present invention, the patient may be a SARS-coronavirus infection (COVID-19) mild, moderate or severe patient, and SARS-coronavirus infection (COVID-19) ) also includes subjects at risk of diagnosis or at risk of detecting SARS-CoV-2.

In one embodiment of the present invention, the SARS-coronavirus infection (COVID-19) is caused by SARS-coronavirus-2

a) hot flashes;

b) sneeze;

b) shortness of breath or shortness of breath;

c) Sore throat;

d) body aches or muscle aches;

e) fatigue;

f) headache;

g) chills;

h) breathing difficulties or nasal congestion;

i) loss of taste or smell;

j) nausea or vomiting; and

k) diarrhea

At least one or more symptoms selected from the group consisting of may be induced.

In one embodiment of the present invention, after administration of the composition comprising the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof to a patient, the patient is free of all of the following symptoms or maintained at a good level for at least 24 hours. Preferably:

a) heat;

b) sneeze;

b) shortness of breath;

c) Sore throat;

d) body aches or muscle aches;

e) fatigue; and

f) headache.

In another aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof, from 1 to 120 mg/ It provides a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) by administering a composition comprising the antibody or antigen-binding fragment thereof in kg dose.

In another aspect of the invention, the invention provides a composition comprising (a) an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; and (b) instructions for administering the composition at a dose of 1 to 120 mg/kg for the treatment of a patient with coronavirus infection (COVID-19).

In another aspect of the present invention, the present invention is administered to a patient in the preparation of a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19), anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof As a use of a composition comprising

The prevention or treatment method, composition, kit or use according to the present invention is a SARS-coronavirus infection (COVID-19) to be prevented or treated by administering a composition of a monoclonal antibody having neutralizing activity against SARS-coronavirus-2 make it possible

1 shows an overview of the clinical trial CT-P59 1.1 evaluating the safety and tolerability of CT-P59 in healthy subjects.
2 shows an overview of the clinical trial CT-P59 1.2 evaluating the safety and tolerability of CT-P59 in SARS-coronavirus-2 infected subjects with mild symptoms.
3 shows an overview of the clinical trial CT-P59 3.1 evaluating the effectiveness of CT-P59 in hospitalized patients due to SARS-coronavirus-2 infection.
Figure 4 shows an overview of the clinical trial CT-P59 3.2 evaluating the efficacy of CT-P59 in outpatient patients due to SARS-coronavirus-2 infection.
5 shows an overview of CT-P59 3.3 evaluating the prophylactic efficacy of CT-P59 in close contact subjects of SARS-coronavirus-2 patients.
6A and 6B show the average blood concentration (±SD) of CT-P59 for each CT-P59 treatment group in a linear scale ( FIG. 6A ) and a semi-log scale ( FIG. 6B ), respectively, according to the 1.1 clinical results.
7 shows the average corona-19 virus (SARS-CoV-2) quantitative polymerase chain reaction (qPCR) results according to the 1.2 clinical results.
8A to 8D show the average concentration of Corona-19 virus (SARS-CoV-2) for each group according to the highest virus concentration, according to the 1.2 clinical results. (Fig. 8a: maximum virus concentration < 10 ⁵ cp/mL, Fig. 8b: maximum virus concentration > 10 ⁵ cp/mL, Figure 8c: Maximum virus concentration >10 ⁶ cp/mL, FIG. 8D: maximum virus concentration >10 ⁷ cp/mL)
9A and 9B show the mean (± standard deviation) blood CT-P59 concentration according to the sampling time for each CT-P59 treatment group in linear ( FIG. 9A ) and semi-log ( FIG. 9B ) scales according to the 1.2 clinical results.
10A to 10C show Kaplan-Meier curves for each treatment group according to the 3.2 clinical results. 10A shows the Kaplan-Meier curve for the cumulative proportion of patients with clinical recovery up to 14 days in all patients, FIG. 10B in moderately ill patients, and FIG. 10C in moderately ill patients aged 50 years or older.
11 shows the mean change (± standard error) virus concentration from baseline over time for each RT-qPCR-based treatment group in all patients.
12A is a Kaplan-Meier curve for the cumulative proportion of patients who developed negative conversion by RT-qPCR by day 28 in all patients, and FIG. 3 log10 cp/mL) is a Kaplan-Meier curve for the cumulative proportion of patients who developed The Kaplan-Meier curve for the cumulative ratio is shown.

The present invention provides a method of preventing or treating SARS-coronavirus infection (COVID-19), comprising administering to the patient a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof, to the patient It relates to a method of administering a composition comprising the antibody or antigen-binding fragment thereof at a dose of 1 to 120 mg/kg.

In order to more readily understand the present invention, the terms used in the present invention are defined below.

In the present invention, “antibody” is used in its broadest sense and may include polyclonal antibodies, monoclonal antibodies, recombinant antibodies, single-chain antibodies, hybrid antibodies, chimeric antibodies, humanized antibodies, human antibodies, or fragments thereof. have. Other naturally occurring antibodies with altered structures, such as camelid antibodies, are also included in this definition. An intact antibody refers to an immunoglobulin molecule consisting of four polypeptide chains in which two heavy chains and two light chains are connected to each other by disulfide bonds. Fragments of antibodies are inter alia Fab, F(ab'), F(ab')2, Fv, dAb, Fd, complementarity determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single-chain Antibodies, single-chain phage antibodies, diabodies, triabodies, tetrabodies, polypeptides containing one or more fragments of an immunoglobulin sufficient to bind a particular antigen to the polypeptide, etc. include Each heavy chain consists of a heavy chain variable region and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region and a light chain constant region. The light chain constant region consists of one domain (CL). The heavy and light chain variable regions can be further subdivided into hypervariable regions called complementarity determining regions (CDRs) co-located with more conserved regions called framework regions (FR). Each heavy chain variable region and light chain variable region consists of three CDRs and four FRs, arranged from amino terminus to carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

In the present invention, the CDRs of the variable region were determined by a conventional method according to the system devised by Kabat et al. (Kabat et al., Sequences of Proteins of Immunological Interest (5th), National Institutes of Health, Bethesda, MD. (1991) )] Reference). Although the Kabat method was used for CDR numbering used in the present invention, antibodies comprising CDRs determined according to other methods such as the IMGT method, Chothia method, and AbM method are also included in the present invention.

In the present invention, the antibody includes a functional variant of the antibody. Functional variants of the antibody are considered functional variants of the antibody of the present invention if they can compete with the antibody of the present invention for specific binding to SARS-coronavirus-2. Functional variants may include, but are not limited to, derivatives that are substantially similar in primary structural sequence. A functional variant may be an antibody comprising an amino acid sequence optionally comprising one or more amino acid substitutions, insertions, deletions, or combinations thereof compared to the amino acid sequence of the parent antibody. Furthermore, functional variants may include truncated forms of the amino acid sequence at either or both the amino terminus or the carboxy terminus. Functional variants of the invention may have the same, different, higher or lower binding affinity compared to the parent antibody of the invention, but still be capable of binding SARS-Coronavirus-2. Functional variants within the scope of the present invention include antibodies disclosed herein and about 50-99%, about 60-99%, about 80-99%, about 90-99%, about 95-99%, or about 97-99%. % amino acid sequence identity. In order to optimally align the amino acid sequences to be compared and to define similar or identical amino acid residues, Gap or Bestfit known to those skilled in the art among computer algorithms may be used. Functional variants can be obtained by organic synthesis or by changing the parent antibody or a part thereof by known general molecular biological methods including PCR method, mutagenesis using oligomeric nucleotides and partial mutagenesis, but is not limited thereto. .

As used herein, "antigen-binding fragment" refers to one or more fragments of an antibody that retain the ability to specifically bind to the antigen bound by the intact antibody. Exemplary antigen binding fragments include, but are not limited to, Fab, Fab', F(ab')2 and Fv, and the like.

In the present invention, “mixture” refers to a substance in which two or more kinds of substances are physically mixed without causing a chemical reaction.

In the present invention, "administration" means the administration of a substance (eg, anti-SARS-coronavirus-2 antibody composition) to achieve a prophylactic or therapeutic purpose (eg, SARS-coronavirus infection (COVID-19)) .

In the present invention, "SARS-coronavirus-2 (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2)" is a positive sense single-stranded RNA corona on genetic sequence (DNA sequencing) As a virus, it is contagious to humans and is the cause of coronavirus disease 2019 (COVID-19).People infected with SARS-CoV-2 have mild to severe symptoms such as fever, cough, shortness of breath, and diarrhea. People with complications or diseases and the elderly are more likely to die.

The World Health Organization (WHO) classifies SARS-coronavirus-2 into six types based on amino acid changes caused by differences in gene sequence. First, it was classified into S and L types, then again into L, V, and G types, and as G was divided into GH and GR, it is classified into a total of 6 types: S, L, V, G, GH, GR. S and V types were prevalent in Asia, including Wuhan, China, in the early stages of the outbreak of COVID-19, and after that, different types were discovered for each continent. Among them, it has been reported that the GH type has the potential to appear high in transmission power. In Korea, as a result of classifying the genes collected from patients with coronavirus infection, most of them were found to be the GH type, a variant of the G type prevalent in Europe and the United States, and this type is known to have high virus transmission power. Among these, type G virus, in which amino acid 614 of the spike protein, which plays an important role in virus invasion, is changed from aspartic acid (D) to glycine (G), has increased rapidly in Europe and the United States since March, and is now almost It appears in most areas. According to a recent report, more than 70 coronavirus mutations have been identified, 8 mutations with increased transmission power (D614G, etc.), 10 mutations that avoid neutralizing antibodies (A841V, etc.), mutations with low plasma treatment effect 17 (I472V, etc.) were identified.

In one embodiment, the anti-SARS-coronavirus-2 antibody of the present invention is S-type (amino acid at position 614 of the S protein is D), G-type (614 of the S protein) based on the SARS-CoV-2 virus amino acid mutation. The amino acid at position No. may exhibit neutralizing ability in strains such as G) and V, but is not limited to this strain. An example of the SARS-CoV-2 virus type S is the BetaCoV/Korea/KCDC03/2020 strain, but is not limited thereto. An example of the SARS-CoV-2 virus type G includes, but is not limited to, the hCoV-19/South Korea/KUMC17/2020 strain. In one embodiment, the anti-SARS-coronavirus-2 antibody of the present invention is a neutralizing binding molecule in which D614G mutation occurs at amino acid position 614 of the spike protein S1 region of SARS-coronavirus-2 (SARS-CoV-2) It also exhibited excellent neutralizing ability against mutated viruses.

In one embodiment, the anti-SARS-coronavirus-2 antibody of the present invention is a SARS-coronavirus-2 strain isolated to date, for example, UNKNOWN-LR757996 strain (Strain), SARS of unknown date and place of isolation. -CoV-2/Hu/DP/Kng/19-027 strain; Wuhan-Hu-1 strain isolated from China in December 2019; BetaCoV/Wuhan/IPBCAMS-WH-01/2019 strain first isolated in China on December 23, 2019; BetaCoV/Wuhan/IPBCAMS-WH-02/2019 strain, BetaCoV/Wuhan/IPBCAMS-WH-03/2019 strain, BetaCoV/Wuhan/IPBCAMS-WH-04/2019 strain, WIV02 isolated on December 30, 2019 in China strain, WIV04 strain, WIV05 strain, WIV06 strain, WIV07 strain; 2019-nCoV/Japan/TY/WK-521/2020 strain isolated from Japan in January 2020, 2019-nCoV/Japan/TY/WK-501/2020 strain, 2019-nCoV/Japan/TY/WK-012/ 2020 strain, 2019-nCoV/Japan/KY/V-029/2020 strain; SNU01 strain isolated from Korea in January 2020; BetaCoV/Korea/KCDC03/2020 strain isolated from Korea; BetaCoV/Wuhan/IPBCAMS-WH-05/2020 strain isolated from China on January 1, 2020; 2019-nCoV WHU02 strain, 2019-nCoV WHU01 strain isolated on January 2, 2020 in China; SARS-CoV-2/WH-09/human/2020/CHN strain isolated from China on January 8, 2020; 2019-nCoV_HKU-SZ-002a_2020 strain isolated from China on January 10, 2020; 2019-nCoV_HKU-SZ-005b_2020 strain isolated from China on January 11, 2020; SARS-CoV-2/Yunnan-01/human/2020/CHN strain isolated from China on January 17, 2020; 2019-nCoV/USA-WA1/2020 strain isolated in the United States on January 19, 2020; HZ-1 strain isolated in China on January 20, 2020; 2019-nCoV/USA-IL1/2020 strain isolated in the United States on January 21, 2020; 2019-nCoV/USA-CA2/2020 strain, 2019-nCoV/USA-AZ1/2020 strain isolated in the United States on January 22, 2020; 2019-nCoV/USA-CA1/2020 strain isolated in the United States on January 23, 2020; Australia/VIC01/2020 strain isolated in Australia on 25 January 2020; 2019-nCoV/USA-WA1-F6/2020 strain, 2019-nCoV/USA-WA1-A12/2020 strain isolated in the United States on January 25, 2020; 2019-nCoV/USA-CA6/2020 strain isolated in the United States on January 27, 2020; 2019-nCoV/USA-IL2/2020 strain isolated in the United States on January 28, 2020; 2019-nCoV/USA-MA1/2020 strain, 2019-nCoV/USA-CA5/2020 strain, 2019-nCoV/USA-CA4/2020 strain, 2019-nCoV/USA-CA3 isolated in USA on January 29, 2020 /2020 strain; nCoV-FIN-29-Jan-2020 strain isolated on January 29, 2020 in Finland; SARS-CoV-2/IQTC02/human/2020/CHN strain isolated from China on January 29, 2020; 2019-nCoV/USA-WI1/2020 strain isolated in the United States on January 31, 2020; SARS-CoV-2/NTU01/2020/TWN strain isolated in Taiwan on January 31, 2020; SARS-CoV-2/NTU02/2020/TWN strain isolated on February 5, 2020 in Taiwan; 2019-nCoV/USA-CA7/2020 strain isolated in the United States on February 6, 2020; SARS-CoV-2/01/human/2020/SWE strain isolated on February 7, 2020 in Sweden; 2019-nCoV/USA-CA8/2020 strain isolated in the United States on February 10, 2020; 2019-nCoV/USA-TX1/2020 strain isolated in the United States on February 11, 2020; 2019-nCoV/USA-CA9/2020 strain isolated in the United States on February 23, 2020; SARS-CoV-2/SP02/human/2020/BRA strain isolated on February 28, 2020 in Brazil; UNKNOWN-LR757995, UNKNOWN-LR757997, UNKNOWN-LR757998, SARS-CoV-2/Hu/DP/Kng/19-020 of unknown date and place of isolation; 2019-nCoV/Japan/AI/I-004/2020 isolated from Japan in January 2020; SARS0CoV-2/61-TW/human/2020/NPL isolated from Nepal on January 13, 2020; SARS-CoV-2/IQTC01/human/2020/CHN strain isolated from China on February 5, 2020; It is possible to neutralize the hCoV-19/South Korea/KUMC17/2020 strain isolated in Korea and the SARS-coronavirus-2 strain to be isolated in the future, but is not limited to these strains.

Antibody-dependent enhancement (ADE) phenomenon is a well-known phenomenon in dengue virus, in which immune cells are infected by non-neutralizing antibodies, thereby exacerbating the disease. Specifically, it refers to a phenomenon in which an antibody binds to a virus, and the virus bound to the antibody is infected into immune cells through the interaction between the Fc of the antibody and the FcR of an immune cell. In some literatures, it has been reported that the serum of SARS patients does not neutralize the virus, but rather increases the viral infection of immune cells (Journal of Virology 85: 10582). With respect to SARS-coronavirus-2, a strong virus infection phenomenon due to the interaction between the Fc of the antibody of the present invention and the Fcγ receptor of immune cells, that is, the ADE phenomenon was not observed.

In the present invention, "subject" includes any human or non-human animal. The term "non-human animal" includes vertebrates such as non-human primates, sheep, dogs, cats, rabbits and ferrets, rodents such as mice, rats and guinea pigs, avian species such as chickens, amphibians, and reptiles However, it is not limited thereto. In a preferred embodiment, the subject is a mammal, such as a non-human primate, sheep, dog, cat, rabbit, ferret or rodent. In a more preferred embodiment, the subject is a human (human). The terms “subject”, “patient” and “individual” are used interchangeably herein.

In the present invention, the "patient" may be, for example, a SARS-coronavirus infection (COVID-19) mild, moderate, or severe patient, and a SARS-coronavirus infection (COVID-19) diagnosis risk or subjects at risk of detecting SARS-Coronavirus-2. In one embodiment, the terms "mild patient, moderate patient, severe patient" used in the present invention are each defined as follows:

- Mild patients: have been diagnosed with COVID-19 virus (SARS-CoV-2) infection by reverse transcription polymerase chain reaction (RT-PCR) test, and have mild symptoms of COVID-19 virus infection Adult male or female subjects who develop within 7 days of administration and who are over 18 years of age and under 60 years of age

- Moderate patients: Outpatients of male or female 18 years of age or older who have been diagnosed with COVID-19 virus (SARS-CoV-2) infection. 'Outpatient' means patients who visit the clinical trial site as an outpatient, hospitalized patients at the clinical trial site, and those who are quarantined at home according to the quarantine regulations of regulatory authorities, public health guidelines, or the judgment of the principal investigator.

- Severe patients: have been diagnosed with COVID-19 virus (SARS-CoV-2) infection by reverse transcription polymerase chain reaction (RT-PCR) test, and have an oxygen saturation of less than 94% and/or Patients with an oxygenation index (PaO ₂ /FiO ₂ ratio) of less than 300 mmHg and needing supplemental oxygen supply, who are currently hospitalized or expected to be hospitalized, and patients with lung abnormalities.

In the present invention, "kit" refers to the components for administering a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof of the present invention for the prevention or treatment of SARS-coronavirus infection (COVID-19). Refers to the packaged product comprising.The kit preferably comprises a container or box for holding the kit's components.The box or container is accompanied by a food and drug administration approved protocol or label.The box or container contains plastic; Contains the components of the present invention contained in polyethylene, polypropylene, ethylene or propylene container.The container can be a tube or bottle with a lid.The kit can also be used for the treatment of patients with coronavirus infection (COVID-19) of the present invention. For this purpose, instructions for administration, dosage, administration regimen, etc. are included.

Various aspects of the invention are described in further detail herein.

Anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof of the present invention

In one embodiment of the present invention, the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof is a polyclonal antibody, a monoclonal antibody, a recombinant antibody, a single chain antibody, a hybrid antibody, a chimeric antibody, a humanized antibody or fragments thereof.

In another embodiment of the present invention, the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof may comprise a human antibody.

In another embodiment of the present invention, the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof may be included in the IgG class of the antibody.

In another embodiment of the present invention, the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof is a light chain comprising the CDR1 region of SEQ ID NO: 829, the CDR2 region of SEQ ID NO: 830, and the CDR3 region of SEQ ID NO: 831 variable region; and a heavy chain variable region comprising a CDR1 region of SEQ ID NO: 832, a CDR2 region of SEQ ID NO: 833, and a CDR3 region of SEQ ID NO: 834. In the present invention, the antibody or antigen-binding fragment thereof of the above sequence is referred to as a CT-P59 or CT-P59 antibody, and are used interchangeably.

In another embodiment of the present invention, the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof comprises a light chain variable region of the polypeptide sequence of SEQ ID NO: 2017; and a heavy chain variable region of the polypeptide sequence of SEQ ID NO: 2018. In the present invention, the antibody or antigen-binding fragment thereof of the above sequence is referred to as a CT-P59 or CT-P59 antibody, and are used interchangeably.

Composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof of the present invention

As used herein, the term “composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof” may be used interchangeably with “stable liquid pharmaceutical formulation”.

In one embodiment of the present invention, the composition according to the present invention comprises (A) an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; (B) a surfactant; (C) sugars or derivatives of sugars; and (D) amino acids.

In addition, the composition according to the present invention is a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof, in a dose of 1 to 120 mg/kg It provides a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) by administering a composition comprising the antibody or antigen-binding fragment thereof.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 5 to 100 mg/kg may be administered to a patient.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 10-80 mg/kg may be administered to a patient.

In one embodiment of the invention, the antibody is administered at a dose of 20 to 80 mg/kg, 40 to 80 mg/kg, 20 to 40 mg/kg, 10 to 40 mg/kg, or 10 to 20 mg/kg to the patient, or A composition comprising an antigen-binding fragment thereof may be administered.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 10 mg/kg, 20 mg/kg, 40 mg/kg, or 80 mg/kg may be administered to a patient.

In the specification of the present application, the term “not including” means not including the corresponding component at all. In addition, the term refers to those that are substantially free of the component, i.e., to a range that does not affect the activity of the antibody, stability and viscosity of the liquid pharmaceutical formulation, e.g., the total weight of the liquid pharmaceutical formulation. It means to include 0 to 1% (w/v), 0 to 1 ppm (w/v), or 0 to 1 ppb (w/v) as a standard.

The composition comprising the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof according to the present invention is an oral form such as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, and the like, respectively, according to a conventional method. Formulations, external preparations, suppositories, sterile injection solutions, pre-filled syringe solutions, auto-injectors, or lyophilized forms can be formulated. Specifically, in the case of formulation, it can be prepared using a diluent or excipient such as a filler, extender, binder, wetting agent, disintegrant, surfactant, etc. usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations include at least one excipient in the extract, for example, starch, calcium carbonate, sucrose. , lactose, gelatin, etc. can be mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral use include suspensions, solutions, emulsions, and syrups. In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives are included. can Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized formulations and suppositories. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like can be used.

(A) Antibody or antigen-binding fragment thereof

The composition according to the present invention, in one embodiment, may include the above-described anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof of the present invention.

The concentration of the antibody or antigen-binding fragment thereof can be freely adjusted within a range that does not substantially adversely affect the stability and viscosity of the composition according to the present invention.

In one embodiment of the present invention, the concentration of the antibody or antigen-binding fragment thereof may be 5 to 200 mg/mL. In another embodiment of the present invention, the concentration may be 10 to 120 mg/mL. In another embodiment of the present invention, the concentration may be 20 to 100 mg/mL. When the concentration is within this range, long-term stability may be excellent. The concentration can be freely adjusted within a range that does not substantially adversely affect the stability of the liquid pharmaceutical formulation according to the present invention.

(B) Surfactants

In the present invention, "surfactant" is polyoxyethylene sorbitan fatty acid ester (for example, polysorbate (Polysorbate)), polyoxyethylene alkyl ether (for example, bridge (Brij)), alkylphenyl polyoxyethylene ether ( For example, Triton-X), polyoxyethylene-polyoxypropylene copolymer (eg, Poloxamer, Pluronic), sodium dodecyl sulfate (SDS), etc. and is not limited thereto.

In one embodiment of the present invention, the surfactant may include a polysorbate, a poloxamer, or a mixture thereof. In another embodiment of the present invention, the surfactant may include polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a mixture of two or more thereof. In another embodiment of the invention, the surfactant may include polysorbate 80.

In one embodiment of the present invention, the concentration of the surfactant may be 0.001 to 10% (w/v). In another embodiment of the present invention, the concentration may be 0.01 to 1.0% (w/v). In another embodiment of the present invention, the concentration may be 0.05 to 0.5% (w/v).

When the concentration is within this range, the stability of the composition of the present invention may be excellently exhibited. The concentration can be freely adjusted within a range that does not substantially adversely affect the stability of the liquid pharmaceutical formulation according to the present invention.

(C) Sugars or derivatives of sugars

In the present invention, “sugar” may include monosaccharides, disaccharides, oligosaccharides, polysaccharides, or a mixture of two or more thereof. Examples of monosaccharides include, but are not limited to, glucose, fructose, galactose, and the like. Examples of disaccharides include, but are not limited to, sucrose, lactose, maltose, trehalose, and the like. Examples of oligosaccharides include, but are not limited to, fructooligosaccharides, galactooligosaccharides, mannan oligosaccharides, and the like. Examples of polysaccharides include, but are not limited to, starch, glycogen, cellulose, chitin, pectin, and the like.

In the present invention, "sugar derivatives" may include sugar alcohols, sugar acids, or mixtures thereof. Examples of sugar alcohols include glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fusitol, iditol, inositol, bolemitol, isomalt, maltitol, lactitol, maltotriitol , maltotetraitol, polyglycitol, and the like, but are not limited thereto. Examples of sugar acids include, but are not limited to, aldonic acid (such as glyceric acid), ulosonic acid (such as neuramic acid), uronic acid (such as glucuronic acid), and aldaric acid (such as tartaric acid).

In one embodiment of the present invention, the sugar includes a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, or a mixture of two or more thereof, and the derivative of the sugar may include a sugar alcohol, a sugar acid, or a mixture thereof. In one embodiment of the present invention, sugar or a derivative of sugar may include sorbitol, mannitol, trehalose, sucrose, or a mixture of two or more thereof.

In one embodiment of the present invention, the concentration of sugar or sugar derivative may be 0.01 to 30% (w/v). In another embodiment of the present invention, the concentration may be 0.1 to 15% (w/v). In another embodiment of the present invention, the concentration may be 1.0 to 10% (w/v). When the concentration is within this range, the stability of the composition of the present invention may be excellently exhibited. The concentration can be freely adjusted within a range that does not substantially adversely affect the stability of the liquid pharmaceutical formulation according to the present invention.

(D) amino acid

In the present invention, “amino acid” may include free amino acids, amino acid salts, or mixtures thereof. The free amino acid refers to a free amino acid that does not form a peptide bond between amino acids or an ester bond between an amino acid and another molecule. Examples of amino acids include, but are not limited to, aspartic acid, histidine, lysine, arginine, and the like. Examples of the amino acid salt include, but are not limited to, aspartate, histidine, lysine, and arginine.

In one embodiment of the present invention, the amino acid may include aspartic acid, histidine, lysine, arginine, or a salt thereof.

In one embodiment of the present invention, the amino acid may include an amino acid, an amino acid salt, or a mixture thereof.

In another embodiment of the present invention, the amino acid may be a buffer.

The “buffer” refers to a neutralizing material that minimizes changes in pH caused by acid or alkali, and refers to a material that maintains a pH in a specific range without a pH adjuster.

In one embodiment of the present invention, the concentration of the amino acid may be 0.1 to 40 mM. In another embodiment of the present invention, the concentration may be 1 to 20 mM. In another embodiment of the present invention, the concentration may be 5 to 15 mM. When the concentration is within this range, the stability of the composition of the present invention may be excellently exhibited. The concentration can be freely adjusted within a range that does not substantially adversely affect the stability of the liquid pharmaceutical formulation according to the present invention.

(E) pH

The pH of the stable liquid pharmaceutical formulation in the present invention may be 5.5 to 6.5. When the pH is within this range, it can exhibit excellent long-term stability. The pH can be adjusted using buffers or amino acids. In other words, when a buffer or amino acid is included in a small amount, the pH in the above range can be exhibited without a separate pH adjusting agent.

In another embodiment of the present invention, the pH may be adjusted with an additional pH adjusting agent. The pH adjusting agent includes, but is not limited to, an acid or a base (eg, sodium hydroxide).

(F) other ingredients

The composition comprising the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof of the present invention may additionally include additives known in the art within a range that does not substantially adversely affect the activity of the antibody or the stability of the formulation. can

In another embodiment of the present invention, the additive may include additional buffers, diluents, solubilizers, pH adjusting agents, sedatives, other inorganic or organic salts, antioxidants, aqueous carriers, or mixtures thereof, and the like, but is limited thereto. it is not In another embodiment of the present invention, an aqueous carrier, an antioxidant, or a mixture of two or more thereof may be further included. Aqueous carriers are pharmaceutically acceptable (safe and non-toxic when administered to humans) and may include carriers useful for the preparation of the liquid pharmaceutical formulations of the present invention.

(G) “stable” liquid pharmaceutical formulations

The term “stable” in the “stable” liquid pharmaceutical formulation of the present invention means that the antibody according to the present invention substantially retains its physical stability and/or chemical stability and/or biological activity during the manufacturing process and/or upon storage/storage. means to do Various analytical techniques for determining the stability of an antibody are readily available in the art.

Physical stability can be assessed by methods known in the art, which include measuring the sample apparent attenuation of light (absorption or optical density). This light attenuation measurement is related to the turbidity of the formulation. In addition, the content of high molecular weight components, the content of low molecular weight components, the amount of intact protein, the number of insoluble foreign matter particles, etc. can be measured for physical stability.

Chemical stability can be assessed, for example, by detecting and quantifying the chemically altered form of the antibody. Chemical stability includes charge changes (eg, occurring as a result of deamidation or oxidation) that can be assessed, for example, by ion exchange chromatography. Charge variants (acidic or basic peaks) and the like can be measured for chemical stability.

Biological activity can be assessed by methods known in the art, for example, antigen binding affinity can be measured through ELISA.

In one embodiment of the present invention, the liquid pharmaceutical formulation may be stable for a long period of time.

In one embodiment of the present invention, the term “stable” liquid pharmaceutical preparation means a liquid pharmaceutical preparation satisfying one or more of the following.

turbidity

_{- a liquid pharmaceutical formulation having an absorbance A 600} of 0 to 0.0300 or 0 to 0.0700 measured with a spectrophotometer after storage at a temperature of 40°C±2°C for 4 weeks;

_{- a liquid pharmaceutical formulation having an absorbance A 600} of 0 to 0.0300 or 0 to 0.0700 measured with a spectrophotometer after storage for 4 weeks at a temperature of 40° C.±2° C., a relative humidity of 75±5%, and a closed condition;

Main component content (main peak)

- Liquid pharmaceutical preparations containing 98% to 100% of the main component as measured by SE-HPLC after storage at a temperature of 40°C±2°C for 4 weeks;

- A liquid pharmaceutical formulation containing 98 to 100% of the main component as measured by SE-HPLC after storage for 4 weeks at a temperature of 40°C±2°C, a relative humidity of 75±5%, and a closed condition;

High molecular weight components (peaks with retention time ahead of the main peak (intact IgG))

- a liquid pharmaceutical preparation containing 0 to 1.00% of a high molecular weight component as measured by SE-HPLC after storage at a temperature of 5°C±3°C for 12 months;

- a liquid pharmaceutical formulation having a high molecular weight component of 0 to 1.00% as measured by SE-HPLC after storage at a temperature of 5°C±3°C and sealed conditions for 12 months;

Low molecular weight components (peaks with retention time lag behind the main peak (intact IgG))

- Liquid pharmaceutical formulations containing 0 to 0.40% of low molecular weight components as measured by SE-HPLC after storage at a temperature of 5°C±3°C for 12 months;

- Liquid pharmaceutical formulations containing 0 to 0.40% of low molecular weight components as measured by SE-HPLC after storage for 12 months at a temperature of 5°C±3°C and sealed conditions;

Content of intact immunoglobulin G

- A liquid pharmaceutical preparation having an intact immunoglobulin G content (Intact IgG%) of 94.0% to 100% as measured by non-reducing CE-SDS after storage at a temperature of 5°C±3°C for 12 months;

- A liquid pharmaceutical preparation having an intact immunoglobulin G content (Intact IgG%) of 94.0% to 100% as measured by non-reducing CE-SDS after storage for 12 months at a temperature of 5°C±3°C and sealed conditions;

- a liquid pharmaceutical preparation having an intact immunoglobulin G content (Intact IgG%) of 94.0% to 100% as measured by non-reducing CE-SDS after storage at a temperature of 40°C±2°C for 4 weeks;

- The content of intact immunoglobulin G (Intact IgG%) measured by non-reducing CE-SDS after storage for 4 weeks at a temperature of 40°C±2°C, relative humidity of 75±5%, and airtight conditions is 94.0% to 100% liquid pharmaceutical preparations;

Content of intact heavy and light chains

- A liquid pharmaceutical preparation having an intact heavy chain and light chain content (Intact HC+LC%) of 99.0% to 100% as measured by reduced CE-SDS after storage at a temperature of 5°C±3°C for 12 months;

- A liquid pharmaceutical formulation having an intact heavy chain and light chain content (Intact HC+LC%) of 99.0% to 100% as measured by reduced CE-SDS after storage for 12 months at a temperature of 5°C±3°C and sealed conditions;

- A liquid pharmaceutical formulation having an intact heavy chain and light chain content (Intact HC+LC%) of 98.0% to 100% as measured by reduced CE-SDS after storage at a temperature of 40°C±2°C for 4 weeks;

- The content of intact heavy and light chains (Intact HC+LC%) measured by reduced CE-SDS after storage for 4 weeks at a temperature of 40°C±2°C, relative humidity of 75±5%, and airtight conditions was 98.0% to 100 % of liquid pharmaceutical formulations;

Number of insoluble foreign matter particles

- A liquid pharmaceutical formulation in which the number of insoluble foreign particles (10.00 μm≤, <400.00 μm) measured by HIAC after storage for 12 months at a temperature of 5° C.±3° C. is 0 to 1,000;

- A liquid pharmaceutical formulation in which the number of insoluble foreign particles (10.00 μm≤, <400.00 μm) measured by HIAC after storage for 12 months at a temperature of 5° C.±3° C. and sealed conditions is 0 to 1,000;

- A liquid pharmaceutical formulation in which the number of insoluble foreign particles (1.00 μm≤, <100.00 μm) measured by MFI after storage for 4 weeks at a temperature of 40° C.±2° C. is 0 to 30,000;

- The number of insoluble foreign particles (1.00㎛≤, <100.00㎛) measured by MFI after storage for 4 weeks at a temperature of 40℃±2℃, a relative humidity of 75±5%, and a sealed condition is 0 to 30,000. medical preparations;

- A liquid pharmaceutical formulation in which the number of insoluble foreign particles (10.00 μm≤, <100.00 μm) measured by MFI after storage for 4 weeks at a temperature of 40° C.±2° C. is 0 to 200;

- The number of insoluble foreign particles (10.00㎛≤, <100.00㎛) measured by MFI after storage for 4 weeks at a temperature of 40℃±2℃, a relative humidity of 75±5%, and a sealed condition is 0 to 200 liquid drugs medical preparations;

- A liquid pharmaceutical formulation in which the number of insoluble foreign particles (10.00 μm≤, <100.00 μm) measured by MFI after storage at a temperature of 40° C.±2° C. for 6 weeks is 0 to 500;

- The number of insoluble foreign particles (10.00㎛≤, <100.00㎛) measured by MFI after storage for 6 weeks at a temperature of 40℃±2℃, a relative humidity of 75±5%, and a closed condition is 0 to 500 liquid drugs medical preparations;

oxidation rate

- a liquid pharmaceutical formulation having an oxidation rate of 0% to 2.5% of heavy chain Met 255 measured by LC-MS after storage at a temperature of 40°C±2°C for 4 weeks;

- a liquid pharmaceutical formulation having an oxidation rate of 0% to 2.5% of heavy chain Met 255 measured by LC-MS after storage at a temperature of 40°C±2°C, relative humidity of 75±5%, and sealed conditions for 4 weeks;

charge variant

- a liquid pharmaceutical preparation having an acidic peak of 20% to 35% measured by IEC-HPLC after storage at a temperature of 40°C±2°C for 4 weeks;

- a liquid pharmaceutical formulation having an acidic peak of 20% to 35% as measured by IEC-HPLC after storage at a temperature of 40°C±2°C, a relative humidity of 75±5%, and sealed conditions for 4 weeks;

- a liquid pharmaceutical formulation having a basic peak of 33% to 40% measured by IEC-HPLC after storage at a temperature of 40°C±2°C for 4 weeks;

- a liquid pharmaceutical formulation having a basic peak of 33% to 40% measured by IEC-HPLC after storage for 4 weeks at a temperature of 40°C±2°C, a relative humidity of 75±5%, and sealed conditions;

SARS-Coronavirus-2 binding affinity

- a liquid pharmaceutical formulation having an S protein binding affinity of 80% to 120% of SARS-coronavirus-2 measured by ELISA after storage at a temperature of 5°C±3°C for 12 months; and

- A liquid pharmaceutical formulation having an S protein binding affinity of 80% to 120% of SARS-coronavirus-2 measured by ELISA after storage for 12 months at a temperature of 5°C±3°C and sealed conditions.

In one embodiment of the present invention, the viscosity measured after one month at a temperature of 40 °C ± 2 °C may be 0.5cp to 10.0cp. In another embodiment of the present invention, the viscosity measured after 6 months at a temperature of 5 ℃ ± 3 ℃ may be 0.5cp to 5.0cp.

(H) a method for preparing a stable liquid pharmaceutical formulation

The stable liquid pharmaceutical formulation of the present invention can be prepared using a known method, and is not limited to a specific method. For example, after adjusting the pH while adding a buffer to a solution containing a surfactant and sugar or a derivative thereof, an antibody may be added to the mixed solution to prepare a liquid pharmaceutical formulation. In addition, after preparing a solution containing some excipients in the final step of the purification process, the remaining ingredients may be added to prepare a liquid pharmaceutical formulation. For example, after preparing a solution containing the antibody, buffer, and sugar or derivative thereof in the final step of the purification process, a surfactant may be added to the solution to prepare a liquid pharmaceutical formulation.

In addition, the preparation may not include a freeze-drying process during manufacture or may include a freeze-drying process.

If the freeze-drying process is not included, for example, the liquid pharmaceutical preparation of the present invention may be prepared and placed in an airtight container immediately after treatment such as sterilization.

When including a freeze-drying process, for example, after preparing and freeze-drying the liquid pharmaceutical preparation of the present invention, or after preparing, freeze-drying and storing/storing the liquid pharmaceutical preparation of the present invention, freeze-drying and/or Alternatively, the liquid pharmaceutical formulation according to the present invention may be prepared by supplementing or replacing the components removed or modified by storage/storage. In addition, in the liquid pharmaceutical formulation of the present invention, after freeze-drying only components excluding components that can be removed or modified by freeze-drying and/or storage/storage, or after freeze-drying only those components and storing/storing them , it is possible to prepare a liquid pharmaceutical formulation according to the present invention by adding the ingredients excluded above.

Use of stable liquid pharmaceutical formulations

The stable liquid pharmaceutical formulation of the present invention may be used for preventing or treating SARS-coronavirus-2 infection. In one embodiment of the present invention, the stable liquid pharmaceutical formulation of the present invention may be used for the prevention or treatment of diseases caused by SARS-coronavirus-2 infection. In another embodiment of the present invention, the disease derived from SARS-coronavirus-2 infection includes pneumonia, acute respiratory distress syndrome, septic shock, and the like, but is not limited thereto.

In one embodiment of the present invention, the stable liquid pharmaceutical formulation may be for intravenous, intramuscular, intradermal, subcutaneous, intraperitoneal, topical, or a combination thereof.

In one embodiment of the present invention, the stable liquid pharmaceutical formulation may be for single or multiple administration.

In one embodiment of the present invention, the concentration of other components including the antibody in the liquid pharmaceutical formulation is as described above, and the total volume of the liquid pharmaceutical formulation may be 0.1 to 100 mL.

The dosage and administration timing of the liquid pharmaceutical preparation of the present invention may vary depending on the type of disease, the severity and course of the disease, the patient's health and response to treatment, and the judgment of the treating physician, and the specific dosage and It is not limited to the timing of administration.

Prevention or treatment method

The present invention provides a method for preventing or treating SARS-coronavirus infection (COVID-19), comprising administering to the patient a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof, to the patient It provides a method of administering a composition comprising the antibody or antigen-binding fragment thereof at a dose of 1 to 120 mg/kg.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 5 to 100 mg/kg may be administered to a patient.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 10-80 mg/kg may be administered to a patient.

In one embodiment of the invention, the antibody is administered at a dose of 20 to 80 mg/kg, 40 to 80 mg/kg, 20 to 40 mg/kg, 10 to 40 mg/kg, or 10 to 20 mg/kg to the patient, or A composition comprising an antigen-binding fragment thereof may be administered.

In one embodiment of the present invention, a composition comprising the antibody or antigen-binding fragment thereof at a dose of 10 mg/kg, 20 mg/kg, 40 mg/kg, or 80 mg/kg may be administered to a patient.

In one embodiment of the present invention, the composition comprising the antibody or antigen-binding fragment thereof may be administered once or several times.

In another embodiment of the present invention, the present invention provides (A) an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; (B) a surfactant; (C) sugars or derivatives of sugars; And (D) it provides a method for preventing or treating SARS-coronavirus infection (COVID-19), comprising administering a composition comprising an amino acid to a patient.

In addition, the present invention is administered to a patient in the manufacture of a pharmaceutical composition for preventing or treating SARS-coronavirus infection (COVID-19), as the use of an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof. , provides a use in which a composition comprising the antibody or antigen-binding fragment thereof in a dose of 1 to 120 mg/kg is administered.

In one embodiment of the present invention, the prevention or treatment method may be administered together with a therapeutic agent known to those skilled in the art. In another embodiment of the present invention, the prophylactic or therapeutic method may further comprise administering an anti-viral drug in combination.

In another embodiment of the present invention, the composition comprising the antibody or antigen-binding fragment thereof of the present invention is a SARS-coronavirus-2 activity inhibitory drug, an antiviral agent, the plasma of a person recovering from SARS-coronavirus-2 infection, It may be administered in combination with an anti-TNFα (tumor necrosis factor-α) antibody or a mixture of any one or more thereof.

In one embodiment of the present invention, the SARS-coronavirus-2 activity inhibitory drug may be a binding molecule that binds to the SARS-coronavirus-2 surface spike protein (S protein).

In one embodiment of the present invention, the SARS-coronavirus-2 binding molecule binding to the spike protein (S protein) on the surface is a) different from the antibody of claim 1 or an antigen-binding fragment thereof anti-SARS-corona Virus-2 antibody or antigen-binding fragment thereof; And b) angiotensin-converting enzyme inhibitor 2 (Angiotensin-converting enzyme 2, ACE2) may be any one or more selected from the group consisting of a recombinant protein, a fragment thereof, or a variant thereof. The b) angiotensin-converting enzyme inhibitor 2 (Angiotensin-converting enzyme 2, ACE2) recombinant protein, a fragment thereof, or a variant thereof may be a fusion protein fused to the Fc region of an antibody.

In one embodiment of the present invention, the antiviral agent may be remdesivir, chloroquine, hydroxychloroquine, or a mixture of any one or more thereof, but is not limited thereto.

In one embodiment of the present invention, the anti-TNFα antibody may be infliximab, adalimumab, cetorizumab pegol, golimumab, or a mixture of any one or more thereof, but is not limited thereto.

In one embodiment of the present invention, the patient may be a SARS-coronavirus infection (COVID-19) mild, moderate or severe patient, and SARS-coronavirus infection (COVID-19) ) also includes subjects at risk of diagnosis or at risk of detecting SARS-CoV-2.

In one embodiment of the present invention, the SARS-coronavirus infection (COVID-19) is caused by SARS-coronavirus-2

a) hot flashes;

b) sneeze;

b) shortness of breath or shortness of breath;

c) Sore throat;

d) body aches or muscle aches;

e) fatigue;

f) headache;

g) chills;

h) breathing difficulties or nasal congestion;

i) loss of taste or smell;

j) nausea or vomiting; and

k) diarrhea

At least one or more symptoms selected from the group consisting of may be induced.

In one embodiment of the present invention, after administration of the composition comprising the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof to a patient, the patient is free of all of the following symptoms or maintained at a good stage for at least 24 hours. it is preferable

a) hot flashes;

b) sneeze;

b) shortness of breath;

c) Sore throat;

d) body aches or muscle aches;

e) fatigue; and

f) headache.

Stabilization method

In one embodiment of the present invention, the present invention provides (A) an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; (B) a surfactant; (C) sugars or derivatives of sugars; and (D) preparing a stable liquid pharmaceutical formulation comprising the amino acid.

kit

In one embodiment of the present invention, the present invention provides (A) an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; (B) a surfactant; (C) sugars or derivatives of sugars; and (D) a stable liquid pharmaceutical formulation comprising an amino acid; and a container containing the stable liquid pharmaceutical formulation in an airtight state.

Further, in one embodiment of the present invention, the present invention provides a composition comprising (a) an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; and (b) instructions for administering the composition at a dose of 1 to 120 mg/kg for the treatment of a patient with coronavirus infection (COVID-19).

In one embodiment of the present invention, the container may be formed from a material such as glass, polymer (plastic), or metal, but is not limited thereto. In one embodiment of the present invention, the container is, but is not limited to, a bottle, a vial, a syringe, or a tube.

In one embodiment of the present invention, the container may be a glass or polymer vial, or a glass or polymer prefilled syringe.

In one embodiment of the present invention, the silicone oil may not be coated on the inside of the container. If silicone oil is coated, stability may be reduced. The container may be for single administration or for multiple administration.

Specific product forms such as the vial, cartridge, pre-filled syringe, auto-injector, etc. and the method for filling the stable liquid pharmaceutical formulation into the vial, cartridge, pre-filled syringe, auto-injector, etc. are commonly known in the art to which the present invention pertains. Anyone with the knowledge of can easily obtain or implement it. For example, US Patent Nos. 4,861,335 and 6,331,174, etc. disclose specific product types and filling methods of pre-filled syringes. For example, U.S. Patent Nos. 5,085,642 and 5,681,291 disclose a specific product form and assembly method of an autoinjector. Commercially available products as the vial, cartridge, pre-filled syringe, auto-injector, etc. may be used as it is, or a separately customized product may be used in consideration of the physical properties, administration site, dosage, etc. of the stable liquid pharmaceutical formulation.

In one embodiment of the present invention, the kit may further include instructions for providing a method of use, a method of storage, or both of the stable liquid pharmaceutical formulation. The method of use includes a method of diagnosis, prevention, or treatment of SARS-coronavirus-2 infection, and may include an administration route, dosage, and timing of administration.

In one embodiment of the present invention, the kit may include other tools necessary from a commercial and user standpoint. In another embodiment of the present invention, the other tool may include a needle, a syringe, and the like.

In one embodiment of the present invention, the kit may further comprise a pharmaceutically acceptable excipient, which comprises an active molecule such as an antibody for preparing an acceptable or convenient dosage form; means an inert substance to be combined. Pharmaceutically acceptable excipients are excipients that are nontoxic to recipients at the dosages and concentrations employed and are compatible with the other ingredients of the composition comprising the monoclonal antibody.

Each of the features described herein may be used in combination, and the fact that each of the features is recited in different dependent claims of the claims does not indicate that they cannot be used in combination.

Hereinafter, the present invention will be described in detail according to examples. However, the following examples only illustrate the content of the present invention, and the scope of the invention is not limited by the examples.

Documents cited in the present invention and Korean Patent Application No. 10-2020-0034747, Korean Patent Application No. 10-2020-0035291, Korean Patent Application No. 10-2020-0043685, Korean Patent Application No. previously filed by the present applicant 10-2020-0044346, Korean Patent Application No. 10-2020-0052871, Korean Patent Application No. 10-2020-0082406, and Korean Patent Application No. 10-2020-0088512 are incorporated herein by reference.

Example 1. Evaluation of safety, tolerability and pharmacokinetics of anti-SARS-coronavirus-2 antibody administration (intravenous administration) in healthy subjects

1-1. CT-P59 1.1 Clinical Protocol

This clinical trial is a phase 1, randomized, double-blind, placebo designed to evaluate the safety, tolerability, and pharmacokinetics of CT-P59 in healthy subjects after the preparation of the SARS-coronavirus-2 antibody, CT-P59. This is a controlled, parallel-group, single-dose escalation clinical trial.

Subjects who meet all of the following criteria are considered eligible for clinical trial participation:

One. A healthy male or female aged 19 years or older and 55 years old or younger (If healthy, a detailed medical history review before administration of the investigational drug, a comprehensive physical examination including blood pressure (systolic and diastolic), pulse rate, respiration rate and body temperature (tympanic membrane) measurement; Defined as the determination by the Principal Investigator (or authorized co-investigator) that no clinically significant abnormalities were identified on 12-lead electrocardiogram (ECG) and laboratory tests)

2. Those who were confirmed negative in the screening and test for COVID-19 virus (SARS-CoV-2) infection performed on the first day.

3. Those with a body weight of 50 kg or more and a BMI of 18.0 kg/m2 or more and 29.9 kg/m2 or less.

4. A person who understands and agrees to follow the requirements, instructions and compliance of the clinical trial.

5. A person who voluntarily decides to participate in a clinical trial and voluntarily consents in writing to the subject consent form before performing the screening procedure.

6. Subjects and their fertility partners must agree to use a highly effective method of contraception or two medically acceptable methods of contraception for 6 months after administration of the investigational drug. A male or female is potentially fertile if, in the opinion of the Principal Investigator (or authorized collaborator), is biologically capable of bearing children and is sexually active. Subjects and their partners who have been surgically sterile for less than 6 months prior to the date of signing the informed consent form must consent to the use of a medically acceptable method of contraception.

In addition, subjects who meet any of the following criteria are considered ineligible to participate in the clinical trial.

One. Persons with a medical history and/or medical condition including one or more of the following diseases:

a) Past history of asthma, urticaria, angioedema, eczema dermatitis, or a current allergic reaction is judged to be clinically significant under the judgment of the principal investigator (or authorized co-investigator), or allergy to excipients or monoclonal antibodies of investigational drugs Those with hypersensitivity reactions such as

b) Past related to gastrointestinal, renal, endocrine, nervous, autoimmune, hepatic, hematological, metabolic (including diabetes), cardiovascular, and psychiatric conditions determined to be clinically significant by the principal investigator (or authorized co-investigator) or those with current medical history.

c) Those with a past or present history of malignancy.

d) Those with a past or present history of HIV, syphilis, hepatitis B or hepatitis C.

e) Those with a history of systemic anti-infection that ended within 28 days prior to administration of the investigational drug, or a history of infection with hospitalization or intravenous antibiotics administered within 6 months prior to administration of the investigational drug.

f) Those who have a clinically significant medical history from the principal investigator (or delegated co-investigator) within 28 days prior to administration of the investigational drug, or who are judged to need hospitalization.

g) Those who have undergone surgical intervention or surgery within 28 days prior to clinical trial administration, or are expected to undergo surgical intervention during the clinical trial period.

2. Those who, in the past or present, are receiving treatment for:

a) Prescription drugs (ETCs), over-the-counter drugs (OTCs), dietary supplements, or herbal remedies excluding hormonal contraceptives, whichever is longer, within 7 days prior to administration of the clinical trial drug or five times the half-life of elimination, whichever is longer who took it.

b) Those who received the vaccine within 4 weeks prior to administration of the clinical trial drug.

c) Those who have received monoclonal antibody or fusion protein, have received a blood transfusion, or are currently using biologics within 6 months prior to administration of the investigational drug or 5 times the elimination half-life, whichever is longer.

d) A person who has received an investigational drug other than this clinical trial within 6 months prior to administration of the investigational drug or 5 times the elimination half-life, whichever is longer.

3. Male subjects who plan to have children or who plan to donate sperm within 6 months of administration of the investigational drug, or female subjects who are breastfeeding, are pregnant or plan to breastfeed.

4. Persons with reasonable evidence of drug/alcohol/nicotine abuse in the judgment of the Principal Investigator (or authorized collaborator) or:

a) If a positive result is confirmed by screening or urine drug test performed on Day -1.

b) Ingestion or consumption of alcohol in excess of 14 units per week on average within 3 months prior to administration of the investigational drug.

c) If you smoked more than 10 cigarettes per day within 1 month before administration of the clinical trial drug.

5. Those who cannot comply with the prohibition of alcohol or alcohol-containing food, drugs, and beverages 48 hours before administration of clinical investigational drugs and 24 hours before each outpatient visit, or who cannot keep smoking when hospitalized.

6. Subjects who have donated or lost more than 400mL of whole blood within 8 weeks prior to administration of investigational drugs, or those who have donated plasma/platelets within 4 weeks prior to administration of investigational drugs.

7. Conditions (e.g., psychological or emotional problems or A person who has reasonable evidence of a disease or treatment for it).

8. Persons in vulnerable circumstances (e.g., employees of the conducting institution, individuals or immediate family members of individuals involved in conducting this clinical trial, persons incarcerated in prisons, or persons held in institutions due to law enforcement).

9. A person who is judged unsuitable for participation in the clinical trial by the principal investigator (or delegated co-researcher) for reasons other than the above exclusion criteria.

An overview of the CT-P59 1.1 clinical trial is shown in FIG. 1 . Patients who meet all of the above inclusion criteria and do not meet the exclusion criteria will be randomized to one of two groups, either CT-P59 or placebo, by a randomization system. Subjects in each cohort will receive investigational medicinal products as follows: Investigational medicinal products will be administered for 90 minutes (±15 minutes) by intravenous infusion on Day 1. When calculating the total dose of the investigational drug, the body weight of each subject measured on Day 1 will be used. Placebo will be administered in an amount equal to the active dose of CT-P59 in each cohort (Table 3).

cohort number Investigational drugs dosing method number of subjects cohort 1 CT-P59 10 mg/kg single intravenous injection 6 placebo 2 cohort 2 CT-P59 20 mg/kg 6 placebo 2 cohort 3 CT-P59 40 mg/kg 6 placebo 2 cohort 4 CT-P59 80 mg/kg 6 placebo 2

This clinical trial includes a screening period and takes approximately 90 days for each subject. All clinical trial procedures are performed at the time points indicated by X in Table 4. (Table 4).

Subject record items and schedule screening hospitalization period outpatient visit exam
end test day -21 to -2 -One One 2 3 4 5 7 10 14 28 56 90 Visit allowed period - - ±1 ±3 ±5 ±5 Subject consent X Gathering demographic information X troop gathering X X Check selection/exclusion criteria X X Weight and height measurement X X X urine drug test X X pregnancy test X X X SARS-coronavirus-2 infection test X X viral serologic test X chest x-ray examination X vital signs X X X X X X X X X X X X X randomization X Administration of clinical trial drugs X Drug Hypersensitivity Monitor X X Physical examination X X X X X X X X X X X X clinical laboratory examination X X X X X X X X X 12-lead electrocardiogram (ECG) X X X X X X Pharmacokinetic sampling X X X X X X X X X X Immunogenicity Sampling X X X X X X Compliance evaluation X Medication history and concomitant drug collection X Adverse reaction collection X

This clinical trial is designed to demonstrate the safety and tolerability of CT-P59 compared to placebo. Until the 14th day of the last enrolled subject, the evaluation is based on the following safety variable data.

- Treatment-emergent adverse events (TEAEs) after administration

- Serious adverse reactions after administration (Treatment-emergent serious AEs, TESAEs)

- Treatment-emergent adverse events of special interest, TEAESI; drug-related reactions including hypersensitivity reaction/anaphylaxis

- Measurement of vital signs (systolic and diastolic blood pressure, heart rate, eardrum temperature, respiration rate)

- Monitoring of drug hypersensitivity reactions

- 12-lead electrocardiogram (ECG)

- Physical examination

- Clinical diagnostic tests (clinical chemistry tests, hematology tests, urinalysis)

1-2. CT-P59 1.1 Clinical Results

test population

A total of 32 subjects planned to cohort 4 were enrolled. All 32 subjects were classified into intention-to-treat (ITT set) and safety set (Safety set), and 24 (75%) of them were classified into pharmacokinetics (PK set). All subjects were male and Asian (32 out of 32, 100%). The subjects' ages ranged from 19 to 43 years, and the overall median age was 24.0 years. The overall average BMI was 23.843 kg/m ² .

All 32 subjects completed by the study end (Day 90) visit (24 patients [100%] in the CT-P59 group, 8 patients [100%] in the placebo group) and no subjects discontinued the study during the entire period.

Significant protocol deviation

No significant protocol deviations were reported.

test drug administration

All 32 (100%) randomized subjects received the investigational drug, and the dose actually administered was consistent with the prescribed dose.

Safety Results:

In the treatment group, 0, 4 (66.7%), 3 (50%), and 0 subjects reported at least one post-treatment adverse event (TEAE) in the CT-P59 10, 20, 40, and 80 mg/kg treatment group, respectively. . Post-treatment adverse events (TEAEs) were reported in one (12.5%) subject in the placebo group (Table 5).

Adverse events after administration of clinical investigational drugs (safety population) representative term
(Preferred Term, PT)
Causality and severity
(Causality and Severity) CT-P59
10 mg/kg
(N=6) CT-P59
20 mg/kg
(N=6) CT-P59
40 mg/kg
(N=6) CT-P59
80 mg/kg
(N=6) placebo
(N=8) Sum
(N=32) Number of test subjects (%) Sum of the number of adverse events that occurred after administration of clinical investigational drugs 0 5 4 0 One 10 Number of subjects who reported adverse events after taking at least one investigational drug 0 4 (66.7%) 3 (50%) 0 1 (12.5%) 8 (25%) Investigational drug and number of causal subjects 0 2 (33.3%) 1 (16.7%) 0 1 (12.5%) 4 (12.5%) Grade 1 0 2 (33.3%) 1 (16.7%) 0 1 (12.5%) 4 (12.5%) Investigational drug and number of non-causal subjects 0 2 (33.3%) 2 (33.3%) 0 0 4 (12.5%) Grade 2 0 1 (16.7%) 2 (33.3%) 0 0 3 (9.4%) Grade 3 0 1 (16.7%) 0 0 0 1 (3.1%) Number of subjects who experienced serious adverse events after taking at least one investigational drug 0 1 (16.7%) 0 0 0 1 (3.1%) Investigational drug and number of non-causal subjects 0 1 (16.7%) 0 0 0 1 (3.1%) Number of subjects who experienced adverse events after administration of the clinical trial drug due to at least one infusion related reaction 0 0 0 0 1 (12.5%) 1 (3.1) Pyrexia
Related, Grade 1 0 0 1 (16.7%) 0 0 1 (3.1%) Infusion Related Reaction
Related, Grade 1 0 0 0 0 1 (12.5%) 1 (3.1%) Limb injury
Unrelated, Grade 3 0 1 (16.7%) 0 0 0 1 (3.1%) Blood creatine phosphokinase Increased
Unrelated, Grade 2 0 1 (16.7%) 1 (16.7%) 0 0 2 (6.3%) C-Reactive Protein Increased
Related, Grade 1 0 1 (16.7%) 0 0 0 1 (3.1%) Gamma-glutamyltransferase Increased
Unrelated, Grade 2 0 0 1 (16.7%) 0 0 1 (3.1%) White blood cells urine positive
Unrelated, Grade 1 0 0 1 (16.7%) 0 0 1 (3.1%) Headache
Related, Grade 1 0 1 (16.7%) 0 0 0 1 (3.1%) Urticaria
Unrelated, Grade 3 0 1 (16.7%) 0 0 0 1 (3.1%)

For reference, if more than one case was reported by the subject in each summary section, only one case was counted and only the most severe case was counted. Each case was judged to be relevant only if the relationship was defined as 'Possible', 'Probable' or 'Definite'. Common Terminology Criteria for Adverse Events (CTCAE) grades are defined as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death. The percentage was calculated using the number of subjects who received the investigational drug as the denominator.

In the CT-P59 treatment group, no subjects reported infusion related reactions. Out of a total of 10 TEAEs, 10 recovered when confirmed at the end of the clinical trial. One serious adverse event (Limb injury, unrelated, Grade 3) was reported among subjects in Cohorts 1 to 4 by the time of clinical termination. There was no causal relationship with drugs, and it was reported that the accident occurred due to the subject's accident. There were no reports of dropouts or deaths during the clinical trial. There were no significant trends observed in safety evaluations such as vital signs, drug hypersensitivity observation, electrocardiogram, and physical examination.

Immunogenicity Results

By the end of the clinical trial, none of the subjects tested positive for an antibody to the drug (ADA).

Immunogenicity (safety population) visit
ADA ^* Results CT-P59
10 mg/kg
(N=6) CT-P59
20 mg/kg
(N=6) CT-P59
40 mg/kg
(N=6) CT-P59
80 mg/kg
(N=6) placebo
(N=8) sum
(N=32) Day 1
Positive subjects (%)
Negative subjects (%) 0
6 (100) 0
6 (100) 0
6 (100) 0
6 (100) 0
8 (100) 0
32 (100) Day 7 trainees (%)
Negative subjects (%) 0
6 (100) 0
6 (100) 0
6 (100) 0
6 (100) 0
8 (100) 0
32 (100) 14th day trainees (%)
Negative subjects (%) 0
6 (100) 0
6 (100) 0
6 (100) 0
6 (100) 0
8 (100) 0
32 (100) Day 28 Subjects to be nurtured (%)
Negative subjects (%) 0
6 (100) 0
6 (100) 0
6 (100) 0
6 (100) 0
8 (100) 0
32 (100) Day 56 Subjects to be fostered (%)
Negative subjects (%) 0
6 (100) 0
6 (100) 0
6 (100) 0
6 (100) 0
8 (100) 0
32 (100) Day 90 (EOS) positive subjects (%)
Negative subjects (%) 0
6 (100) 0
6 (100) 0
6 (100) 0
6 (100) 0
8 (100) 0
32 (100)

^* ADA=Anti-Drug Antibody

Pharmacokinetic Results

The mean (± SD) blood concentration of CT-P59 for each CT-P59 treatment group versus the reserved sampling time were plotted on a linear and semi-log scale, as shown in FIGS. 6A and 6B . The overall form of mean (± SD) blood concentration of CT-P59 showed that the higher the dose, the higher the mean blood concentration at all time points after single intravenous infusion up to 2,136 hours after administration.

The calculated time to median peak plasma concentration (T _max ) of CT-P59 in the treatment group was approximately 2 hours (range 1.575 to 2.430 hours).

In this study, as the dose of CT-P59 increased from 10 mg/kg to 80 mg/kg, the serum drug concentration also increased. At all doses, t _1/2 and CL of CT-P59 were similarly confirmed, and CT-P59 t _1/2 was confirmed to be approximately 16.6 to 22.0 days, and it was confirmed that the C _max and AUC _0-inf of CT-P59 increased in a linearly proportional manner in the cohort range of this study.

Summary of Results of Pharmacokinetic Indicators of CT-P59 in the CT-P59 1.1 Study Indicator (unit) CT-P59
10 mg/kg
(N=6) CT-P59
20 mg/kg
(N=6) CT-P59
40 mg/kg
(N=6) CT-P59
80 mg/kg
(N=6) C _max (ng/mL) geometric mean 230290.3 404385.4 994192.2 1925564.8 coefficient of variation 16.2 10.7 23.5 13.8 median (min, max) 236500.0
(165000, 269000) 408000.0
(353000, 470000) 1034500.0
(650000, 1270000) 2050000.0
(1560000, 2210000) AUC _0-last (hr*ng/mL) geometric mean 48019346.3 85108462.1 163416316.0 318588719.3 coefficient of variation 30.9 18.2 13.0 14.7 median (min, max) 44025087.6
(38902669, 79805261) 84712918.7
(67586933, 113082951) 161854025.1
(132726552, 197048366) 307631447.9
(277796177, 413676972) t _1/2 (hr) geometric mean 452.0 420.1 397.2 518.6 median (min, max) 409.5
(373, 841) 419.7
(350, 583) 397.6
(350, 441) 486.1
(429, 709) Total CL (mL/hr) geometric mean 15.05 14.59 18.36 17.08 coefficient of variation 22.67 24.13 11.53 12.81 median (min, max) 16.30
(8.88, 19.1) 15.22
(9.22, 20.4) 17.78
(16.2, 21.6) 17.43
(13.9, 19.3)

AUC _0-last : Area under the serum concentration-time curve from time zero to the last quantifiable concentration; CL: Total body clearance; C _max : maximum observed serum concentration; t _1/2 : terminal elimination half-life

Example 2. Evaluation of safety, tolerability and viral indicators when administering anti-SARS-coronavirus-2 antibody (intravenous administration) to patients with mild SARS-coronavirus-2

2-1. CT-P59 1.2 Clinical Protocol

This clinical trial is a Phase 1, randomized, placebo-controlled, double-blind, single-dose escalation trial designed to evaluate the safety, tolerability, and virus-related markers of CT-P59 in patients with SARS-CoV-2 infection with mild symptoms. It is a dosing test.

Patients must meet all of the following criteria to be enrolled in this clinical trial.

One. An adult male or female 18 years of age or older and 60 years old or younger.

2. Persons diagnosed with SARS-coronavirus-2 infection in the reverse transcription polymerase chain reaction (RT-PCR) test performed during screening.

Note: If a consent form for the test subject was written within 7 days of the onset of symptoms, and if there is an RT-PCR test result that was diagnosed with SARS-coronavirus-2 infection before the consent form was written, the test result will be accepted.

Note: Based on the retest results during the screening period, only one retest of RT-PCR is allowed if the investigational drug can be administered within 7 days of symptom onset.

3. A person who satisfies the following criteria and is in good physical condition.

a) Those with an oxygen saturation of 94% or higher indoors.

b) Those who do not need oxygen supplementation therapy.

4. Those who have one or more of the following symptoms related to SARS-CoV-2 infection within 7 days prior to administration of the investigational drug:

a) fever

b) sneeze

c) shortness of breath or shortness of breath

d) Sore throat

e) body aches or muscle aches

f) fatigue

g) headache

h) chills

i) breathing difficulties or nasal congestion

j) loss of taste or smell

k) nausea or vomiting

l) diarrhea

5. Those who have one or more of the following SARS-coronavirus-2 infection-related symptoms within 48 hours before administration of the clinical trial drug.

a) fever

b) sneeze

c) shortness of breath or shortness of breath

d) Sore throat

e) body aches or muscle aches

f) fatigue

g) headache

6. Symptoms must begin within 7 days prior to administration of the investigational drug, and the onset time of symptoms is based on when the test subject experiences at least 1 symptom of SARS-coronavirus-2 infection.

7. Those with a weight of 50 kg or more and 100 kg or less and a body mass index of 18.0 kg/m ² or more.

8. A person who understands and agrees to follow the requirements, instructions, and compliance of the clinical trial.

9. A person who voluntarily decided to participate in a clinical trial and voluntarily consented in writing to the subject consent form before performing the screening procedure.

10. The study subject and the subject's fertility partner must agree to use a highly effective method of contraception or two medically acceptable methods of contraception for 6 months after administration of the investigational drug. Unless permanently infertile, a woman can become pregnant from menarche to menopause. In order to be classified as non-fertile, postmenopausal women must have not menstruated for at least 12 months prior to the date of signing the consent form. Men can become pregnant after puberty, unless permanent infertility by bilateral orchiectomy. Subjects and their partners who have been surgically sterile for less than 6 months prior to the date of signing the subject consent form must consent to the use of medically acceptable methods of contraception.

In addition, patients are considered ineligible for this clinical trial if they meet any of the following criteria.

One. People with severe symptoms including one or more of the following:

a) Difficulty breathing at a rate of 30 breaths/min or more

b) Additional oxygen adjuvant therapy required

c) shock experience

d) Those whose symptoms have worsened due to other organ failure and who need monitoring in the intensive care unit at the discretion of the investigator.

e) Suspected severe symptoms of SARS-CoV-2 infection at the discretion of the Investigator (or authorized collaborator) (including but not limited to radiological findings of the lung area)

2. A person with a medical history or current medical history including one or more of the following conditions:

a) Those with a neutrophil count of less than 1.0Х10 ³ cells/μL (International System of Units < 1.0×10 ⁹ cells/L) at screening and clinical blood test on Day 1.

b) Clinically significant allergic reactions (e.g., urticaria, angioedema), atopic conditions (asthma and eczema dermatitis), and/or monoclonal antibodies or clinically clinically significant components Persons with associated drug sensitivities.

c) Subjects with a history or current disease of a clinically significant gastrointestinal, renal, endocrine, neurological, autoimmune, hepatic, blood, metabolic (including diabetes), cardiovascular, or psychiatric condition at the discretion of the Investigator (or authorized collaborator) .

d) Those with a past or present history of malignancy.

e) Those with a past or present history of human immunodeficiency virus, hepatitis B or hepatitis C.

f) Those who have had a history of serious infection requiring hospitalization or intravenous antibiotics within 6 months of administration of the investigational drug, or who currently have symptoms of infection except for SARS-CoV-2 infection requiring systemic anti-infective treatment.

g) Those who have a clinically significant medical history excluding SARS-coronavirus-2 infection from the principal investigator (or delegated co-investigator) within 28 days prior to administration of the investigational drug or are judged to need hospitalization.

h) Those who have undergone surgical intervention and/or surgery within 28 days prior to administration of the investigational drug, or are expected to undergo surgical intervention during the clinical trial period.

3. Study subjects who, in the past or present, are receiving treatment for:

a) Those who received the vaccine within 4 weeks prior to administration of the clinical trial drug.

b) Those who received a blood transfusion within 3 months prior to administration of the investigational drug or participated in another clinical trial.

c) Those who are using monoclonal antibodies, fusion proteins, or biological agents within 6 months prior to administration of investigational drugs.

d) Persons who have received pre-approval or other investigational drugs for the treatment of SARS-coronavirus-2 infection.

e) Those who have received potential antiviral agents and/or immune-based therapy for the treatment of SARS-CoV-2 infection.

f) Persons who have used prohibited substances according to the standard of treatment procedures.

4. Male subjects planning to raise children or donating sperm, or female subjects planning to breastfeed within 6 months prior to administration of the investigational drug or who are lactating or planning to become pregnant.

5. Persons with reasonable evidence of drug/alcohol/nicotine abuse in the judgment of the Investigator (or authorized collaborator) or:

a) If a positive result is confirmed in the urine drug test performed during screening

b) In the case of ingestion or consumption of alcohol in excess of 14 units per week on average within 3 months prior to administration of the investigational drug

c) If the number of cigarettes smoked 10 or more per day within 1 month before administration of the clinical trial drug

6. Persons who are unable to follow abstaining from alcohol or alcohol-containing food, drugs or food 48 hours before admission and 24 hours before each outpatient visit, or who are unable to abstain from smoking during admission.

7. Subjects who have donated or lost more than 400mL of whole blood within 8 weeks prior to administration of investigational medicinal products, or those who have donated plasma/platelets within 4 weeks before administration of investigational medicinal products.

8. Conditions (e.g., psychological or emotional problems or A person who has reasonable evidence of a disease or treatment for it).

9. Persons in vulnerable circumstances (e.g., laboratory employees, individuals or immediate family members of individuals involved in conducting this clinical trial, persons incarcerated in prisons, or persons held in institutions due to law enforcement).

10. A person who is judged unsuitable for participation in the clinical trial by the principal investigator (or delegated co-researcher) for reasons other than the above exclusion criteria.

An overview of the CT-P59 1.2 clinical trial is shown in FIG. 2 . Patients who meet all of the above inclusion criteria but do not meet the exclusion criteria will be assigned to 3 cohorts according to the randomization scheme. Each cohort consists of 6 subjects and is assigned to either the CT-P59 or placebo arm in a 5:1 ratio (Table 8).

cohort number Investigational drugs dosing method number of patients cohort 1 CT-P59 20 mg/kg for 90 minutes (±15 minutes)
single intravenous injection 5 placebo One cohort 2 CT-P59 40 mg/kg 5 placebo One cohort 3 CT-P59 80 mg/kg 5 placebo One

This clinical trial consists of three clinical trial periods: screening, dosing period, and follow-up period, and it takes approximately 180 days for each test subject. All clinical trial procedures are performed at the time points indicated by X in Table 9. The evaluation designated by (X) in Table 9 is performed as necessary.

All test subjects are admitted to the clinical trial center research ward on the 1st day, and it is recommended that they only live in the research ward until the 7th day. Subjects' stay-at-home period will be determined at the discretion of the Investigator (or authorized collaborator), taking into account national quarantine regulations and/or public health capacity, but all subjects must remain at home for at least 72 hours (until the completion of the Day 3 evaluation). ) to live in the research ward. Clinical trial visits after discharge are performed outpatiently.

Subject record items and schedule test day
(Permitted visit period) screening treatment period cure
end follow-up period -7 to 1 One 2 3 4 5 6 7 10 14 (±1) 21 (±1) 28 (±3) 56 (±5) 90 (±5) Up to 180 days every 2 weeks
(±5) length of hospitalization X X X (X) (X) (X) (X) Follow-up through wired contact X Subject consent X troop gathering X Gathering demographic information X Check selection/exclusion criteria X X Measurement of weight, height and body mass index X X X Physical examination X X X urine drug test X viral serologic test X serum pregnancy test X X clinical laboratory examination X X X X X X X X X X X Vital signs (blood pressure, pulse, respiration rate, transcutaneous oxygenation and body temperature) X X X X X X X X X X X X 12-lead electrocardiogram (ECG) X X X X X X X X radiography X X randomization X Administration of clinical trial drugs X Respiratory/nasopharyngeal sampling Reverse Transcription Polymerase Chain Reaction (Regional Laboratory) X Virus titer (qPCR and cell culture) (central laboratory) X X X X X X X X X X X SARS-Coronavirus-2 Isolation Gene Analysis (Central Laboratory) X (X) SARS-Coronavirus-2 Infection Symptoms Questionnaire X X (X) (X) SARS-COVID-19-2 Infection Symptoms and Signs Questionnaire X X X X X X X X X X X X Pharmacokinetic sampling X X X X X X X X X X Immunogenicity Sampling X X X X X X Drug hypersensitivity monitoring X X disease status monitoring X Compliance evaluation X Medication history and concomitant drug collection X Adverse reaction collection X

This clinical trial is designed to demonstrate the safety and tolerability of CT-P59 compared to placebo. Evaluate based on the following safety parameter data up to Day 14 of the last enrolled patient.

- Treatment-emergent adverse events (TEAEs) after administration

- Serious adverse reactions after administration (Treatment-emergent serious AEs, TESAEs)

- Treatment-emergent adverse events of special interest, TEAESI; drug-related reactions including hypersensitivity reaction/anaphylaxis

- Potential efficacy for antibody immune enhancing response

- Measurement of vital signs (systolic and diastolic blood pressure, heart rate, eardrum temperature, respiration rate)

- Monitoring of drug hypersensitivity reactions

- 12-lead electrocardiogram (ECG)

- Signs and symptoms associated with SARS-CoV-2 infection

- Radiography examination (chest X-ray and/or chest CT scan)

- Clinical diagnostic tests (clinical chemistry tests, hematology tests, urinalysis)

2-2. CT-P59 1.2 Clinical Results

test population

A total of 18 (100%) patients with mild COVID-19 virus infection were enrolled. All enrolled patients (18 patients) were included in the intent-to-treat (ITT set) and safety set (Safety set), of which 15 (83.3%) were included in the pharmacokinetics (PK set). The age range of the enrolled patients was 25 to 61 years, and the overall median age was 52.0 years. The proportion of male patients (11 patients [61.1%]) was higher than that of female patients (7 patients [38.9%]), and the proportion of white patients (12 patients [66.7%]) was higher than that of Asian patients (6 patients [33.3%]). . The mean body mass index (BMI) at screening of all patients was 26.832 kg/m ² .

Of all enrolled patients (15 patients [100%] in the CT-P59 treatment group and 3 patients [100%] in the placebo group), no patients withdrew from the study until the Day 14 visit.

Significant protocol deviation

A significant protocol deviation was reported in one patient. The patient was receiving adjuvant oxygen therapy at screening and did not meet the inclusion criteria for this clinical trial, but was enrolled. At screening, the patient's percutaneous oxygen saturation in room air was 95%, but it was confirmed that oxygen was prescribed by the clinical trial center and was conservatively regarded as a serious protocol deviation.

test drug administration

All 18 (100%) patients randomized were actually administered the same dose as the prescribed dose of the investigational drug.

Safety Results

A total of 19 adverse events were reported after administration of the investigational drug, and all were judged to have no causal relationship with the investigational drug. A total of 11 patients reported adverse events even once after administration of the clinical trial drug. In the CT-P59 20, 40, and 80 mg/kg treatment groups, 3 (60.0%), 4 (80.0%), and 3 (60.0%) patients, respectively %) and 1 patient (33.3%) in the placebo group (Table 10).

Adverse events after administration of clinical investigational drugs (safety population) Abnormal case name CT-P59
20 mg/kg
(N=5) CT-P59
40 mg/kg
(N=5) CT-P59
80 mg/kg
(N=5) placebo
(N=3) Sum
(N=18) Number of patients (%) Sum of the number of adverse events that occurred after administration of clinical investigational drugs 5 8 3 3 19 Number of patients who reported adverse events after taking at least one investigational drug 3 (60%) 4 (80%) 3 (60%) 1 (33.3%) 11 (61.1%) Investigational drugs and number of causal patients 0 0 0 0 0 Investigational drugs and the number of non-causal patients 3 (60%) 4 (80%) 3 (60%) 1 (33.3%) 11 (61.1%) Grade 1 3 (60%) 0 1 (20%) 0 4 (22.2%) Grade 2 0 1 (20%) 2 (40%) 0 3 (16.7%) Grade 3 0 2 (40%) 0 1 (33.3%) 3 (16.7%) Grade 4 0 1 (20%) 0 0 1 (5.6%) Number of patients who experienced serious adverse events after taking at least one investigational drug 0 0 0 0 0 Number of patients who experienced adverse events after administration of investigational drugs due to at least one infusion related reaction 0 0 0 0 0 Palpitations
Grade 2 0 1 (20%) 0 0 1 (5.6%) Diarrhoea
Grade 1 2 (40%) 0 0 0 2 (11.1%) Dysphagia
Grade 1 0 1 (20%) 0 0 1 (5.6%) Hepatocellular injury
Grade 3 0 1 (20%) 0 0 1 (5.6%) Candida infection
Grade 2 0 0 1 (20%) 0 1 (5.6%) COVID-19 pneumonia
Grade 3 0 0 0 1 (33.3%) 1 (5.6%) Alanine aminotransferase increased
Grade 1 0 0 1 (20%) 0 1 (5.6%) Grade 3 0 1 (20%) 0 0 1 (5.6%) Blood creatine phosphokinase increased
Grade 2 0 0 1 (20%) 0 1 (5.6%) Hypertriglyceridaemia
Grade 4 0 1 (20%) 0 0 1 (5.6%) Flank pain
Grade 1 1 (20%) 0 0 0 1 (5.6%) Insomnia
Grade 1 1 (20%) 0 0 0 1 (5.6%) productive cough
Grade 1 1 (20%) 0 0 0 1 (5.6%) Hypertension
Grade 2 0 0 0 1 (33.3%) 1 (5.6%)

For reference, patients were included only once if one or more adverse events were reported. Common Terminology Criteria for Adverse Events (CTCAE) grades are defined as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening, and Grade 5 = death. The percentage was calculated using the number of patients who received the investigational drug as the denominator.

Among the data up to the 14th day of dosing visit of the last registered patient, serious adverse events occurring after administration of the clinical trial drug, adverse reactions of special interest after administration (dose-related reactions including hypersensitivity reaction/anaphylaxis) and adverse reactions occurring after administration There were no reports of cases where the study was discontinued due to

The reported adverse events overall corresponded to CTCAE Grade 1, and 12 of the 19 adverse events all recovered. Ongoing adverse events will be followed up.

Among the clinical test (clinical chemistry test, hematology test, urinalysis) results, clinically significant and reported adverse events were 3 patients in the CT-P59 40 mg/kg group and 3 patients in the CT-P59 80 mg/kg group. to be. As a result of clinical examination, most of the related adverse events were CTCAE Grade 3, and all were judged to have no causality with the investigational drug.

A patient in the placebo group was reported as an adverse event of hypertension due to vital signs assessment on Day 5, and Corona-19 pneumonia was reported as an adverse event due to radiographic examination, physical examination, and assessment of symptoms and signs related to COVID-19 virus infection.

In addition, overall, clinical tests (clinical chemistry, hematology, urinalysis), drug hypersensitivity monitoring, vital signs, 12-lead electrocardiography, COVID-19 infection-related symptoms and signs questionnaire, radiography in CT-P59 treatment and placebo groups. , physical examination, and safety evaluation including antibody-dependent promotion of infection (ADE) were not specific.

Immunogenicity Results

There were no patients who had converted to positive for an antibody to the investigational drug (ADA) until the 14th visit after administration of the investigational medicinal product.

Table 11 shows the results of immunogenicity according to the date of visit for each treatment group.

Immunogenicity (safety population) visit
ADA ^* Results CT-P59
20 mg/kg
(N=5) CT-P59
40 mg/kg
(N=5) CT-P59
80 mg/kg
(N=5) placebo
(N=3) Sum
(N=18) Number of patients (%) Day 1
positivity
voice 0
5 (100%) 1 (20%)
4 (80%) 0
5 (100%) 0
3 (100%) 1 (5.6%)
17 (94.4%) Day 7
positivity
voice 0
5 (100%) 0
5 (100%) 0
5 (100%) 0
3 (100%) 0
18 (100%) Day 14
positivity
voice 0
5 (100%) 0
5 (100%) 0
5 (100%) 0
3 (100%) 0
18 (100%)

^* ADA = Anti-Drug Antibody (Antibody to clinical investigational drugs)

Virus Validation Results

Until the 7th day, the concentration of COVID-19 virus (SARS-CoV-2) in the nasopharyngeal specimens of patients was analyzed using quantitative polymerase chain reaction (qPCR).

The number of patients with confirmed COVID-19 virus (SARS-CoV-2) at screening based on quantitative polymerase chain reaction (qPCR) is CT-P59 (20 mg/kg, 40 mg/kg or 80 mg/kg) treatment group 15 patients (100%) and 3 patients (100%) in the placebo group. The average (± standard deviation) virus concentration over time for each treatment group based on polymerase chain reaction (qPCR) is shown in FIG. 7 . Over time, the average virus concentration decreased in all four treatment groups.

The virus concentration at the time of screening of the patients recruited for the study was very diverse, so the post-hoc test was performed by classifying the patients according to the maximum virus concentration range for each patient. The average (± standard error) virus concentration over time for each treatment group based on polymerase chain reaction (qPCR) according to the highest virus concentration is shown in FIGS. 8A, 8B, 8C and 8D. Patients with a peak virus concentration of 10 ⁵ cp/mL or less had a decrease in virus concentration regardless of investigational drug administration. In patients with a high peak virus concentration of 10 ⁵ cp/mL or higher, the virus concentration increased rapidly in the CT-P59 (20 mg/kg, 40 mg/kg or 80 mg/kg) treatment group after administration of the investigational drug compared to the placebo group. decreased. Through this, the antiviral effect of CT-P59 was confirmed in patients infected with mild COVID-19 virus (SARS-CoV-2).

Pharmacokinetic Results

The mean (± standard deviation) blood CT-P59 concentration according to the sampling time for each CT-P59 treatment group is shown in FIGS. 9A and 9B on a linear and semi-log scale. Overall, it was confirmed that the mean blood CT-P59 concentration increased as the dose of CT-P59 increased (CT-P59 20 mg/kg, 40 mg/kg, and 80 mg/kg) at all time points of the pharmacokinetic analysis.

The mean peak plasma concentration (C _max ) of CT-P59 increased more than the dose dose administered in this study (range of CT-P59 20 mg/kg to 80 mg/kg). In the CT-P59 treatment group, the median time (T _{max ) to reach the highest blood concentration (C max} ) was 2.5 hours.

Example 3. Evaluation of treatment efficacy and safety when anti-SARS-coronavirus-2 antibody administration (intravenous administration) in hospitalized patients due to SARS-coronavirus-2 infection

3-1. CT-P59 3.1 Clinical Protocol

This two-part phase 2/3, randomized, placebo clinical trial was conducted to evaluate the efficacy and safety of CT-P59 in combination with standard treatment in hospitalized patients due to SARS-coronavirus-2 infection. It is a controlled, double-blind, multicenter trial.

Patients must meet all of the following criteria to be enrolled in this clinical trial.

One. Male or female patients 18 years of age or older.

2. Patients diagnosed with SARS-coronavirus-2 infection by RT-PCR in the laboratory of the conducting institution from upper or lower respiratory tract samples within 4 days of administration of the test drug.

Note: If there is a test result for SARS-coronavirus-2 infection prior to written consent (however, 4 days before administration of the test drug), and the result is an RT-PCR result from an upper or lower respiratory specimen, Test results are acceptable.

Note: One retest for RT-PCR is permitted during the screening period if the test drug can be administered within 10 days of symptom onset based on the retest results.

3. If the onset of symptoms does not exceed 10 days prior to administration of the test drug.

4. Patients who meet the following criteria and are currently hospitalized (or are expected to be hospitalized prior to taking study drug):

a. Oxygen saturation in room air ≤ 94% and/or _{PaO 2} / _{FiO 2} ≤ 300 mgHg, and

b. If oxygen therapy is required.

5. Patients with abnormal radiographic findings suggestive of SARS-CoV-2 infection in the lungs, as determined by the investigator.

6. Patients weighing less than or equal to 99.9 kg.

7. Sufficient time and opportunity should be provided to patients and/or their legally authorized representatives to read and/or understand the nature and purpose of this study, including possible risks and side effects, and provide informed consent (ICF) prior to any study procedure. ) must be signed and agreed to.

8. The patient and the patient's fertility partner must agree to use a highly effective method of contraception throughout the study for at least 6 months after administration of the study drug.

In addition, patients cannot be enrolled in this clinical trial if they meet any of the following criteria.

One. Patients requiring extracorporeal membrane oxygenation (ECMO) or invasive mechanical ventilation.

2. Patients who, in the past or present, are receiving treatment for:

a) Remdesivir, chloroquine, hydroxychloroquine (except for chronic use in autoimmune diseases), tocilizumab, sarilumab, and other immunosuppressants and human immunodeficiency virus (HIV) protein inhibitors (chronic for HIV infection) When a candidate drug for inhibiting SARS-coronavirus-2 activity, including but not limited to), is administered within 30 days of administration of the test drug.

b) SARS-coronavirus-2 human intravenous immunoglobulin (HIVIG), plasma from a person recovering from SARS-coronavirus-2 infection, or SARS-coronavirus-2 nMAB for the treatment of SARS-coronavirus-2 infection prior to study drug administration if administered.

c) Administration of other test devices or drugs, including but not limited to monoclonal antibodies, fusion proteins, or biologics, for the treatment of SARS-CoV-2 infection prior to study drug administration.

d) The use of drugs contraindicated in standard treatment.

e) If the SARS-Coronavirus-2 vaccine was administered prior to administration of the test drug.

3. Patients with known allergic or hypersensitivity reactions to monoclonal antibodies or components of the test drug.

4. Patients with a medical history and current medical condition including one or more of the following:

a) All currently active malignancies.

b) Severe known liver disease (e.g., cirrhosis or serum alanine transaminase [ALT] test result at least 5 times the upper limit of normal or serum aspartate transaminase [AST] test result at upper limit of normal 5 times or more).

c) Persons with renal function problems (estimated glomerular filtration rate ^{less than 50 mL/min/1.73 m 2} ) or who are receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis.

d) Any medical condition that, in the investigator's judgment, would place the patient at an unreasonably increased risk for participation in the study, including any medical history and current disease that could prevent randomization to a treatment group.

e) A person who has had a stroke or myocardial infarction suspected to be related to SARS-coronavirus-2 infection after the onset of symptoms.

f) Persons with a current history of infection with HIV, hepatitis B or hepatitis C.

5. A person who has received a test device or drug other than this clinical trial within 4 weeks before administration of the test drug or 5 times the half-life of elimination, whichever is longer

6. Patients who currently abuse alcohol or drugs.

7. Female patients who are currently pregnant or breastfeeding.

8. If, in the opinion of the Investigator, the patient is ineligible to participate in the study for any reason (including clinical laboratory test results), or if the Investigator shows evidence of a condition that would invalidate informed consent (mental or emotional problem, disability, or consequential treatment), the Investigator If, in our judgment, the patient's ability to comply with the protocol requirements is limited, the protocol requirements, guidelines and limitations related to the study, the nature and purpose of the clinical study and the possible consequences of the clinical study cannot be understood, written prior If a consent form cannot be drawn up, if the protocol cannot be fully complied with.

9. When transfer to a hospital other than a clinical institution is expected.

An overview of the CT-P59 3.1 clinical trial is shown in FIG. 3 . Approximately 700 patients hospitalized for SARS-CoV-2 infection who met all of the above inclusion criteria and did not meet the exclusion criteria were either 80 mg/kg CT-P59 or 80 mg/kg placebo (Part 1 100 included, Part 2). 350 patients in each treatment group) in a 1:1 ratio. On Day 1, a single intravenous dose of CT-P59 or placebo is administered for 90 minutes (±15 minutes) with standard treatment.

This clinical trial consists of three clinical trial periods: screening, dosing period, and follow-up period, and it takes approximately 180 days for each test subject. All clinical trial procedures are performed at the time points indicated by X in Table 12. The evaluation designated by (X) in Table 12 is performed as necessary. The same clinical trial procedure is performed for both parts unless otherwise specified. While analyzing the results of Part 1, Part 2 patient enrollment can begin.

Subject record items and schedule Clinical Dates (Visit Allowance) screening duration of treatment End of treatment follow-up period -10 to 0 One 2 3 5 7 14 (±1) 28 (±3) 56 (±5) 90 (±5) Up to 180 days every 2 weeks (±5) length of hospitalization X X (if required) Subject consent X Demographic information and medical history X Selection/Exclusion Criteria X X weight, body mass index, height X X X body ejaculation X X Hepatitis B/C and Human Immunodeficiency Virus Test X blood pregnancy test X X clinical laboratory examination X X X X X X X X X vital signs X X X X X X X X X X 12-lead electrocardiogram X X X X X radiography X X X X X X randomization X Test drug administration X standard treatment X (if required) Pharmacokinetic sampling (central analysis, only in the pharmacokinetic subgroup) X X X X X X X X Immunogenicity sampling (central analysis) X X X X X X Serological sampling (central analysis) X X X X X X Observation of hypersensitivity reactions X Virus Analysis Sampling SARS-coronavirus-2 infection RT-PCR test X Virus titer (central analysis, RT-qPCR and cell culture) and SARS-coronavirus-2 genotyping (central analysis) X X X X X X X Assessment of SARS-CoV-2 Related Symptoms X X X X X X X X X X X SARS-Coronavirus-2 Symptom Self-Assessment (X) 7 point ordinal scale X X X X X X X X X X NEWS X X X X X X X X (X) (X) Additional evaluation (ICU transfer, hospitalization, oxygen-assisted therapy) X (if required) Medication history and concomitant drug collection X Adverse events collection X

This clinical trial evaluates the primary efficacy endpoints of Part 1 and Part 2, respectively. The following 7-point ordinal scale is used for the two-part primary endpoints.

1) discharge;

2) a condition that does not require hospitalization, treatment;

3) No hospitalization, no oxygen treatment;

4) hospitalization, low-flow oxygen therapy;

5) hospitalization, high flow/non-invasive oxygen therapy;

6) hospitalization, extracorporeal membrane oxygenation (ECMO)/invasive mechanical ventilation;

7) death;

Part 1 is designed to confirm the potential therapeutic efficacy of CT-P59 compared to the placebo group, and evaluates the 7-point ordinal scale of clinical status at 14 days. In addition, the time to recovery, defined as the first day of satisfaction of categories 1, 2, and 3 on a 7-point ordinal scale, was evaluated for 28 days after clinical enrollment.

Part 2 was designed to determine the clinically significant therapeutic efficacy of CT-P59 versus placebo, and the time to recovery, defined as the first day of satisfaction of categories 1, 2, and 3 on a 7-point ordinal scale, for 28 days after clinical enrollment. evaluate

Example 4. Evaluation of treatment efficacy and safety when administering anti-SARS-coronavirus-2 antibody (intravenous administration) to an outpatient due to SARS-coronavirus-2 infection

4-1. CT-P59 3.2 Clinical Protocol

This clinical trial was a two-part, phase 2/3, randomized, two-part clinical trial to evaluate the efficacy and safety of CT-P59 in combination with standard treatment in outpatient patients due to SARS-coronavirus-2 infection. It is a placebo-controlled, double-blind, multicenter trial.

Patients must meet all of the following criteria to be enrolled in this clinical trial.

One. Adult male or female 18 years of age or older

2. A person who has been diagnosed with SARS-coronavirus-2 infection in the SARS-coronavirus-2 diagnostic test provided by the sponsor at the time of screening.

Note: If there is a diagnosis of SARS-coronavirus-2 infection through RT-PCR before the consent form was written during screening (however, the test result must be within 72 hours before administration of the clinical trial drug), provided by the sponsor Even if there is no SARS-coronavirus-2 diagnostic test result, it is possible to register for the clinical trial.

Note: Based on the retest results during the screening period, if the clinical trial drug can be administered within 7 days of symptom onset, one SARS-coronavirus-2 retest is permitted.

3. A person in good physical condition who meets the following criteria:

a) Those with a dispersion saturation of more than 94% indoors.

b) Those who do not need oxygen supplementation therapy.

Note: Individuals suffering from pneumonia but without symptoms of severe pneumonia, at the discretion of the study director, are eligible to participate in the clinical trial.

4. Patients whose symptom onset period was less than 7 days before administration of the investigational drug, the symptom onset time is based on when the test subject experienced at least one SARS-coronavirus-2 infection-related symptom.

5. Patients presenting with one or more of the following SARS-CoV-2 infection-related symptoms within 7 days prior to administration of the investigational drug:

a) fever

b) sneeze

c) shortness of breath or shortness of breath

d) Sore throat

e) body aches or muscle aches

f) fatigue

g) headache

h) chills

i) stuffy nose or nasal congestion

j) loss of taste or smell

k) nausea or vomiting

l) diarrhea

6. Patients presenting with one or more of the following symptoms related to SARS-CoV-2 infection within 48 hours prior to administration of the investigational drug:

a) fever

b) sneeze

c) shortness of breath or shortness of breath

d) Sore throat

e) body aches or muscle aches

f) fatigue

g) headache

7. Patients (or their legally authorized representatives) must be given sufficient time and opportunity to read and/or understand the nature and purpose of this study, including possible risks and side effects, and must be aware of, and be aware of, all studies Prior to the procedure, the subject consent form must be signed and consented.

8. In all male and female patients, patients and their fertility partners who have consented to use highly effective or medically acceptable methods of contraception for 6 months after administration of the investigational drug, including during the clinical trial period. For information on contraceptive methods, see below.

- Estrogen and progestogen complex or progestogen-only hormonal contraceptives associated with ovulation suppression

- intrauterine device

- Abstinence preferred by the patient and consistent with the patient's general lifestyle. Periodic abstinence (e.g. date, ovulation, symptom-related contraception [basal body temperature measurement, cervical secretions, other fertility symptoms, etc.], post-ovulation methods), declaration of abstinence during exposure to investigational medicinal products, extravaginal ejaculation is not permitted as a contraceptive method No.

- Condoms and additionally contraceptive spermicides, hormonal contraceptives, or endometrium contraceptive methods are applicable to female patients and female partners of male patients. The use of contraceptive spermicide condoms alone is not permitted.

Female and male patients and their partners who were surgically infertile 6 months prior to the signing of the subject consent form should use a highly effective method of contraception or a medically acceptable method of contraception. Postmenopausal women were not classified as fertile until at least 12 months after they had their last menstrual period before signing the consent form.

In addition, patients are considered ineligible for this clinical trial if they meet any of the following criteria.

1. Patients currently with severe symptoms including one or more of the following:

a) You have been hospitalized or require hospitalization because of a past or present serious SARS-CoV-2 infection.

b) Difficulty breathing at a rate of 30 breaths/min or more

c) Oxygen adjuvant therapy required

d) shock experience

e) Those who have complications of other organ failure and who need monitoring in the intensive care unit at the discretion of the researcher

2. Patients who, in the past or present, have received or are planning to receive any of the following prohibited therapies:

a) Before administration of the test drug, remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or a corticosteroid that can replace dexamethasone), interferon beta-1b (interferon beta-1b), ribavirin ( ribavirin), and actual or possible antiviral drugs and/or antiviral drugs including, but not limited to, other immunomodulatory agents and human immunodeficiency virus (HIV) protease inhibitors (lopinavir-ritonavir, etc.) Drugs with potential for SARS-Coronavirus-2 activity.

b) All SARS-coronavirus-2 human intravenous immunoglobulin and reparative plasma therapeutics for the treatment of SARS-coronavirus-2 infection prior to dosing of the test drug.

c) Other test medical care including, but not limited to, monoclonal antibodies (eg, tocilizumab [tocilizumab], sarilumab], etc.), fusion proteins, or biologics for the treatment of SARS-coronavirus-2 infection before administration of the test drug product or other test drug.

d) The use of drugs contraindicated in standard treatment.

e) SARS-coronavirus-2 vaccine before administration of test drug.

3. Persons with a history of hypersensitivity to monoclonal antibodies or a known hypersensitivity to a therapeutic component of the study drug.

4. Those who have had any of the following infections in the past or present:

a) Active infections other than SARS-coronavirus-2 infections that require treatment.

b) Severely infected patients who require parenteral antibiotic use or hospitalization within 30 days prior to administration of the study drug at the discretion of the study director.

5. People with medical conditions including one or more of the following:

a) Subjects with clinically significant respiratory disease (eg, chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, asthma) not controlled at the discretion of the Investigator.

b) Serum aspartate transaminase (AST), serum alanine transaminase (ALT), or alkaline phosphatase (ALP) test results including more than 5 times the upper limit of normal Those with abnormal results in liver function tests, but not limited thereto.

c) Those with renal function problems (the estimated glomerular filtration rate is ^{less than 30 mL/min/1.73 m 2} ) or those who are receiving continuous renal replacement therapy, hemodialysis, or peritoneal dialysis

d) Past or present history of symptomatic congestive heart failure consistent with New York Heart Association Grade III or IV functional status within 6 months of study drug administration

e) When there is a clinically significant abnormal result on the 12-lead ECG during the screening test, and it may interfere with the safety of the subject or affect the test result according to the clinical judgment of the principal investigator.

f) Diabetes or hypertension not controlled at the discretion of the Investigator

g) All currently active malignancies

h) Current weakened immunity due to pre-existing medical history (eg malignant tumor, organ transplant) or medical treatment (eg therapeutic drugs, chemotherapy, radiation therapy).

i) Those who must undergo surgery within 7 days prior to administration of the study drug, or have comorbidities that are considered life-threatening within 30 days.

j) Conditions that affect the nervous system clinically significantly (eg neuropathy or neurological disorder).

k) Those who, at the discretion of the Principal Investigator, have health-related information or a condition that could invalidate the signed consent (mental or emotional problem, disability, or treatment thereof), or lack the ability to comply with the conditions required by the clinical trial protocol.

l) Persons with any medical conditions that, at the discretion of the Investigator, place the patient at unreasonably increased risk for participation in this study, including any past or present conditions that could preclude randomization to the assigned treatment arm.

6. Those who are expected to be transferred to a hospital other than the planned clinical trial site.

7. Those who currently abuse drugs or alcohol, or have a history of administering clinical trial drugs within 12 months

8. Those who were treated with another investigational medicinal product within 4 weeks (or 5-fold half-life, based on a longer period) prior to administration of the investigational medicinal product.

9. Those who are judged inappropriate by the study director to participate in the clinical trial due to reasons other than the above exclusion criteria.

10. A person who is judged unsuitable for participation in a clinical trial under the judgment of a general physician or the principal investigator.

11. Male patients who are planning to have children or donate sperm during clinical trials or within 6 months of administration of investigational medicinal products, or female patients who are currently lactating or pregnant, or who are lactating or planning to become pregnant (during 6 months after administration of investigational medicinal products) .

An overview of the CT-P59 3.2 clinical trial is shown in FIG. 4 . A total of 1020 patients (300 in Part 1, 720 in Part 2) who met all of the above inclusion criteria and were hospitalized for SARS-coronavirus-2 infection who did not meet the exclusion criteria will be enrolled in this clinical trial. . Part 1 300 subjects were enrolled in one of three cohorts: CT-P59 at 80 mg/kg, CT-P59 at 40 mg/kg, or placebo (equivalent dose of CT-P59 80 mg/kg) in a 1:1:1 ratio. are randomly assigned to Afterwards, in Part 2, 720 follow-up subjects will be randomized in a 1:1 ratio to one of two groups in the 80 mg/kg (or 40 mg/kg) CT-P59, placebo group. The actual dose administered for Part 2 (CT-P59 at 80 mg/kg or 40 mg/kg) will be determined according to the results of Part 1. On Day 1, a single intravenous dose of CT-P59 or placebo is administered for 90 minutes (±15 minutes) with standard treatment.

This clinical trial consists of three clinical trial periods: screening, treatment period, and follow-up period, and it takes approximately 180 days for each test subject. All clinical trial procedures are performed at the time points indicated by X in Table 13. The evaluation designated by (X) in Table 13 is performed as necessary. The same clinical trial procedure is performed for both parts unless otherwise specified.

Subject record items and schedule clinical date
(Visit Allowance) screening duration of treatment End of treatment follow-up period -7 to 1 One 2 3 4 5 6 7 10 14 (±1) 21 (±1) 28 (±3) 56 (±5) 90 (±5) Up to 180 days every 2 weeks (±5) Follow-up period via landline contact X Subject consent X medical history X demographic information X weight, body mass index, height X X X Urine drug abuse test (if consent to participate in optional pharmacokinetic study) X Hepatitis B/C and Human Immunodeficiency Virus Test (Central Analysis) X serum pregnancy test X X Selection/Exclusion Criteria X X randomization X Test drug administration X nasopharyngeal smear sampling Infection testing by SARS-COVID-19 diagnostic kit or RT-PCR X Virus titer (central analysis, RT-qPCR and cell culture), genotype or phenotypic sampling of SARS-coronavirus-2 isolates (central analysis) X X X X X X X X X X X patient diary X X (X) Assessment of signs and symptoms associated with SARS-CoV-2 infection X X X X X X X X X X X X X X X NEWS2 X X X X X X X X X X X X X X Immunogenicity sampling (central analysis) X X X X X X SARS-coronavirus-2 antibody test (central analysis) X X X X X X Pharmacokinetic sample collection (central analysis, if consent to participate in optional pharmacokinetic study) X X X X X X X X X X Physical examination X X X Clinical laboratory examination (central analysis) X X X X X X X X X X Vital signs (blood pressure, heart rate, respiration rate, blood oxygen saturation, body temperature) X X X X X X X X X X X X X X New York Heart Association Step Check X X 12-lead electrocardiogram X X X X X X X X radiography X Observation of hypersensitivity reactions X disease status monitoring X Compliance Assessment X Medication history and concomitant drug collection X Adverse events collection X

The primary evaluation indicators of this clinical trial are as follows.

Part 1

- Time until the virus was not detected in nasopharyngeal specimens analyzed by RT-qPCR or cell culture test until day 28; and

- Time to clinical recovery by day 14

Clinical recovery means that the intensity of all symptoms included in the symptom checklist 1 of SARS-coronavirus-2 infection must be recorded as 'none or weak', and this condition must be maintained for at least 24 hours. In order to meet clinical recovery, symptoms of 'moderate or severe' intensity at baseline must be rated as 'weak or none', and symptoms of baseline 'weak' intensity as 'none' after administration of the investigational drug. Its strength should be indicated. If a symptom identified as 'none' at baseline in intensity is changed to 'severe, moderate or mild' during the clinical trial period, it must be changed back to 'none' for at least 24 hours to be considered to satisfy clinical recovery. . The symptoms included in the SARS-COVID-19 infection checklist 1 consisted of 'fever, cough, shortness of breath or shortness of breath, sore throat, general or muscle aches, fatigue, and headache'.

part 2

- Proportion of subjects requiring hospitalization, oxygen therapy, or death due to SARS-COV-2 infection by day 28

CT-P59 3.2 Part 1 Clinical Results

Key Validity Results

Proportion of subjects requiring hospitalization, oxygen therapy, or dying due to SARS-COVID-19 virus infection by day 28

No subjects died in this clinical trial, and the proportion of subjects who received hospitalization or oxygen therapy due to SARS-COVID-19 virus infection were all CT-P59 treatment groups (CT-P59 40 mg/kg, CT-P59 80 mg/kg and CT-P59 sum) were lower than in the placebo group (Table 14).

When an exploratory subgroup analysis was performed based on the severity of the disease, it could be confirmed that hospitalization or oxygen therapy occurred only in patients with moderate disease (accompanied by pneumonia). When subgroup analysis of these patients aged 50 years or older with moderate disease (with pneumonia), the treatment difference between the CT-P59 treatment group and the placebo group was larger, and the total CT-P59 treatment group (CT-P59 40 mg/kg and CT -P59 80 mg/kg) was statistically significantly superior to the placebo group (Table 14).

Table 13 shows the proportion of patients who received hospitalization or oxygen therapy due to SARS-COVID-19 virus infection by the 28th day by treatment group.

statistics CT-P59 40 mg/kg
(N=101) CT-P59 80 mg/kg
(N=103) CT-P59 Total
(N=204) placebo
(N=103) whole patient
4/101 (4.0) 5/103 (4.9) 9/204 (4.4) 9/103 (8.7) p-value* 0.2513 0.4073 0.1962 Patients with moderate disease (accompanied by pneumonia) 4/62 (6.5) 5/63 (7.9) 9/125 (7.2) 9/57 (15.8) p-value* 0.1426 0.2558 0.1055 Moderately ill (with pneumonia) patients over 50 years of age 3/40 (7.5) 4/40 (10.0) 7/80 (8.8) 9/38 (23.7) p-value* 0.0626 0.1343 0.0418**

* No adjustment for multiplicity

** Nominal significance

Time to clinical recovery by day 14

The median (95% CI) time to clinical recovery was 5.7 days in the CT-P59 treatment group (CT-P59 40 mg/kg and CT-P59 80 mg/kg) and 8.8 days in the placebo group in the CT-P59 treatment group. was shortened by more than 3 days (Table 15). The median (95% CI) time to clinical recovery was the shortest in the CT-P59 40 mg/kg treatment group, and statistically shorter than the placebo group.

When an exploratory subgroup analysis was performed based on disease severity and age, the time to clinical recovery was shortened by more than 4 to 6 days in the CT-P59 treatment group in patients with moderate disease or over 50 years of age (Table 15).

Table 15 shows the time to clinical recovery on the 14th day by treatment group.

The Kaplan-Meier curve for the cumulative proportion of patients with clinical recovery by day 14 showed that the proportion gradually increased in all groups and all CT-P59 treatment groups (CT-P59 40 mg/kg, CT-P59 80 mg/kg and CT-P59 sum) showed a steeper increase than in the placebo group. Through this, the effect of CT-P59 was confirmed in patients with mild and moderate COVID-19 virus (SARS-CoV-2) infection.

Kaplan-Meier curves for each treatment group are shown in FIGS. 10a, 10b and 10c.

whole patient statistics CT-P59 40 mg/kg
(N=101) CT-P59 80 mg/kg
(N=103) CT-P59 Total
(N=204) placebo
(N=103) Median (95% CI) 5.35
(3.97, 6.78) 6.23
(5.53, 7.85) 5.72
(5.15, 7.00) 8.77
(6.72, 11.73) p-value (log-rank test) 0.0097 0.0392 0.0084 p-value (Wilcoxon test) 0.0054 0.1416 0.0151 Clinical Recovery ratio (95% CI) 1.562 (1.11, 2.20) 1.429
(1.02, 2.01) 1.489
(1.11, 2.01) Patients with moderate disease (accompanied by pneumonia) statistics CT-P59 40 mg/kg
(N=62) CT-P59 80 mg/kg
(N=63) CT-P59 Total
(N=125) placebo
(N=57) Median (95% CI) 5.73
(4.13, 7.33) 7.30
(5.58,10.72) 6.52
(5.53, 7.69) 10.81
(6.81, NC) p-value (log-rank test) 0.0261 0.2245 0.0524 p-value (Wilcoxon test) 0.0192 0.3295 0.0583 Clinical Recovery ratio (95% CI) 1.689 (1.06, 2.70) 1.347 (0.83, 2.18) 1.511
(0.99, 2.30) Patients aged 50 years or older with moderate disease (accompanied by pneumonia) statistics CT-P59 40 mg/kg
(N=40) CT-P59 80 mg/kg
(N=40) CT-P59 Total
(N=80) placebo
(N=38) Median (95% CI) 6.64
(4.13,11.94) 7.29
(5.54, 12.33) 6.79
(5.50, 10.72) 12.97
(6.81, NC) p-value (log-rank test) 0.1350 0.1893 0.1124 p-value (Wilcoxon test) 0.1015 0.2380 0.1109 Clinical Recovery ratio (95% CI) 1.584　(0.86, 2.91) 1.504　 (0.81, 2.78) 1.545
(0.90, 2.65)

Abbreviations: CI, confidence interval; N.C., not calculated

Virus Validation Results

Time until the virus is not detected in nasopharyngeal specimens analyzed by RT-qPCR until day 28

The average change (± standard error) from the baseline over time for each treatment group based on polymerase chain reaction (RT-qPCR) is shown in FIG. 11 . Over time, the mean virus concentration decreased in all groups, and the virus concentration was higher in all CT-P59 treatment groups (CT-P59 40 mg/kg, CT-P59 80 mg/kg, and CT-P59 sum) than in the placebo group. decreased rapidly.

Table 16 shows the time until the virus was not detected in the nasopharyngeal samples analyzed by RT-qPCR until the 28th day for each treatment group.

The Kaplan-Meier curve for the cumulative proportion of patients who developed negative conversion by RT-qPCR by day 28 showed that the proportion progressively increased in all groups and all CT-P59 treatment groups (CT-P59 40 mg/kg, CT-P59 80 mg/kg and CT-P59 sum) showed a steeper increase than in the placebo group.

The Kaplan-Meier curves for each treatment group are shown in FIGS. 12A, 12B and 12C.

statistics CT-P59 40 mg/kg
(N=101) CT-P59 80 mg/kg
(N=103) CT-P59 Total
(N=204) placebo
(N=103) Median (95% CI) 12.75
(9.00, 12.84) 11.89
(8.94, 12.91) 12.65
(9.03, 12.83) 12.94
(12.75, 13.99) P-value (log-rank test) 0.0483 0.1978 0.0634 P-value (Wilcoxon test) 0.0603 0.1170 0.0500 Negative Conversion Ratio (95% CI) 1.340 (1.00, 1.80) 1.215
(0.90, 1.63) 1.275
(0.99, 1.65) Threshold of negative conversion: <3 log ₁₀ cp/mL CT-P59 40 mg/kg
(N=99) CT-P59 80 mg/kg
(N=99) CT-P59 Total
(N=198) placebo
(N=101) Median (95% CI) 5.94 (5.72, 8.83) 6.08
(5.82, 8.89) 5.96
(5.85, 8.83) 8.92 (8.84,12.79) P-value (log-rank test) 0.0020 0.0716 0.0047 P-value (Wilcoxon test) 0.0022 0.0925 0.0071 Negative Conversion Ratio (95% CI) 1.599 (1.19, 2.16) 1.316 (0.98, 1.77) 1.451
(1.12, 1.88) Threshold of negative conversion: <4 log ₁₀ cp/mL CT-P59 40 mg/kg
(N=95) CT-P59 80 mg/kg
(N=94) CT-P59 Total
(N=189) placebo
(N=92) Median (95% CI) 4.03 (3.73, 4.86) 4.81
(3.97, 5.85) 4.69
(3.97, 4.9) 5.80
(4.85, 8.80) P-value (log-rank test) 0.0015 0.2747 0.0156 P-value (Wilcoxon test) 0.0058 0.1640 0.0184 Negative Conversion Ratio (95% CI) 1.642 (1.21, 2.24) 1.188 (0.87, 1.62) 1.389
(1.06, 1.81)

Abbreviation: CI, confidence interval

Average change from baseline over time based on polymerase chain reaction considering time-weighted virus concentration (in log ₁₀ cp/mL)

Table 17 shows the average virus concentration change from the baseline over time based on the polymerase chain reaction considering time-weighted on the 7th and 10th days for each treatment group.

The reduction rate of the viral exposure area in the body was also significantly higher in the CT-P59 treatment group.

statistics CT-P59 40 mg/kg
(N=101) CT-P59 80 mg/kg
(N=103) CT-P59 Total
(N=204) placebo
(N=103) Day 7 n 96 101 197 103 Least Square Mean (SE) -1.72 (0.084) -1.75 (0.082) -1.74 (0.0065) -1.33 (0.082) 95% CI -1.89, -1.56 -1.91, -1.59 -1.87, -1.61 -1.49, -1.16 Difference vs. Placebo by Day 7 Least Square Mean (SE) -0.40 (0.104) -0.43 (0.103) -0.41 (0.089) 95% CI -0.60, -0.19 -0.63, -0.22 -0.59, -0.24 P-value 0.0002 <0.0001 <0.0001 Day 10 N 96 101 197 103 Least Square Mean (SE) -2.13 (0.085) -2.21 (0.085) -2.17 (0.065) -1.78 (0.083) 95% CI -2.30, -1.96 -2.37, -2.04 -2.30, -2.04 -1.94, -1.62 Difference vs. Placebo by Day 10 Least Square Mean (SE) -0.35 (0.105) -0.43 (0.103) -0.39 (0.090) 95% CI -0.56, -0.15 -0.63, -0.22 -0.57, -0.21 P-value 0.0009 <0.0001 <0.0001

Safety Results

The number of patients who experienced one or more adverse events after administration of the investigational drug was similar in the CT-P59 treatment group and the placebo group. There were no reports of serious adverse events, death, or study discontinuation due to adverse events occurring after administration of the investigational drug. Infusion-related reactions were reported in 1 patient in the CT-P59 treatment group and 2 patients in the placebo group (Table 18). In addition, overall safety was not observed in the CT-P59 treatment group, demonstrating very good safety.

Number of patients (%) CT-P59 40 mg/kg
(N=105) CT-P59 80 mg/kg
(N=110) CT-P59 Total
(N=215) placebo
(N=110) Number of patients who experienced one or more adverse events total 31 (29.5) 27 (24.5) 58 (27.0) 34 (30.9) drug related 7 (6.7) 5 (4.5) 12 (5.6) 5 (4.5) Number of patients who experienced one or more serious adverse events total 0 0 0 0 Infusion-related reactions (IRR) Total (=drug related) 1 (1.0) 0 1 (0.5) 2 (1.8) Clinical dropout due to adverse reactions total 0 0 0 0

Example 5. SARS-Coronavirus-2 Antibody Administration in Close Contacts (Intravenous Administration) Prophylactic Efficacy, Viral Indicators, and Safety Evaluation

5-1. CT-P59 3.3 Clinical Protocol

This clinical trial is a Phase 3, randomized, placebo-controlled, double-blind, multicenter trial designed to evaluate the prophylactic efficacy, viral markers, and safety of CT-P59 in close-contact subjects of SARS-CoV-2 patients. .

Subjects must meet all of the following criteria to be enrolled in this clinical trial.

One. Male or female test subjects 18 years of age or older.

2. Persons with mild SARS-CoV-2 exposure within 6 feet (2 meters) for at least 15 minutes without wearing appropriate protective equipment (high risk exposure). The SARS-coronavirus-2 patient must satisfy all of the following conditions:

a) Those who have at least one of the symptoms of SARS-CoV-2 infection (fever, cough, shortness of breath or shortness of breath, sore throat, general pain or muscle pain, fatigue, headache) 5 days before contact with the test subject.

b) Prior to screening test subjects, confirmation should be made with a reverse transcription polymerase chain reaction (RT-PCR) specimen collected within 5 days of the onset of the patient's symptoms. Subjects must be randomized within 96 hours of the patient's positive SARS-coronavirus-2 sample collection.

3. Those who have no symptoms of SARS-coronavirus-2 infection for the past 1 month prior to treatment with the test drug, as determined by the investigator.

4. Those who have been confirmed to have no history of SARS-coronavirus-2 by rapid SARS-coronavirus-2 antibody diagnostic test.

5. Those with a weight of 50 kg or more and a body mass index of 18.0 kg/m ² or more.

6. A person who can understand and comply with the requirements and instructions of the clinical trial protocol.

7. The subject/legal representative must understand the nature and scope of this study, and consent to participate in the study, to sign a consent form prior to the study procedure.

8. Female subjects must agree to use a highly effective method of contraception in accordance with local regulations for 6 months after administration of the study drug (excluding women of infertility). Here is an example:

a) Combined or progestogen-only hormonal contraceptives, including estrogen and progestogen, in relation to ovulation suppression

b) Intrauterine device or intrauterine hormone secretion system

c) Abstinence when subjects are preferred and consistent with their usual lifestyle (e.g., date, ovulation, post-ovulation method); .

Unless permanently infertile, a woman can become pregnant from menarche to menopause. Postmenopausal women must be menstrual free for at least 12 months prior to treatment with the study drug to be classified as not fertile.

Women of childbearing potential and sexually active male subjects were tested for 6 months after administration of study drug, using the above or two methods of contraception consistent with local regulations (e.g., male/female condoms and additional hormones other than condoms by female partners). or have agreed to use a highly effective method of contraception described as a barrier contraceptive method). Contraception is not required for study subjects or their partners who have been surgically infertile 6 months prior to administration of the study drug.

In addition, subjects cannot be enrolled in this clinical trial if they meet any of the following criteria.

One. A person with a medical history and current medical condition including one or more of the following:

a) A history of suspected or confirmed bacterial, fungal, or other septic pulmonary or systemic complications or active infection requiring treatment within 30 days prior to receiving study drug treatment.

b) History of known or suspected clinical drug-related hypersensitivity reactions to components of the study drug or to monoclonal antibodies.

c) All concomitant active malignancies.

d) Current infection with documented human immunodeficiency virus, hepatitis B or hepatitis C.

e) Current disease or medical history within 28 days prior to study drug treatment, as determined by the investigator to be clinically significant.

f) Those who have a major surgery history within 28 days prior to treatment with the study drug or plan to operate during the study period.

g) Organ transplant history.

h) Those with clinically significant respiratory disease not controlled at the investigator's judgment (eg chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, asthma).

i) Those with abnormal liver function levels. At screening, serum aspartate transaminase (AST), serum alanine transaminase (ALT) or alkaline phosphatase (ALP) values are more than 3 times the upper limit of normal.

j) Persons with renal impairment (estimated glomerular filtration rate ^{less than 59 mL/min/1.73 m 2} ) or undergoing ongoing renal replacement therapy, hemodialysis, or peritoneal dialysis.

k) Presence or history of congestive heart failure with New York Heart Association Class III or IV functional status within 6 months prior to study drug treatment.

l) According to the clinical judgment of the investigator, if there is a clinically significant abnormality in the 12-lead ECG at screening, it may harm the safety of the test subject or affect the study results.

m) Those who have diabetes that is not controlled according to the judgment of the researcher.

n) Those with uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg).

o) Those who must have surgery within 7 days prior to treatment with the study drug, or have comorbidities that are considered life-threatening within 30 days.

p) Any medical condition that, in the opinion of the investigator, puts the study subject at an excessively increased risk by participating in this study, including any past or present conditions that could prevent randomization to one or more treatment groups.

2. Those who have received or have history of any of the following drugs or treatments:

a) SARS-Coronavirus-2 vaccine prior to study drug treatment.

b) Anti-SARS, including remdesivir, chloroquine, hydroxychloroquine, if not chronically used for autoimmune disease), immunosuppressants, and human immunodeficiency virus protease inhibitors prior to study drug treatment -Antiviral drugs with potential for coronavirus-2 activity.

c) All SARS-coronavirus-2 human intravenous immunoglobulin and reparative plasma therapy for the treatment of SARS-coronavirus-2 infection prior to study drug treatment.

d) Other investigational devices or medical products, including, but not limited to, mononuclear antibodies, fusion proteins, or biologics for the treatment of SARS-CoV-2 infection prior to investigational drug treatment.

e) Use of medications contraindicated in standard of care (except for potential antiviral and anti-SARS-coronavirus-2 drugs).

3. Within 6 months of treatment with the test drug, female test subjects are those who plan or are currently pregnant or breastfeed, or male test subjects are those who plan to become fathers or donate sperm

4. Those who currently abuse alcohol or drugs, or have a history of abuse within 6 months prior to treatment with the study drug.

5. A person who has reasonable evidence of a condition (mental or emotional problem, disease or treatment) that, at the discretion of the investigator, could invalidate the subject's consent, or lacks the ability to comply with the conditions required by the clinical trial protocol.

6. Persons in vulnerable circumstances (e.g., laboratory employees, individuals or immediate family members of individuals involved in conducting this clinical trial, persons incarcerated in prisons, or persons held in institutions due to law enforcement).

7. Those who may not complete the research for any reason at the discretion of the researcher.

An overview of the CT-P59 3.3 clinical trial is shown in FIG. 5 . Subjects who meet all of the above inclusion criteria but do not meet the exclusion criteria will be randomly assigned to either CT-P59 or placebo 2 treatment groups according to the randomization scheme. On Day 1, a single intravenous dose of CT-P59 or placebo is administered for 90 minutes (±15 minutes).

Patients will receive the following study medications:

Treatment group 1: CT-P59 40 mg/kg

Treatment group 2: placebo 40 mg/kg

※Note: The actual dose in this study is determined according to the results of study CT-P59 1.1.

This clinical trial consists of three clinical trial periods: screening, dosing period, and follow-up period, and it takes approximately 180 days for each test subject. All clinical trial procedures are performed at the time points indicated by X in Table 19. The evaluation designated by (X) in Table 19 is performed as needed.

Subject record items and schedule evaluation screening treatment period End of treatment follow-up period -3 to 1 One 2 4 7 10 14 (±1) 28 (±3) 90 (±5) Up to 180 days every 2 weeks
(±5) length of hospitalization X X Follow-up through wired contact X Subject consent X Demographic information, medical history, height X Selection/Exclusion Criteria X X Physical examination X X Height, weight and body mass index X X X Hepatitis B/C and Human Immunodeficiency Virus Test X blood pregnancy test X X diagnostic test X X X X X X Vital signs (blood pressure, heart rate, respiration rate, body temperature, oxygen saturation) X X X X X X X 12-lead ECG X X X radiography X X (X) randomization X CT-P59 or placebo X Standard of care (excluding potential antiviral and anti-SARS-coronavirus-2 drugs) (X) Nasopharyngeal smear collection Rapid SARS-coronavirus-2 diagnostic test X Virus titer (qPCR and cell culture) X X X X X X X Isolated SARS-coronavirus-2 genotyping analysis X (X) Rapid SARS-coronavirus-2 antibody diagnostic test X X X X Subject diary (self-assessment) X (X) SARS-Coronavirus-2 Symptoms Physician Assessment X X X X X X X X immunogenic blood draw X X X Immediate hypersensitivity monitoring X disease status monitoring X concomitant drug X adverse reaction X

This clinical trial is designed to demonstrate the prophylactic efficacy of CT-P59 compared to placebo. Evaluate the proportion of clinical SARS-coronavirus-2 infected subjects of diagnostic test confirmation by day 14.

Confirmation of diagnostic test means positive qPCR and cell culture test results, and clinical infection means that any symptoms included in the SARS-COVID-19 infection symptom checklist must be recorded other than the 'none' stage. Symptoms included in the SARS-COVID-19 infection checklist are 'fever, cough, shortness of breath, sore throat, body or muscle aches, fatigue and headache'.

<110> CELLTRION, INC. <120> Dosage Regimen For Preventing Or Treating COVID-19 <130> CPD2021001KR <150> KR 10-2020-0089231 <151> 2020-07-17 <150> KR 10-2020-0145587 <151> 2020-11-03 <150> KR 10-2020-0185224 <151> 2020-12-28 <160> 2320 <170> KoPatentIn 3.0 <210> 1 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 1 LC CDR1 <400> 1 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 2 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 1 LC CDR2 <400> 2 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 3 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No. 1 LC CDR3 <400> 3 Gln Gln Ser Tyr Ser Thr Pro Phe Thr 1 5 <210> 4 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 1 HC CDR1 <400> 4 Asp Tyr Ala Met His 1 5 <210> 5 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 1 HC CDR2 <400> 5 Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 6 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 1 HC CDR3 <400> 6 Gly Asp Cys Gly Gly Asp Cys Tyr Ser Phe Leu Leu Gly Glu Asp Ala 1 5 10 15 Phe Asp Ile <210> 7 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 2 LC CDR1 <400> 7 Arg Ala Ser Gln Ser Ile Ser Thr Tyr Leu Asn 1 5 10 <210> 8 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 2 LC CDR2 <400> 8 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 9 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No. 2 LC CDR3 <400> 9 Gln Gln Ser Tyr Ser Ile Pro His Thr 1 5 <210> 10 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 2 HC CDR1 <400> 10 Asp Tyr Ala Met His 1 5 <210> 11 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 2 HC CDR2 <400> 11 Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 12 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 2 HC CDR3 <400> 12 Gly Asp Cys Gly Gly Asp Cys Tyr Ser Phe Leu Leu Gly Glu Asp Ala 1 5 10 15 Phe Asp Ile <210> 13 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 3 LC CDR1 <400> 13 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 14 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 3 LC CDR2 <400> 14 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 15 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No. 3 LC CDR3 <400> 15 Gln Gln Tyr Asp Asn Leu Pro Ile Thr 1 5 <210> 16 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 3 HC CDR1 <400> 16 Ser Tyr Ala Met Ser 1 5 <210> 17 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 3 HC CDR2 <400> 17 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 18 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 3 HC CDR3 <400> 18 Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp 1 5 10 15 Phe Asp Pro <210> 19 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 4 LC CDR1 <400> 19 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 20 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 4 LC CDR2 <400> 20 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 21 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No. 4 LC CDR3 <400> 21 Gln Gln Tyr Asp Asp Leu Pro Ile Thr 1 5 <210> 22 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 4 HC CDR1 <400> 22 Ser Tyr Ala Met Ser 1 5 <210> 23 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 4 HC CDR2 <400> 23 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 24 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 4 HC CDR3 <400> 24 Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp 1 5 10 15 Phe Asp Pro <210> 25 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 5 LC CDR1 <400> 25 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 26 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 5 LC CDR2 <400> 26 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 27 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No. 5 LC CDR3 <400> 27 Gln Gln Tyr Asp Asn Leu Pro Ile Thr 1 5 <210> 28 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 5 HC CDR1 <400> 28 Ser Tyr Ala Met Ser 1 5 <210> 29 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 5 HC CDR2 <400> 29 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 30 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 5 HC CDR3 <400> 30 Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr Ser Trp 1 5 10 15 Phe Asp Pro <210> 31 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 6 LC CDR1 <400> 31 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 32 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 6 LC CDR2 <400> 32 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 33 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 6 LC CDR3 <400> 33 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 34 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 6 HC CDR1 <400> 34 Ser Tyr Ala Ile Ser 1 5 <210> 35 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 6 HC CDR2 <400> 35 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 36 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 6 HC CDR3 <400> 36 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 37 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 7 LC CDR1 <400> 37 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 38 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 7 LC CDR2 <400> 38 Arg Asn Asn Gln Arg Pro Pro 1 5 <210> 39 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 7 LC CDR3 <400> 39 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 40 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 7 HC CDR1 <400> 40 Ser Tyr Ala Ile Ser 1 5 <210> 41 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 7 HC CDR2 <400> 41 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 42 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 7 HC CDR3 <400> 42 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 43 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.8 LC CDR1 <400> 43 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 44 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.8 LC CDR2 <400> 44 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 45 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.8 LC CDR3 <400> 45 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 46 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.8 HC CDR1 <400> 46 Ser Tyr Ala Ile Ser 1 5 <210> 47 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.8 HC CDR2 <400> 47 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 48 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.8 HC CDR3 <400> 48 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 49 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 9 LC CDR1 <400> 49 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 50 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 9 LC CDR2 <400> 50 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 51 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 9 LC CDR3 <400> 51 Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val 1 5 10 <210> 52 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 9 HC CDR1 <400> 52 Ser Tyr Ala Ile Ser 1 5 <210> 53 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 9 HC CDR2 <400> 53 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 54 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 9 HC CDR3 <400> 54 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 55 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.10 LC CDR1 <400> 55 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 56 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.10 LC CDR2 <400> 56 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 57 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.10 LC CDR3 <400> 57 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 58 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.10 HC CDR1 <400> 58 Ser Tyr Ala Ile Ser 1 5 <210> 59 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.10 HC CDR2 <400> 59 Gly Ile Ile Pro Ile Phe Gly Thr Glu Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 60 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.10 HC CDR3 <400> 60 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 61 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 11 LC CDR1 <400> 61 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 62 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 11 LC CDR2 <400> 62 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 63 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 11 LC CDR3 <400> 63 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 64 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 11 HC CDR1 <400> 64 Ser Tyr Ala Ile Ser 1 5 <210> 65 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 11 HC CDR2 <400> 65 Gly Ile Ile Pro Ile Phe Gly Thr Glu Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 66 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 11 HC CDR3 <400> 66 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 67 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.12 LC CDR1 <400> 67 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 68 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 12 LC CDR2 <400> 68 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 69 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 12 LC CDR3 <400> 69 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 70 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 12 HC CDR1 <400> 70 Ser Tyr Ala Ile Ser 1 5 <210> 71 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 12 HC CDR2 <400> 71 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 72 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.12 HC CDR3 <400> 72 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 73 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 13 LC CDR1 <400> 73 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Tyr 1 5 10 <210> 74 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 13 LC CDR2 <400> 74 Gly Asn Tyr Gln Arg Pro Ser 1 5 <210> 75 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 13 LC CDR3 <400> 75 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 76 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 13 HC CDR1 <400> 76 Ser Tyr Ala Ile Ser 1 5 <210> 77 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 13 HC CDR2 <400> 77 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 78 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 13 HC CDR3 <400> 78 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 79 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 14 LC CDR1 <400> 79 Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val His 1 5 10 <210> 80 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 14 LC CDR2 <400> 80 Ser Asn Asp Gln Arg Pro Ser 1 5 <210> 81 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 14 LC CDR3 <400> 81 Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val 1 5 10 <210> 82 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 14 HC CDR1 <400> 82 Ser Tyr Ala Ile Ser 1 5 <210> 83 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 14 HC CDR2 <400> 83 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 84 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 14 HC CDR3 <400> 84 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 85 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.15 LC CDR1 <400> 85 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 86 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.15 LC CDR2 <400> 86 Arg Asn Asn Gln Arg Pro Pro 1 5 <210> 87 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 15 LC CDR3 <400> 87 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 88 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 15 HC CDR1 <400> 88 Ser Tyr Ala Ile Ser 1 5 <210> 89 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.15 HC CDR2 <400> 89 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 90 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.15 HC CDR3 <400> 90 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 91 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.16 LC CDR1 <400> 91 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 92 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.16 LC CDR2 <400> 92 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 93 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.16 LC CDR3 <400> 93 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 94 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.16 HC CDR1 <400> 94 Ser Tyr Ala Ile Ser 1 5 <210> 95 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.16 HC CDR2 <400> 95 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 96 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.16 HC CDR3 <400> 96 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 97 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.17 LC CDR1 <400> 97 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 98 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.17 LC CDR2 <400> 98 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 99 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.17 LC CDR3 <400> 99 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 100 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.17 HC CDR1 <400> 100 Ser Tyr Ala Ile Ser 1 5 <210> 101 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.17 HC CDR2 <400> 101 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 102 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.17 HC CDR3 <400> 102 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 103 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No. 18 LC CDR1 <400> 103 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 104 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 18 LC CDR2 <400> 104 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 105 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.18 LC CDR3 <400> 105 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Lys Val 1 5 10 <210> 106 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 18 HC CDR1 <400> 106 Ser Tyr Ala Ile Ser 1 5 <210> 107 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.18 HC CDR2 <400> 107 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 108 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 18 HC CDR3 <400> 108 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 109 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.19 LC CDR1 <400> 109 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 110 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.19 LC CDR2 <400> 110 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 111 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.19 LC CDR3 <400> 111 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 112 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 19 HC CDR1 <400> 112 Ser Tyr Ala Ile Ser 1 5 <210> 113 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 19 HC CDR2 <400> 113 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 114 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 19 HC CDR3 <400> 114 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 115 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 20 LC CDR1 <400> 115 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 116 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 20 LC CDR2 <400> 116 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 117 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 20 LC CDR3 <400> 117 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 118 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 20 HC CDR1 <400> 118 Ser Tyr Ala Ile Ser 1 5 <210> 119 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 20 HC CDR2 <400> 119 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 120 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 20 HC CDR3 <400> 120 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 121 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.21 LC CDR1 <400> 121 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 122 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.21 LC CDR2 <400> 122 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 123 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.21 LC CDR3 <400> 123 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 124 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.21 HC CDR1 <400> 124 Ser Tyr Ala Ile Ser 1 5 <210> 125 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.21 HC CDR2 <400> 125 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 126 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.21 HC CDR3 <400> 126 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 127 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 22 LC CDR1 <400> 127 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 128 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 22 LC CDR2 <400> 128 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 129 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.22 LC CDR3 <400> 129 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 130 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.22 HC CDR1 <400> 130 Ser Tyr Ala Ile Ser 1 5 <210> 131 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 22 HC CDR2 <400> 131 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 132 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 22 HC CDR3 <400> 132 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 133 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.23 LC CDR1 <400> 133 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 134 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.23 LC CDR2 <400> 134 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 135 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.23 LC CDR3 <400> 135 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 136 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 23 HC CDR1 <400> 136 Ser Tyr Ala Ile Ser 1 5 <210> 137 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.23 HC CDR2 <400> 137 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 138 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.23 HC CDR3 <400> 138 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 139 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 24 LC CDR1 <400> 139 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 140 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 24 LC CDR2 <400> 140 Arg Asn Asn Gln Arg Pro Pro 1 5 <210> 141 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 24 LC CDR3 <400> 141 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 142 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 24 HC CDR1 <400> 142 Ser Tyr Ala Ile Ser 1 5 <210> 143 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 24 HC CDR2 <400> 143 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 144 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 24 HC CDR3 <400> 144 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 145 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.25 LC CDR1 <400> 145 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 146 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.25 LC CDR2 <400> 146 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 147 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.25 LC CDR3 <400> 147 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 148 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.25 HC CDR1 <400> 148 Ser Tyr Ala Ile Ser 1 5 <210> 149 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.25 HC CDR2 <400> 149 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 150 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.25 HC CDR3 <400> 150 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 151 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.26 LC CDR1 <400> 151 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 152 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.26 LC CDR2 <400> 152 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 153 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.26 LC CDR3 <400> 153 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 154 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.26 HC CDR1 <400> 154 Ser Tyr Ala Ile Ser 1 5 <210> 155 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.26 HC CDR2 <400> 155 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 156 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.26 HC CDR3 <400> 156 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 157 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.27 LC CDR1 <400> 157 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 158 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.27 LC CDR2 <400> 158 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 159 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.27 LC CDR3 <400> 159 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 160 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.27 HC CDR1 <400> 160 Ser Tyr Ala Ile Ser 1 5 <210> 161 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.27 HC CDR2 <400> 161 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 162 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.27 HC CDR3 <400> 162 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 163 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.28 LC CDR1 <400> 163 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 164 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.28 LC CDR2 <400> 164 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 165 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.28 LC CDR3 <400> 165 Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val 1 5 10 <210> 166 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.28 HC CDR1 <400> 166 Ser Tyr Ala Ile Ser 1 5 <210> 167 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.28 HC CDR2 <400> 167 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 168 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.28 HC CDR3 <400> 168 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 169 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.29 LC CDR1 <400> 169 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 170 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.29 LC CDR2 <400> 170 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 171 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.29 LC CDR3 <400> 171 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 172 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.29 HC CDR1 <400> 172 Ser Tyr Ala Ile Ser 1 5 <210> 173 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.29 HC CDR2 <400> 173 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 174 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.29 HC CDR3 <400> 174 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 175 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 30 LC CDR1 <400> 175 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 176 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 30 LC CDR2 <400> 176 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 177 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 30 LC CDR3 <400> 177 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 178 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 30 HC CDR1 <400> 178 Ser Tyr Ala Ile Ser 1 5 <210> 179 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 30 HC CDR2 <400> 179 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 180 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 30 HC CDR3 <400> 180 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 181 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 31 LC CDR1 <400> 181 Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn Tyr Val His 1 5 10 <210> 182 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 31 LC CDR2 <400> 182 Ser Asn Asp Gln Arg Pro Ser 1 5 <210> 183 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 31 LC CDR3 <400> 183 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 184 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 31 HC CDR1 <400> 184 Ser Tyr Ala Ile Ser 1 5 <210> 185 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 31 HC CDR2 <400> 185 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 186 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 31 HC CDR3 <400> 186 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 187 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.32 LC CDR1 <400> 187 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 188 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.32 LC CDR2 <400> 188 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 189 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.32 LC CDR3 <400> 189 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 190 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.32 HC CDR1 <400> 190 Ser Tyr Ala Ile Ser 1 5 <210> 191 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.32 HC CDR2 <400> 191 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 192 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.32 HC CDR3 <400> 192 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 193 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.33 LC CDR1 <400> 193 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 194 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.33 LC CDR2 <400> 194 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 195 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.33 LC CDR3 <400> 195 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 196 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.33 HC CDR1 <400> 196 Ser Tyr Ala Ile Ser 1 5 <210> 197 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.33 HC CDR2 <400> 197 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 198 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.33 HC CDR3 <400> 198 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 199 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.34 LC CDR1 <400> 199 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 200 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.34 LC CDR2 <400> 200 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 201 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.34 LC CDR3 <400> 201 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 202 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.34 HC CDR1 <400> 202 Ser Tyr Ala Ile Ser 1 5 <210> 203 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.34 HC CDR2 <400> 203 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 204 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.34 HC CDR3 <400> 204 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 205 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.35 LC CDR1 <400> 205 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 206 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.35 LC CDR2 <400> 206 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 207 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.35 LC CDR3 <400> 207 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 208 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.35 HC CDR1 <400> 208 Ser Tyr Ala Ile Ser 1 5 <210> 209 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.35 HC CDR2 <400> 209 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 210 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.35 HC CDR3 <400> 210 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 211 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.36 LC CDR1 <400> 211 Ser Gly Gly Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 212 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.36 LC CDR2 <400> 212 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 213 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.36 LC CDR3 <400> 213 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 214 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.36 HC CDR1 <400> 214 Ser Tyr Ala Ile Ser 1 5 <210> 215 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.36 HC CDR2 <400> 215 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 216 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.36 HC CDR3 <400> 216 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 217 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.37 LC CDR1 <400> 217 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 218 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.37 LC CDR2 <400> 218 Arg Asn Asn Gln Arg Pro Pro 1 5 <210> 219 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.37 LC CDR3 <400> 219 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 220 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.37 HC CDR1 <400> 220 Ser Tyr Ala Ile Ser 1 5 <210> 221 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.37 HC CDR2 <400> 221 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 222 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.37 HC CDR3 <400> 222 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 223 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.38 LC CDR1 <400> 223 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 224 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.38 LC CDR2 <400> 224 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 225 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.38 LC CDR3 <400> 225 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 226 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 38 HC CDR1 <400> 226 Ser Tyr Ala Ile Ser 1 5 <210> 227 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.38 HC CDR2 <400> 227 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 228 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.38 HC CDR3 <400> 228 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 229 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.39 LC CDR1 <400> 229 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 230 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.39 LC CDR2 <400> 230 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 231 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.39 LC CDR3 <400> 231 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 232 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.39 HC CDR1 <400> 232 Ser Tyr Ala Ile Ser 1 5 <210> 233 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.39 HC CDR2 <400> 233 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 234 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.39 HC CDR3 <400> 234 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 235 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 40 LC CDR1 <400> 235 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 236 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.40 LC CDR2 <400> 236 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 237 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.40 LC CDR3 <400> 237 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 238 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 40 HC CDR1 <400> 238 Ser Tyr Ala Ile Ser 1 5 <210> 239 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 40 HC CDR2 <400> 239 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 240 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No. 40 HC CDR3 <400> 240 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 241 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.41 LC CDR1 <400> 241 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 242 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.41 LC CDR2 <400> 242 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 243 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.41 LC CDR3 <400> 243 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 244 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.41 HC CDR1 <400> 244 Ser Tyr Ala Ile Ser 1 5 <210> 245 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.41 HC CDR2 <400> 245 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 246 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.41 HC CDR3 <400> 246 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 247 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.42 LC CDR1 <400> 247 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 248 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.42 LC CDR2 <400> 248 Arg Asn Asn Gln Arg Pro Ser 1 5 <210> 249 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.42 LC CDR3 <400> 249 Ala Ala Trp Asp Asp Ser Leu Ser Gly Lys Val 1 5 10 <210> 250 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.42 HC CDR1 <400> 250 Ser Tyr Ala Ile Ser 1 5 <210> 251 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.42 HC CDR2 <400> 251 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Asp <210> 252 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.42 HC CDR3 <400> 252 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 253 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.43 LC CDR1 <400> 253 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr 1 5 10 <210> 254 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.43 LC CDR2 <400> 254 Arg Asn Asn Gln Arg Pro Pro 1 5 <210> 255 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.43 LC CDR3 <400> 255 Ala Ala Trp Asp Asp Ser Leu Ser Gly Arg Val 1 5 10 <210> 256 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.43 HC CDR1 <400> 256 Ser Tyr Ala Ile Ser 1 5 <210> 257 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.43 HC CDR2 <400> 257 Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 258 <211> 22 <212> PRT <213> Artificial Sequence <220> <223> No.43 HC CDR3 <400> 258 Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp Pro Tyr 1 5 10 15 Tyr Tyr Gly Met Asp Val 20 <210> 259 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.44 LC CDR1 <400> 259 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 260 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.44 LC CDR2 <400> 260 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 261 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.44 LC CDR3 <400> 261 Gln Gln Tyr Val Thr Thr Pro Tyr Thr 1 5 <210> 262 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.44 HC CDR1 <400> 262 Arg Ser Ser Tyr Tyr Trp Gly 1 5 <210> 263 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.44 HC CDR2 <400> 263 Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 264 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.44 HC CDR3 <400> 264 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 265 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.45 LC CDR1 <400> 265 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 266 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.45 LC CDR2 <400> 266 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 267 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.45 LC CDR3 <400> 267 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 268 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.45 HC CDR1 <400> 268 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 269 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.45 HC CDR2 <400> 269 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 270 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.45 HC CDR3 <400> 270 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 271 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.46 LC CDR1 <400> 271 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 272 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.46 LC CDR2 <400> 272 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 273 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.46 LC CDR3 <400> 273 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 274 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.46 HC CDR1 <400> 274 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 275 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.46 HC CDR2 <400> 275 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 276 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.46 HC CDR3 <400> 276 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 277 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.47 LC CDR1 <400> 277 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 278 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.47 LC CDR2 <400> 278 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 279 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.47 LC CDR3 <400> 279 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 280 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.47 HC CDR1 <400> 280 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 281 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.47 HC CDR2 <400> 281 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 282 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.47 HC CDR3 <400> 282 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 283 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.48 LC CDR1 <400> 283 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 284 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.48 LC CDR2 <400> 284 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 285 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.48 LC CDR3 <400> 285 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 286 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.48 HC CDR1 <400> 286 His Tyr Phe Trp Ser 1 5 <210> 287 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.48 HC CDR2 <400> 287 Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 288 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.48 HC CDR3 <400> 288 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 289 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No. 49 LC CDR1 <400> 289 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 290 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 49 LC CDR2 <400> 290 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 291 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No. 49 LC CDR3 <400> 291 Ser Ser Tyr Thr Ser Ser Ser Thr Val Val 1 5 10 <210> 292 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 49 HC CDR1 <400> 292 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 293 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 49 HC CDR2 <400> 293 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 294 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 49 HC CDR3 <400> 294 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 295 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.50 LC CDR1 <400> 295 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 296 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.50 LC CDR2 <400> 296 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 297 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.50 LC CDR3 <400> 297 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 298 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.50 HC CDR1 <400> 298 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 299 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.50 HC CDR2 <400> 299 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 300 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.50 HC CDR3 <400> 300 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 301 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.51 LC CDR1 <400> 301 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 302 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.51 LC CDR2 <400> 302 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 303 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.51 LC CDR3 <400> 303 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 304 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.51 HC CDR1 <400> 304 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 305 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.51 HC CDR2 <400> 305 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 306 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.51 HC CDR3 <400> 306 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 307 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No. 52 LC CDR1 <400> 307 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 308 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.52 LC CDR2 <400> 308 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 309 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.52 LC CDR3 <400> 309 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 310 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 52 HC CDR1 <400> 310 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 311 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.52 HC CDR2 <400> 311 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 312 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.52 HC CDR3 <400> 312 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 313 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.53 LC CDR1 <400> 313 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 314 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.53 LC CDR2 <400> 314 Gly Gly Ser Ser Arg Ala Thr 1 5 <210> 315 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.53 LC CDR3 <400> 315 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 316 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.53 HC CDR1 <400> 316 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 317 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.53 HC CDR2 <400> 317 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 318 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.53 HC CDR3 <400> 318 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 319 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.54 LC CDR1 <400> 319 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 320 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.54 LC CDR2 <400> 320 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 321 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.54 LC CDR3 <400> 321 Ser Ser Tyr Thr Ser Ser Ser Thr His Val 1 5 10 <210> 322 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.54 HC CDR1 <400> 322 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 323 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.54 HC CDR2 <400> 323 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 324 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.54 HC CDR3 <400> 324 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 325 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.55 LC CDR1 <400> 325 Arg Ala Ser Gln Ser Val Ser Thr Tyr Leu Ala 1 5 10 <210> 326 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.55 LC CDR2 <400> 326 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 327 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.55 LC CDR3 <400> 327 Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr 1 5 10 <210> 328 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.55 HC CDR1 <400> 328 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 329 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.55 HC CDR2 <400> 329 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 330 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.55 HC CDR3 <400> 330 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 331 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.56 LC CDR1 <400> 331 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 332 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.56 LC CDR2 <400> 332 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 333 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.56 LC CDR3 <400> 333 Gln Glu Tyr Gly Ser Ser Pro Gly Arg Val Thr 1 5 10 <210> 334 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.56 HC CDR1 <400> 334 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 335 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.56 HC CDR2 <400> 335 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 336 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.56 HC CDR3 <400> 336 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 337 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.57 LC CDR1 <400> 337 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 338 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.57 LC CDR2 <400> 338 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 339 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No. 57 LC CDR3 <400> 339 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 340 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.57 HC CDR1 <400> 340 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 341 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.57 HC CDR2 <400> 341 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 342 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 57 HC CDR3 <400> 342 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 343 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.58 LC CDR1 <400> 343 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 344 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 58 LC CDR2 <400> 344 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 345 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.58 LC CDR3 <400> 345 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 346 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 58 HC CDR1 <400> 346 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 347 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 58 HC CDR2 <400> 347 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 348 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 58 HC CDR3 <400> 348 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 349 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.59 LC CDR1 <400> 349 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 350 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.59 LC CDR2 <400> 350 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 351 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.59 LC CDR3 <400> 351 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 352 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.59 HC CDR1 <400> 352 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 353 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.59 HC CDR2 <400> 353 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 354 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.59 HC CDR3 <400> 354 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 355 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.60 LC CDR1 <400> 355 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 356 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.60 LC CDR2 <400> 356 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 357 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.60 LC CDR3 <400> 357 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 358 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 60 HC CDR1 <400> 358 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 359 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.60 HC CDR2 <400> 359 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 360 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.60 HC CDR3 <400> 360 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 361 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.61 LC CDR1 <400> 361 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 362 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.61 LC CDR2 <400> 362 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 363 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.61 LC CDR3 <400> 363 Gln Gln Tyr Tyr Ser Thr Pro Ser Ile Thr 1 5 10 <210> 364 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.61 HC CDR1 <400> 364 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 365 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.61 HC CDR2 <400> 365 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 366 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.61 HC CDR3 <400> 366 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 367 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.62 LC CDR1 <400> 367 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 368 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.62 LC CDR2 <400> 368 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 369 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.62 LC CDR3 <400> 369 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 370 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.62 HC CDR1 <400> 370 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 371 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.62 HC CDR2 <400> 371 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 372 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.62 HC CDR3 <400> 372 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 373 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.63 LC CDR1 <400> 373 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 374 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.63 LC CDR2 <400> 374 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 375 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.63 LC CDR3 <400> 375 Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val 1 5 10 <210> 376 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.63 HC CDR1 <400> 376 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 377 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.63 HC CDR2 <400> 377 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 378 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.63 HC CDR3 <400> 378 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 379 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.64 LC CDR1 <400> 379 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 380 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.64 LC CDR2 <400> 380 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 381 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.64 LC CDR3 <400> 381 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 382 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.64 HC CDR1 <400> 382 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 383 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.64 HC CDR2 <400> 383 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 384 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.64 HC CDR3 <400> 384 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 385 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.65 LC CDR1 <400> 385 Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala 1 5 10 <210> 386 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.65 LC CDR2 <400> 386 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 387 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.65 LC CDR3 <400> 387 Gln Glu Tyr Gly Ser Ser Pro Gly Arg Val Thr 1 5 10 <210> 388 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.65 HC CDR1 <400> 388 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 389 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.65 HC CDR2 <400> 389 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 390 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.65 HC CDR3 <400> 390 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 391 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.66 LC CDR1 <400> 391 Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala 1 5 10 <210> 392 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.66 LC CDR2 <400> 392 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 393 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.66 LC CDR3 <400> 393 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 394 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.66 HC CDR1 <400> 394 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 395 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.66 HC CDR2 <400> 395 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 396 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.66 HC CDR3 <400> 396 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 397 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.67 LC CDR1 <400> 397 Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala 1 5 10 <210> 398 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.67 LC CDR2 <400> 398 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 399 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.67 LC CDR3 <400> 399 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 400 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.67 HC CDR1 <400> 400 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 401 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.67 HC CDR2 <400> 401 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 402 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.67 HC CDR3 <400> 402 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 403 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.68 LC CDR1 <400> 403 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 404 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.68 LC CDR2 <400> 404 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 405 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.68 LC CDR3 <400> 405 Gln Glu Tyr Gly Ser Ser Pro Gly Arg Val Thr 1 5 10 <210> 406 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.68 HC CDR1 <400> 406 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 407 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.68 HC CDR2 <400> 407 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 408 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.68 HC CDR3 <400> 408 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 409 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.69 LC CDR1 <400> 409 Arg Ala Ser Gln Ser Val Arg Ser Ser Tyr Leu Ala 1 5 10 <210> 410 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.69 LC CDR2 <400> 410 Ala Ala Ser Thr Arg Ala Thr 1 5 <210> 411 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.69 LC CDR3 <400> 411 Gln Gln Tyr Gly Asp Ser Leu Ser Ile Thr 1 5 10 <210> 412 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.69 HC CDR1 <400> 412 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 413 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.69 HC CDR2 <400> 413 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 414 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.69 HC CDR3 <400> 414 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 415 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.70 LC CDR1 <400> 415 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 416 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.70 LC CDR2 <400> 416 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 417 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No. 70 LC CDR3 <400> 417 Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr 1 5 10 <210> 418 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 70 HC CDR1 <400> 418 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 419 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 70 HC CDR2 <400> 419 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 420 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No. 70 HC CDR3 <400> 420 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 421 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.71 LC CDR1 <400> 421 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala 1 5 10 <210> 422 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.71 LC CDR2 <400> 422 Asp Ala Ser Thr Arg Ala Thr 1 5 <210> 423 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.71 LC CDR3 <400> 423 Gln Gln Tyr Asn Asn Trp Pro Leu Thr 1 5 <210> 424 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.71 HC CDR1 <400> 424 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 425 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.71 HC CDR2 <400> 425 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 426 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.71 HC CDR3 <400> 426 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 427 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.72 LC CDR1 <400> 427 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Tyr Val Ser 1 5 10 <210> 428 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.72 LC CDR2 <400> 428 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 429 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.72 LC CDR3 <400> 429 Ser Ser Tyr Thr Ser Ser Ser Thr Leu Pro 1 5 10 <210> 430 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.72 HC CDR1 <400> 430 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 431 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.72 HC CDR2 <400> 431 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 432 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.72 HC CDR3 <400> 432 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 433 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.73 LC CDR1 <400> 433 Arg Ala Ser Gln Ser Val Ser Ser Ser Phe Leu Ala 1 5 10 <210> 434 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.73 LC CDR2 <400> 434 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 435 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.73 LC CDR3 <400> 435 Gln Glu Tyr Gly Ser Ser Pro Gly Arg Val Thr 1 5 10 <210> 436 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.73 HC CDR1 <400> 436 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 437 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.73 HC CDR2 <400> 437 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 438 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.73 HC CDR3 <400> 438 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 439 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.74 LC CDR1 <400> 439 Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala 1 5 10 <210> 440 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.74 LC CDR2 <400> 440 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 441 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.74 LC CDR3 <400> 441 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 442 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.74 HC CDR1 <400> 442 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 443 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.74 HC CDR2 <400> 443 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 444 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.74 HC CDR3 <400> 444 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 445 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.75 LC CDR1 <400> 445 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 446 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.75 LC CDR2 <400> 446 Gly Ala Ser Ser Arg Ala Thr 1 5 <210> 447 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.75 LC CDR3 <400> 447 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 448 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.75 HC CDR1 <400> 448 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 449 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.75 HC CDR2 <400> 449 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 450 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.75 HC CDR3 <400> 450 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 451 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.76 LC CDR1 <400> 451 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 452 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.76 LC CDR2 <400> 452 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 453 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.76 LC CDR3 <400> 453 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 454 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.76 HC CDR1 <400> 454 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 455 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.76 HC CDR2 <400> 455 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 456 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.76 HC CDR3 <400> 456 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 457 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.77 LC CDR1 <400> 457 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala 1 5 10 <210> 458 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.77 LC CDR2 <400> 458 Asp Ala Ser Thr Arg Ala Thr 1 5 <210> 459 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.77 LC CDR3 <400> 459 Gln Gln Tyr Asn Asn Trp Pro Leu Thr 1 5 <210> 460 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.77 HC CDR1 <400> 460 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 461 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.77 HC CDR2 <400> 461 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 462 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.77 HC CDR3 <400> 462 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 463 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> No.78 LC CDR1 <400> 463 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala 1 5 10 <210> 464 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.78 LC CDR2 <400> 464 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 465 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.78 LC CDR3 <400> 465 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 466 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.78 HC CDR1 <400> 466 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 467 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.78 HC CDR2 <400> 467 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 468 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.78 HC CDR3 <400> 468 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 469 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.79 LC CDR1 <400> 469 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 470 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.79 LC CDR2 <400> 470 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 471 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.79 LC CDR3 <400> 471 Gln Gln Tyr Tyr Ser Thr Pro Ser Ile Thr 1 5 10 <210> 472 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.79 HC CDR1 <400> 472 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 473 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.79 HC CDR2 <400> 473 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 474 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.79 HC CDR3 <400> 474 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 475 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.80 LC CDR1 <400> 475 Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala 1 5 10 <210> 476 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.80 LC CDR2 <400> 476 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 477 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.80 LC CDR3 <400> 477 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 478 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.80 HC CDR1 <400> 478 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 479 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.80 HC CDR2 <400> 479 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 480 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.80 HC CDR3 <400> 480 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 481 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.81 LC CDR1 <400> 481 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 482 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.81 LC CDR2 <400> 482 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 483 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.81 LC CDR3 <400> 483 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 484 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.81 HC CDR1 <400> 484 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 485 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.81 HC CDR2 <400> 485 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 486 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.81 HC CDR3 <400> 486 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 487 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.82 LC CDR1 <400> 487 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 488 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.82 LC CDR2 <400> 488 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 489 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.82 LC CDR3 <400> 489 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 490 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.82 HC CDR1 <400> 490 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 491 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.82 HC CDR2 <400> 491 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 492 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.82 HC CDR3 <400> 492 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 493 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.83 LC CDR1 <400> 493 Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala 1 5 10 <210> 494 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.83 LC CDR2 <400> 494 Gly Ala Ser Thr Arg Ala Thr 1 5 <210> 495 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.83 LC CDR3 <400> 495 Gln Gln Tyr Asn Asn Trp Pro Leu Thr 1 5 <210> 496 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.83 HC CDR1 <400> 496 Gly Ser Ser Tyr Tyr Trp Gly 1 5 <210> 497 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.83 HC CDR2 <400> 497 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 498 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.83 HC CDR3 <400> 498 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 499 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.84 LC CDR1 <400> 499 Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser 1 5 10 <210> 500 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.84 LC CDR2 <400> 500 Asp Val Ser Asn Arg Pro Ser 1 5 <210> 501 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.84 LC CDR3 <400> 501 Ser Ser Tyr Thr Ser Ser Ser Thr Trp Val 1 5 10 <210> 502 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.84 HC CDR1 <400> 502 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 503 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.84 HC CDR2 <400> 503 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 504 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.84 HC CDR3 <400> 504 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 505 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.85 LC CDR1 <400> 505 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Ala 1 5 10 <210> 506 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.85 LC CDR2 <400> 506 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 507 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.85 LC CDR3 <400> 507 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 508 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.85 HC CDR1 <400> 508 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 509 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.85 HC CDR2 <400> 509 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 510 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.85 HC CDR3 <400> 510 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 511 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.86 LC CDR1 <400> 511 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 512 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.86 LC CDR2 <400> 512 Asp Ala Ser Ser Arg Ala Thr 1 5 <210> 513 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.86 LC CDR3 <400> 513 Gln Gln Tyr Gly Ser Ser Pro Tyr Thr 1 5 <210> 514 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.86 HC CDR1 <400> 514 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 515 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.86 HC CDR2 <400> 515 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 516 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.86 HC CDR3 <400> 516 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 517 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.87 LC CDR1 <400> 517 Arg Ala Ser Gln Ser Val Ser Asn Tyr Leu Ala 1 5 10 <210> 518 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.87 LC CDR2 <400> 518 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 519 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.87 LC CDR3 <400> 519 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 520 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.87 HC CDR1 <400> 520 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 521 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.87 HC CDR2 <400> 521 Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 522 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.87 HC CDR3 <400> 522 Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 523 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.88 LC CDR1 <400> 523 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 524 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.88 LC CDR2 <400> 524 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 525 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.88 LC CDR3 <400> 525 Gln Gln Tyr Gly Ser Ser Pro Ser Ile Thr 1 5 10 <210> 526 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.88 HC CDR1 <400> 526 Ser Ser Ser Tyr Tyr Trp Gly 1 5 <210> 527 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.88 HC CDR2 <400> 527 Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <210> 528 <211> 19 <212> PRT <213> Artificial Sequence <220> <223> No.88 HC CDR3 <400> 528 Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser Thr Gly Gly 1 5 10 15 Phe Asp Tyr <210> 529 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.89 LC CDR1 <400> 529 Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn Tyr Val Ser 1 5 10 <210> 530 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.89 LC CDR2 <400> 530 Asp Asn Asp Lys Arg Pro Ser 1 5 <210> 531 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.89 LC CDR3 <400> 531 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 532 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.89 HC CDR1 <400> 532 Thr Ser Gly Met Gly Val Gly 1 5 <210> 533 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.89 HC CDR2 <400> 533 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 534 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.89 HC CDR3 <400> 534 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 535 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.90 LC CDR1 <400> 535 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 536 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.90 LC CDR2 <400> 536 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 537 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.90 LC CDR3 <400> 537 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 538 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.90 HC CDR1 <400> 538 Thr Ser Gly Met Gly Val Gly 1 5 <210> 539 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.90 HC CDR2 <400> 539 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 540 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.90 HC CDR3 <400> 540 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 541 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.91 LC CDR1 <400> 541 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 542 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.91 LC CDR2 <400> 542 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 543 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.91 LC CDR3 <400> 543 Gly Thr Trp Asp Asn Ser Leu Ser Ala Gly Val 1 5 10 <210> 544 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.91 HC CDR1 <400> 544 Thr Ser Gly Val Gly Val Gly 1 5 <210> 545 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.91 HC CDR2 <400> 545 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 546 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.91 HC CDR3 <400> 546 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 547 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.92 LC CDR1 <400> 547 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 548 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.92 LC CDR2 <400> 548 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 549 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.92 LC CDR3 <400> 549 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 550 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.92 HC CDR1 <400> 550 Thr Ser Gly Met Gly Val Gly 1 5 <210> 551 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.92 HC CDR2 <400> 551 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 552 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.92 HC CDR3 <400> 552 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 553 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.93 LC CDR1 <400> 553 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 554 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.93 LC CDR2 <400> 554 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 555 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.93 LC CDR3 <400> 555 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Arg 1 5 10 <210> 556 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.93 HC CDR1 <400> 556 Thr Ser Gly Val Gly Val Gly 1 5 <210> 557 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.93 HC CDR2 <400> 557 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 558 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.93 HC CDR3 <400> 558 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 559 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.94 LC CDR1 <400> 559 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 560 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.94 LC CDR2 <400> 560 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 561 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.94 LC CDR3 <400> 561 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 562 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.94 HC CDR1 <400> 562 Thr Ser Gly Met Gly Val Gly 1 5 <210> 563 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.94 HC CDR2 <400> 563 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 564 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.94 HC CDR3 <400> 564 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 565 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.95 LC CDR1 <400> 565 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 566 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.95 LC CDR2 <400> 566 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 567 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.95 LC CDR3 <400> 567 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 568 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.95 HC CDR1 <400> 568 Thr Ser Gly Val Gly Val Gly 1 5 <210> 569 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.95 HC CDR2 <400> 569 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 570 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.95 HC CDR3 <400> 570 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 571 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 96 LC CDR1 <400> 571 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 572 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 96 LC CDR2 <400> 572 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 573 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 96 LC CDR3 <400> 573 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 574 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 96 HC CDR1 <400> 574 Thr Ser Gly Met Gly Val Gly 1 5 <210> 575 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 96 HC CDR2 <400> 575 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 576 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 96 HC CDR3 <400> 576 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 577 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.97 LC CDR1 <400> 577 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 578 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.97 LC CDR2 <400> 578 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 579 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.97 LC CDR3 <400> 579 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 580 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.97 HC CDR1 <400> 580 Thr Ser Gly Met Gly Val Ser 1 5 <210> 581 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.97 HC CDR2 <400> 581 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 582 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.97 HC CDR3 <400> 582 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 583 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 98 LC CDR1 <400> 583 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 584 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.98 LC CDR2 <400> 584 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 585 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 98 LC CDR3 <400> 585 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 586 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 98 HC CDR1 <400> 586 Thr Ser Gly Met Gly Val Gly 1 5 <210> 587 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 98 HC CDR2 <400> 587 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 588 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 98 HC CDR3 <400> 588 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 589 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.99 LC CDR1 <400> 589 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 590 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.99 LC CDR2 <400> 590 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 591 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.99 LC CDR3 <400> 591 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 592 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.99 HC CDR1 <400> 592 Thr Ser Gly Met Gly Val Gly 1 5 <210> 593 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.99 HC CDR2 <400> 593 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 594 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.99 HC CDR3 <400> 594 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 595 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.100 LC CDR1 <400> 595 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 596 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.100 LC CDR2 <400> 596 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 597 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.100 LC CDR3 <400> 597 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 598 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 100 HC CDR1 <400> 598 Thr Ser Gly Met Gly Val Gly 1 5 <210> 599 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 100 HC CDR2 <400> 599 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 600 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.100 HC CDR3 <400> 600 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 601 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 101 LC CDR1 <400> 601 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 602 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 101 LC CDR2 <400> 602 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 603 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 101 LC CDR3 <400> 603 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 604 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 101 HC CDR1 <400> 604 Thr Ser Gly Met Gly Val Gly 1 5 <210> 605 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 101 HC CDR2 <400> 605 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 606 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 101 HC CDR3 <400> 606 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 607 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.102 LC CDR1 <400> 607 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 608 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.102 LC CDR2 <400> 608 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 609 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.102 LC CDR3 <400> 609 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 610 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.102 HC CDR1 <400> 610 Thr Ser Gly Met Gly Val Gly 1 5 <210> 611 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.102 HC CDR2 <400> 611 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 612 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.102 HC CDR3 <400> 612 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 613 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.103 LC CDR1 <400> 613 Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn Tyr Val Ser 1 5 10 <210> 614 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.103 LC CDR2 <400> 614 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 615 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.103 LC CDR3 <400> 615 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 616 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.103 HC CDR1 <400> 616 Thr Ser Gly Val Gly Val Gly 1 5 <210> 617 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.103 HC CDR2 <400> 617 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 618 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.103 HC CDR3 <400> 618 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 619 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.104 LC CDR1 <400> 619 Ser Gly Gly Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 620 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.104 LC CDR2 <400> 620 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 621 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.104 LC CDR3 <400> 621 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 622 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.104 HC CDR1 <400> 622 Thr Ser Gly Val Gly Val Gly 1 5 <210> 623 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.104 HC CDR2 <400> 623 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 624 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.104 HC CDR3 <400> 624 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 625 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.105 LC CDR1 <400> 625 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 626 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.105 LC CDR2 <400> 626 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 627 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.105 LC CDR3 <400> 627 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 628 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.105 HC CDR1 <400> 628 Thr Ser Gly Val Gly Val Gly 1 5 <210> 629 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.105 HC CDR2 <400> 629 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 630 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.105 HC CDR3 <400> 630 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 631 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.106 LC CDR1 <400> 631 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 632 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.106 LC CDR2 <400> 632 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 633 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.106 LC CDR3 <400> 633 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 634 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.106 HC CDR1 <400> 634 Thr Ser Gly Met Gly Val Gly 1 5 <210> 635 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.106 HC CDR2 <400> 635 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 636 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.106 HC CDR3 <400> 636 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 637 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.107 LC CDR1 <400> 637 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 638 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.107 LC CDR2 <400> 638 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 639 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.107 LC CDR3 <400> 639 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 640 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.107 HC CDR1 <400> 640 Thr Ser Gly Met Gly Val Gly 1 5 <210> 641 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.107 HC CDR2 <400> 641 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 642 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.107 HC CDR3 <400> 642 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 643 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.108 LC CDR1 <400> 643 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 644 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.108 LC CDR2 <400> 644 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 645 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.108 LC CDR3 <400> 645 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 646 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.108 HC CDR1 <400> 646 Thr Ser Gly Met Gly Val Gly 1 5 <210> 647 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.108 HC CDR2 <400> 647 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 648 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.108 HC CDR3 <400> 648 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 649 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.109 LC CDR1 <400> 649 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 650 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.109 LC CDR2 <400> 650 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 651 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.109 LC CDR3 <400> 651 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 652 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.109 HC CDR1 <400> 652 Thr Ser Gly Met Gly Val Gly 1 5 <210> 653 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.109 HC CDR2 <400> 653 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 654 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.109 HC CDR3 <400> 654 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 655 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.110 LC CDR1 <400> 655 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 656 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.110 LC CDR2 <400> 656 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 657 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.110 LC CDR3 <400> 657 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 658 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 110 HC CDR1 <400> 658 Thr Ser Gly Met Gly Val Gly 1 5 <210> 659 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.110 HC CDR2 <400> 659 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 660 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.110 HC CDR3 <400> 660 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 661 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.111 LC CDR1 <400> 661 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 662 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.111 LC CDR2 <400> 662 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 663 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.111 LC CDR3 <400> 663 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 664 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.111 HC CDR1 <400> 664 Thr Ser Gly Met Gly Val Gly 1 5 <210> 665 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.111 HC CDR2 <400> 665 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 666 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.111 HC CDR3 <400> 666 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 667 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.112 LC CDR1 <400> 667 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 668 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.112 LC CDR2 <400> 668 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 669 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.112 LC CDR3 <400> 669 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 670 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.112 HC CDR1 <400> 670 Thr Ser Gly Val Gly Val Gly 1 5 <210> 671 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.112 HC CDR2 <400> 671 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 672 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.112 HC CDR3 <400> 672 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 673 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.113 LC CDR1 <400> 673 Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Ile Ser 1 5 10 <210> 674 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.113 LC CDR2 <400> 674 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 675 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.113 LC CDR3 <400> 675 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 676 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.113 HC CDR1 <400> 676 Thr Ser Gly Val Gly Val Gly 1 5 <210> 677 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.113 HC CDR2 <400> 677 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 678 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.113 HC CDR3 <400> 678 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 679 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.114 LC CDR1 <400> 679 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 680 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.114 LC CDR2 <400> 680 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 681 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.114 LC CDR3 <400> 681 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 682 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.114 HC CDR1 <400> 682 Thr Ser Gly Met Gly Val Gly 1 5 <210> 683 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.114 HC CDR2 <400> 683 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 684 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.114 HC CDR3 <400> 684 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 685 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.115 LC CDR1 <400> 685 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 686 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.115 LC CDR2 <400> 686 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 687 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.115 LC CDR3 <400> 687 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 688 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.115 HC CDR1 <400> 688 Thr Ser Gly Met Gly Val Gly 1 5 <210> 689 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.115 HC CDR2 <400> 689 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 690 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.115 HC CDR3 <400> 690 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 691 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.116 LC CDR1 <400> 691 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 692 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.116 LC CDR2 <400> 692 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 693 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.116 LC CDR3 <400> 693 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 694 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.116 HC CDR1 <400> 694 Thr Ser Gly Met Gly Val Gly 1 5 <210> 695 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.116 HC CDR2 <400> 695 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 696 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.116 HC CDR3 <400> 696 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 697 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.117 LC CDR1 <400> 697 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 698 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.117 LC CDR2 <400> 698 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 699 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.117 LC CDR3 <400> 699 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 700 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.117 HC CDR1 <400> 700 Thr Ser Gly Met Gly Val Gly 1 5 <210> 701 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.117 HC CDR2 <400> 701 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 702 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.117 HC CDR3 <400> 702 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 703 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.118 LC CDR1 <400> 703 Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 704 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.118 LC CDR2 <400> 704 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 705 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.118 LC CDR3 <400> 705 Gly Thr Trp Asp Asn Ser Leu Ser Ala Gly Val 1 5 10 <210> 706 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.118 HC CDR1 <400> 706 Thr Ser Gly Met Gly Val Gly 1 5 <210> 707 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.118 HC CDR2 <400> 707 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 708 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.118 HC CDR3 <400> 708 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 709 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.119 LC CDR1 <400> 709 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 710 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.119 LC CDR2 <400> 710 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 711 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.119 LC CDR3 <400> 711 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 712 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.119 HC CDR1 <400> 712 Thr Ser Gly Met Gly Val Gly 1 5 <210> 713 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.119 HC CDR2 <400> 713 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 714 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.119 HC CDR3 <400> 714 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 715 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 120 LC CDR1 <400> 715 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 716 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.120 LC CDR2 <400> 716 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 717 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.120 LC CDR3 <400> 717 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 718 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 120 HC CDR1 <400> 718 Thr Ser Gly Val Gly Val Gly 1 5 <210> 719 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 120 HC CDR2 <400> 719 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 720 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 120 HC CDR3 <400> 720 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 721 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.121 LC CDR1 <400> 721 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 722 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.121 LC CDR2 <400> 722 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 723 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.121 LC CDR3 <400> 723 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 724 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.121 HC CDR1 <400> 724 Thr Ser Gly Met Gly Val Gly 1 5 <210> 725 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.121 HC CDR2 <400> 725 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 726 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.121 HC CDR3 <400> 726 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 727 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.122 LC CDR1 <400> 727 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 728 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.122 LC CDR2 <400> 728 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 729 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.122 LC CDR3 <400> 729 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 730 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.122 HC CDR1 <400> 730 Thr Ser Gly Met Gly Val Gly 1 5 <210> 731 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.122 HC CDR2 <400> 731 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 732 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.122 HC CDR3 <400> 732 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 733 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.123 LC CDR1 <400> 733 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 734 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.123 LC CDR2 <400> 734 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 735 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.123 LC CDR3 <400> 735 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 736 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.123 HC CDR1 <400> 736 Thr Ser Gly Met Gly Val Gly 1 5 <210> 737 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.123 HC CDR2 <400> 737 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 738 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.123 HC CDR3 <400> 738 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 739 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.124 LC CDR1 <400> 739 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 740 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.124 LC CDR2 <400> 740 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 741 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.124 LC CDR3 <400> 741 Gly Thr Trp Asp Asn Ser Leu Ser Ala Gly Val 1 5 10 <210> 742 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.124 HC CDR1 <400> 742 Thr Ser Gly Val Gly Val Gly 1 5 <210> 743 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.124 HC CDR2 <400> 743 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 744 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.124 HC CDR3 <400> 744 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 745 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.125 LC CDR1 <400> 745 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 746 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.125 LC CDR2 <400> 746 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 747 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.125 LC CDR3 <400> 747 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 748 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.125 HC CDR1 <400> 748 Thr Ser Gly Met Gly Val Gly 1 5 <210> 749 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.125 HC CDR2 <400> 749 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 750 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.125 HC CDR3 <400> 750 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 751 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.126 LC CDR1 <400> 751 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 752 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.126 LC CDR2 <400> 752 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 753 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.126 LC CDR3 <400> 753 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 754 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.126 HC CDR1 <400> 754 Thr Ser Gly Met Gly Val Gly 1 5 <210> 755 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.126 HC CDR2 <400> 755 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 756 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.126 HC CDR3 <400> 756 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 757 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.127 LC CDR1 <400> 757 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 758 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.127 LC CDR2 <400> 758 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 759 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.127 LC CDR3 <400> 759 Gly Thr Trp Asp Asn Ser Leu Ser Ala Gly Val 1 5 10 <210> 760 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.127 HC CDR1 <400> 760 Thr Ser Gly Val Gly Val Gly 1 5 <210> 761 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.127 HC CDR2 <400> 761 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 762 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.127 HC CDR3 <400> 762 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 763 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.128 LC CDR1 <400> 763 Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Phe Val Ser 1 5 10 <210> 764 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.128 LC CDR2 <400> 764 Asp Asn Asp Lys Arg Pro Ser 1 5 <210> 765 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.128 LC CDR3 <400> 765 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 766 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 128 HC CDR1 <400> 766 Thr Ser Gly Val Gly Val Gly 1 5 <210> 767 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.128 HC CDR2 <400> 767 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 768 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 128 HC CDR3 <400> 768 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 769 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.129 LC CDR1 <400> 769 Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 770 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.129 LC CDR2 <400> 770 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 771 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.129 LC CDR3 <400> 771 Gly Thr Trp Asp Asn Asn Leu Ser Ala Gly Val 1 5 10 <210> 772 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.129 HC CDR1 <400> 772 Thr Ser Gly Val Gly Val Gly 1 5 <210> 773 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.129 HC CDR2 <400> 773 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 774 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.129 HC CDR3 <400> 774 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 775 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.130 LC CDR1 <400> 775 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 776 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.130 LC CDR2 <400> 776 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 777 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 130 LC CDR3 <400> 777 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 778 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 130 HC CDR1 <400> 778 Thr Ser Gly Met Gly Val Gly 1 5 <210> 779 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 130 HC CDR2 <400> 779 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 780 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 130 HC CDR3 <400> 780 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 781 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.131 LC CDR1 <400> 781 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 782 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.131 LC CDR2 <400> 782 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 783 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.131 LC CDR3 <400> 783 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 784 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.131 HC CDR1 <400> 784 Thr Ser Gly Val Gly Val Gly 1 5 <210> 785 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.131 HC CDR2 <400> 785 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 786 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.131 HC CDR3 <400> 786 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 787 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.132 LC CDR1 <400> 787 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 788 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.132 LC CDR2 <400> 788 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 789 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.132 LC CDR3 <400> 789 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 790 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.132 HC CDR1 <400> 790 Thr Ser Gly Met Gly Val Gly 1 5 <210> 791 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.132 HC CDR2 <400> 791 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 792 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.132 HC CDR3 <400> 792 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 793 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.133 LC CDR1 <400> 793 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 794 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.133 LC CDR2 <400> 794 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 795 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.133 LC CDR3 <400> 795 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 796 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.133 HC CDR1 <400> 796 Thr Ser Gly Met Gly Val Gly 1 5 <210> 797 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.133 HC CDR2 <400> 797 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 798 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.133 HC CDR3 <400> 798 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 799 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.134 LC CDR1 <400> 799 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 800 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.134 LC CDR2 <400> 800 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 801 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.134 LC CDR3 <400> 801 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 802 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.134 HC CDR1 <400> 802 Thr Ser Gly Met Gly Val Gly 1 5 <210> 803 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.134 HC CDR2 <400> 803 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 804 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.134 HC CDR3 <400> 804 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 805 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.135 LC CDR1 <400> 805 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 806 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.135 LC CDR2 <400> 806 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 807 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.135 LC CDR3 <400> 807 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 808 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.135 HC CDR1 <400> 808 Thr Ser Gly Met Gly Val Gly 1 5 <210> 809 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.135 HC CDR2 <400> 809 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 810 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.135 HC CDR3 <400> 810 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 811 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.136 LC CDR1 <400> 811 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 812 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.136 LC CDR2 <400> 812 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 813 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.136 LC CDR3 <400> 813 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 814 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.136 HC CDR1 <400> 814 Thr Ser Gly Met Gly Val Gly 1 5 <210> 815 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.136 HC CDR2 <400> 815 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 816 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.136 HC CDR3 <400> 816 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 817 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.137 LC CDR1 <400> 817 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 818 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.137 LC CDR2 <400> 818 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 819 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.137 LC CDR3 <400> 819 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 820 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.137 HC CDR1 <400> 820 Thr Ser Gly Val Gly Val Gly 1 5 <210> 821 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.137 HC CDR2 <400> 821 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 822 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.137 HC CDR3 <400> 822 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 823 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.138 LC CDR1 <400> 823 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 824 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.138 LC CDR2 <400> 824 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 825 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.138 LC CDR3 <400> 825 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 826 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.138 HC CDR1 <400> 826 Thr Ser Gly Val Gly Val Gly 1 5 <210> 827 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.138 HC CDR2 <400> 827 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 828 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.138 HC CDR3 <400> 828 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 829 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.139 LC CDR1 <400> 829 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 830 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.139 LC CDR2 <400> 830 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 831 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.139 LC CDR3 <400> 831 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 832 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.139 HC CDR1 <400> 832 Thr Ser Gly Val Gly Val Gly 1 5 <210> 833 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.139 HC CDR2 <400> 833 Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 834 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.139 HC CDR3 <400> 834 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 835 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 140 LC CDR1 <400> 835 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 836 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 140 LC CDR2 <400> 836 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 837 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 140 LC CDR3 <400> 837 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 838 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 140 HC CDR1 <400> 838 Thr Ser Gly Met Gly Val Ser 1 5 <210> 839 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 140 HC CDR2 <400> 839 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 840 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 140 HC CDR3 <400> 840 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 841 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.141 LC CDR1 <400> 841 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 842 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.141 LC CDR2 <400> 842 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 843 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.141 LC CDR3 <400> 843 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 844 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.141 HC CDR1 <400> 844 Thr Ser Gly Met Gly Val Gly 1 5 <210> 845 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.141 HC CDR2 <400> 845 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 846 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.141 HC CDR3 <400> 846 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 847 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.142 LC CDR1 <400> 847 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 848 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.142 LC CDR2 <400> 848 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 849 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.142 LC CDR3 <400> 849 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 850 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.142 HC CDR1 <400> 850 Thr Ser Gly Met Gly Val Gly 1 5 <210> 851 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.142 HC CDR2 <400> 851 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 852 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.142 HC CDR3 <400> 852 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 853 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.143 LC CDR1 <400> 853 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 854 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.143 LC CDR2 <400> 854 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 855 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.143 LC CDR3 <400> 855 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 856 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.143 HC CDR1 <400> 856 Thr Ser Gly Val Gly Val Gly 1 5 <210> 857 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.143 HC CDR2 <400> 857 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 858 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.143 HC CDR3 <400> 858 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 859 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.144 LC CDR1 <400> 859 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 860 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.144 LC CDR2 <400> 860 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 861 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.144 LC CDR3 <400> 861 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 862 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.144 HC CDR1 <400> 862 Thr Ser Gly Met Gly Val Gly 1 5 <210> 863 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.144 HC CDR2 <400> 863 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 864 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.144 HC CDR3 <400> 864 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 865 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.145 LC CDR1 <400> 865 Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn Tyr Val Ser 1 5 10 <210> 866 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.145 LC CDR2 <400> 866 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 867 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.145 LC CDR3 <400> 867 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 868 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.145 HC CDR1 <400> 868 Thr Ser Gly Val Gly Val Gly 1 5 <210> 869 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.145 HC CDR2 <400> 869 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 870 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.145 HC CDR3 <400> 870 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 871 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.146 LC CDR1 <400> 871 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 872 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.146 LC CDR2 <400> 872 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 873 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.146 LC CDR3 <400> 873 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 874 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.146 HC CDR1 <400> 874 Thr Ser Gly Met Gly Val Gly 1 5 <210> 875 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.146 HC CDR2 <400> 875 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 876 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.146 HC CDR3 <400> 876 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 877 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.147 LC CDR1 <400> 877 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 878 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.147 LC CDR2 <400> 878 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 879 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.147 LC CDR3 <400> 879 Gly Thr Trp Asp Ser Ser Leu Ser Gly Gly Val 1 5 10 <210> 880 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.147 HC CDR1 <400> 880 Thr Ser Gly Met Gly Val Gly 1 5 <210> 881 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.147 HC CDR2 <400> 881 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 882 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.147 HC CDR3 <400> 882 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 883 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.148 LC CDR1 <400> 883 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 884 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.148 LC CDR2 <400> 884 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 885 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.148 LC CDR3 <400> 885 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 886 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.148 HC CDR1 <400> 886 Thr Ser Gly Met Gly Val Gly 1 5 <210> 887 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.148 HC CDR2 <400> 887 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 888 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.148 HC CDR3 <400> 888 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 889 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.149 LC CDR1 <400> 889 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 890 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.149 LC CDR2 <400> 890 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 891 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.149 LC CDR3 <400> 891 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 892 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.149 HC CDR1 <400> 892 Thr Ser Gly Met Gly Val Gly 1 5 <210> 893 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.149 HC CDR2 <400> 893 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 894 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.149 HC CDR3 <400> 894 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 895 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.150 LC CDR1 <400> 895 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 896 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.150 LC CDR2 <400> 896 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 897 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.150 LC CDR3 <400> 897 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 898 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.150 HC CDR1 <400> 898 Thr Ser Gly Met Gly Val Gly 1 5 <210> 899 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.150 HC CDR2 <400> 899 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 900 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.150 HC CDR3 <400> 900 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 901 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.151 LC CDR1 <400> 901 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 902 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.151 LC CDR2 <400> 902 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 903 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.151 LC CDR3 <400> 903 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 904 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.151 HC CDR1 <400> 904 Thr Ser Gly Val Gly Val Gly 1 5 <210> 905 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.151 HC CDR2 <400> 905 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 906 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.151 HC CDR3 <400> 906 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 907 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.152 LC CDR1 <400> 907 Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 908 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.152 LC CDR2 <400> 908 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 909 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.152 LC CDR3 <400> 909 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 910 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.152 HC CDR1 <400> 910 Thr Ser Gly Met Gly Val Gly 1 5 <210> 911 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.152 HC CDR2 <400> 911 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 912 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.152 HC CDR3 <400> 912 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 913 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.153 LC CDR1 <400> 913 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 914 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.153 LC CDR2 <400> 914 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 915 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.153 LC CDR3 <400> 915 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 916 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.153 HC CDR1 <400> 916 Thr Ser Gly Val Gly Val Gly 1 5 <210> 917 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.153 HC CDR2 <400> 917 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 918 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.153 HC CDR3 <400> 918 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 919 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.154 LC CDR1 <400> 919 Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn Tyr Val Ser 1 5 10 <210> 920 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.154 LC CDR2 <400> 920 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 921 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.154 LC CDR3 <400> 921 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 922 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.154 HC CDR1 <400> 922 Thr Ser Gly Val Gly Val Gly 1 5 <210> 923 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.154 HC CDR2 <400> 923 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 924 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.154 HC CDR3 <400> 924 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 925 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.155 LC CDR1 <400> 925 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 926 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.155 LC CDR2 <400> 926 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 927 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.155 LC CDR3 <400> 927 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 928 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.155 HC CDR1 <400> 928 Thr Ser Gly Met Gly Val Gly 1 5 <210> 929 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.155 HC CDR2 <400> 929 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 930 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.155 HC CDR3 <400> 930 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 931 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.156 LC CDR1 <400> 931 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 932 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.156 LC CDR2 <400> 932 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 933 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.156 LC CDR3 <400> 933 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 934 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.156 HC CDR1 <400> 934 Thr Ser Gly Met Gly Val Gly 1 5 <210> 935 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.156 HC CDR2 <400> 935 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 936 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.156 HC CDR3 <400> 936 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 937 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.157 LC CDR1 <400> 937 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 938 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.157 LC CDR2 <400> 938 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 939 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.157 LC CDR3 <400> 939 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 940 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.157 HC CDR1 <400> 940 Thr Ser Gly Val Gly Val Gly 1 5 <210> 941 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.157 HC CDR2 <400> 941 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 942 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.157 HC CDR3 <400> 942 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 943 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.158 LC CDR1 <400> 943 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 944 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.158 LC CDR2 <400> 944 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 945 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.158 LC CDR3 <400> 945 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 946 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.158 HC CDR1 <400> 946 Thr Ser Gly Val Gly Val Gly 1 5 <210> 947 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.158 HC CDR2 <400> 947 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 948 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.158 HC CDR3 <400> 948 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 949 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.159 LC CDR1 <400> 949 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 950 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.159 LC CDR2 <400> 950 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 951 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.159 LC CDR3 <400> 951 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 952 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.159 HC CDR1 <400> 952 Thr Ser Gly Val Gly Val Gly 1 5 <210> 953 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.159 HC CDR2 <400> 953 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 954 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.159 HC CDR3 <400> 954 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 955 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 160 LC CDR1 <400> 955 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 956 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 160 LC CDR2 <400> 956 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 957 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 160 LC CDR3 <400> 957 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 958 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 160 HC CDR1 <400> 958 Thr Ser Gly Val Gly Val Gly 1 5 <210> 959 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 160 HC CDR2 <400> 959 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 960 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 160 HC CDR3 <400> 960 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 961 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.161 LC CDR1 <400> 961 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 962 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.161 LC CDR2 <400> 962 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 963 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.161 LC CDR3 <400> 963 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 964 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.161 HC CDR1 <400> 964 Thr Ser Gly Met Gly Val Gly 1 5 <210> 965 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.161 HC CDR2 <400> 965 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 966 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.161 HC CDR3 <400> 966 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 967 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.162 LC CDR1 <400> 967 Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn Tyr Val Ser 1 5 10 <210> 968 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.162 LC CDR2 <400> 968 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 969 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.162 LC CDR3 <400> 969 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 970 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.162 HC CDR1 <400> 970 Thr Ser Gly Val Gly Val Gly 1 5 <210> 971 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.162 HC CDR2 <400> 971 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 972 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.162 HC CDR3 <400> 972 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 973 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.163 LC CDR1 <400> 973 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 974 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.163 LC CDR2 <400> 974 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 975 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.163 LC CDR3 <400> 975 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 976 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.163 HC CDR1 <400> 976 Thr Ser Gly Met Gly Val Gly 1 5 <210> 977 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.163 HC CDR2 <400> 977 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 978 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.163 HC CDR3 <400> 978 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 979 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.164 LC CDR1 <400> 979 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 980 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.164 LC CDR2 <400> 980 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 981 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.164 LC CDR3 <400> 981 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 982 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.164 HC CDR1 <400> 982 Thr Ser Gly Val Gly Val Gly 1 5 <210> 983 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.164 HC CDR2 <400> 983 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 984 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.164 HC CDR3 <400> 984 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 985 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.165 LC CDR1 <400> 985 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 986 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.165 LC CDR2 <400> 986 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 987 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.165 LC CDR3 <400> 987 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 988 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.165 HC CDR1 <400> 988 Thr Ser Gly Met Gly Val Gly 1 5 <210> 989 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.165 HC CDR2 <400> 989 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 990 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.165 HC CDR3 <400> 990 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 991 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.166 LC CDR1 <400> 991 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 992 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.166 LC CDR2 <400> 992 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 993 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.166 LC CDR3 <400> 993 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 994 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.166 HC CDR1 <400> 994 Thr Ser Gly Met Gly Val Gly 1 5 <210> 995 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.166 HC CDR2 <400> 995 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 996 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.166 HC CDR3 <400> 996 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 997 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.167 LC CDR1 <400> 997 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 998 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.167 LC CDR2 <400> 998 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 999 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.167 LC CDR3 <400> 999 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1000 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.167 HC CDR1 <400> 1000 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1001 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.167 HC CDR2 <400> 1001 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1002 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.167 HC CDR3 <400> 1002 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1003 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.168 LC CDR1 <400> 1003 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1004 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.168 LC CDR2 <400> 1004 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1005 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.168 LC CDR3 <400> 1005 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1006 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.168 HC CDR1 <400> 1006 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1007 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.168 HC CDR2 <400> 1007 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1008 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.168 HC CDR3 <400> 1008 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1009 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.169 LC CDR1 <400> 1009 Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn Tyr Val Ser 1 5 10 <210> 1010 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.169 LC CDR2 <400> 1010 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1011 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.169 LC CDR3 <400> 1011 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 1012 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.169 HC CDR1 <400> 1012 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1013 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.169 HC CDR2 <400> 1013 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1014 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.169 HC CDR3 <400> 1014 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1015 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.170 LC CDR1 <400> 1015 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1016 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.170 LC CDR2 <400> 1016 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1017 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.170 LC CDR3 <400> 1017 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1018 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.170 HC CDR1 <400> 1018 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1019 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.170 HC CDR2 <400> 1019 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1020 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.170 HC CDR3 <400> 1020 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1021 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.171 LC CDR1 <400> 1021 Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1022 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.171 LC CDR2 <400> 1022 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1023 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.171 LC CDR3 <400> 1023 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1024 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.171 HC CDR1 <400> 1024 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1025 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.171 HC CDR2 <400> 1025 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1026 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.171 HC CDR3 <400> 1026 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1027 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.172 LC CDR1 <400> 1027 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1028 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 172 LC CDR2 <400> 1028 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1029 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.172 LC CDR3 <400> 1029 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1030 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.172 HC CDR1 <400> 1030 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1031 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.172 HC CDR2 <400> 1031 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1032 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.172 HC CDR3 <400> 1032 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1033 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.173 LC CDR1 <400> 1033 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1034 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.173 LC CDR2 <400> 1034 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1035 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.173 LC CDR3 <400> 1035 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1036 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.173 HC CDR1 <400> 1036 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1037 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.173 HC CDR2 <400> 1037 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1038 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.173 HC CDR3 <400> 1038 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1039 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.174 LC CDR1 <400> 1039 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1040 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.174 LC CDR2 <400> 1040 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1041 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.174 LC CDR3 <400> 1041 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1042 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.174 HC CDR1 <400> 1042 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1043 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.174 HC CDR2 <400> 1043 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1044 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.174 HC CDR3 <400> 1044 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1045 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.175 LC CDR1 <400> 1045 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1046 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.175 LC CDR2 <400> 1046 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1047 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.175 LC CDR3 <400> 1047 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1048 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.175 HC CDR1 <400> 1048 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1049 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.175 HC CDR2 <400> 1049 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1050 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.175 HC CDR3 <400> 1050 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1051 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.176 LC CDR1 <400> 1051 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1052 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.176 LC CDR2 <400> 1052 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1053 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.176 LC CDR3 <400> 1053 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1054 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.176 HC CDR1 <400> 1054 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1055 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.176 HC CDR2 <400> 1055 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1056 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.176 HC CDR3 <400> 1056 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1057 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.177 LC CDR1 <400> 1057 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1058 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.177 LC CDR2 <400> 1058 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1059 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.177 LC CDR3 <400> 1059 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1060 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.177 HC CDR1 <400> 1060 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1061 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.177 HC CDR2 <400> 1061 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1062 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.177 HC CDR3 <400> 1062 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1063 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.178 LC CDR1 <400> 1063 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1064 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.178 LC CDR2 <400> 1064 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1065 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.178 LC CDR3 <400> 1065 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1066 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.178 HC CDR1 <400> 1066 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1067 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.178 HC CDR2 <400> 1067 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1068 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.178 HC CDR3 <400> 1068 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1069 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.179 LC CDR1 <400> 1069 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1070 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.179 LC CDR2 <400> 1070 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1071 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.179 LC CDR3 <400> 1071 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1072 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.179 HC CDR1 <400> 1072 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1073 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.179 HC CDR2 <400> 1073 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1074 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.179 HC CDR3 <400> 1074 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1075 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.180 LC CDR1 <400> 1075 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1076 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.180 LC CDR2 <400> 1076 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1077 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.180 LC CDR3 <400> 1077 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1078 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.180 HC CDR1 <400> 1078 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1079 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.180 HC CDR2 <400> 1079 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1080 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.180 HC CDR3 <400> 1080 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1081 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.181 LC CDR1 <400> 1081 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1082 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.181 LC CDR2 <400> 1082 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1083 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.181 LC CDR3 <400> 1083 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1084 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.181 HC CDR1 <400> 1084 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1085 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.181 HC CDR2 <400> 1085 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1086 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.181 HC CDR3 <400> 1086 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1087 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.182 LC CDR1 <400> 1087 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1088 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.182 LC CDR2 <400> 1088 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1089 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.182 LC CDR3 <400> 1089 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1090 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.182 HC CDR1 <400> 1090 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1091 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.182 HC CDR2 <400> 1091 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1092 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.182 HC CDR3 <400> 1092 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1093 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.183 LC CDR1 <400> 1093 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1094 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.183 LC CDR2 <400> 1094 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1095 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.183 LC CDR3 <400> 1095 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1096 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.183 HC CDR1 <400> 1096 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1097 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.183 HC CDR2 <400> 1097 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1098 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.183 HC CDR3 <400> 1098 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1099 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.184 LC CDR1 <400> 1099 Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn Tyr Val Ser 1 5 10 <210> 1100 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.184 LC CDR2 <400> 1100 Asp Asn Asp Lys Arg Pro Ser 1 5 <210> 1101 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.184 LC CDR3 <400> 1101 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 1102 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.184 HC CDR1 <400> 1102 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1103 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.184 HC CDR2 <400> 1103 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1104 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.184 HC CDR3 <400> 1104 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1105 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.185 LC CDR1 <400> 1105 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1106 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.185 LC CDR2 <400> 1106 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1107 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.185 LC CDR3 <400> 1107 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1108 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.185 HC CDR1 <400> 1108 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1109 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.185 HC CDR2 <400> 1109 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1110 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.185 HC CDR3 <400> 1110 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1111 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.186 LC CDR1 <400> 1111 Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1112 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.186 LC CDR2 <400> 1112 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1113 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.186 LC CDR3 <400> 1113 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1114 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.186 HC CDR1 <400> 1114 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1115 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.186 HC CDR2 <400> 1115 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1116 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.186 HC CDR3 <400> 1116 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1117 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.187 LC CDR1 <400> 1117 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1118 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.187 LC CDR2 <400> 1118 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1119 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.187 LC CDR3 <400> 1119 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1120 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.187 HC CDR1 <400> 1120 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1121 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.187 HC CDR2 <400> 1121 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1122 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.187 HC CDR3 <400> 1122 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1123 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.188 LC CDR1 <400> 1123 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1124 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.188 LC CDR2 <400> 1124 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1125 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.188 LC CDR3 <400> 1125 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1126 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.188 HC CDR1 <400> 1126 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1127 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.188 HC CDR2 <400> 1127 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1128 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.188 HC CDR3 <400> 1128 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1129 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.189 LC CDR1 <400> 1129 Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1130 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.189 LC CDR2 <400> 1130 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1131 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.189 LC CDR3 <400> 1131 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1132 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.189 HC CDR1 <400> 1132 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1133 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.189 HC CDR2 <400> 1133 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1134 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.189 HC CDR3 <400> 1134 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1135 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.190 LC CDR1 <400> 1135 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1136 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.190 LC CDR2 <400> 1136 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1137 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.190 LC CDR3 <400> 1137 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1138 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.190 HC CDR1 <400> 1138 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1139 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.190 HC CDR2 <400> 1139 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1140 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.190 HC CDR3 <400> 1140 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1141 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 191 LC CDR1 <400> 1141 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1142 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 191 LC CDR2 <400> 1142 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1143 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 191 LC CDR3 <400> 1143 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1144 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 191 HC CDR1 <400> 1144 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1145 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No. 191 HC CDR2 <400> 1145 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1146 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 191 HC CDR3 <400> 1146 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1147 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.192 LC CDR1 <400> 1147 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1148 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.192 LC CDR2 <400> 1148 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1149 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.192 LC CDR3 <400> 1149 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1150 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.192 HC CDR1 <400> 1150 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1151 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.192 HC CDR2 <400> 1151 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1152 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.192 HC CDR3 <400> 1152 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1153 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.193 LC CDR1 <400> 1153 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1154 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.193 LC CDR2 <400> 1154 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1155 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.193 LC CDR3 <400> 1155 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1156 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.193 HC CDR1 <400> 1156 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1157 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.193 HC CDR2 <400> 1157 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1158 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.193 HC CDR3 <400> 1158 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1159 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.194 LC CDR1 <400> 1159 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1160 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.194 LC CDR2 <400> 1160 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1161 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.194 LC CDR3 <400> 1161 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1162 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.194 HC CDR1 <400> 1162 Thr Ser Gly Met Gly Val Gly 1 5 <210> 1163 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.194 HC CDR2 <400> 1163 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1164 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.194 HC CDR3 <400> 1164 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1165 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.195 LC CDR1 <400> 1165 Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln 1 5 10 <210> 1166 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.195 LC CDR2 <400> 1166 Glu Asp Asn Gln Arg Pro Ser 1 5 <210> 1167 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.195 LC CDR3 <400> 1167 Gln Ser Tyr Asp Ser Ser Asp Trp Val 1 5 <210> 1168 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.195 HC CDR1 <400> 1168 Arg Tyr Gly Ile Ser 1 5 <210> 1169 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.195 HC CDR2 <400> 1169 Trp Ile Ser Ala Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln 1 5 10 15 Gly <210> 1170 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.195 HC CDR3 <400> 1170 Val Leu Gly Ile Ala Val Ala Gly Thr Pro Ile 1 5 10 <210> 1171 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.196 LC CDR1 <400> 1171 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1172 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.196 LC CDR2 <400> 1172 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1173 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.196 LC CDR3 <400> 1173 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1174 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.196 HC CDR1 <400> 1174 Ser Tyr Ala Ile Ser 1 5 <210> 1175 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.196 HC CDR2 <400> 1175 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1176 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.196 HC CDR3 <400> 1176 Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr 1 5 10 15 <210> 1177 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.197 LC CDR1 <400> 1177 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1178 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.197 LC CDR2 <400> 1178 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1179 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.197 LC CDR3 <400> 1179 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Ile 1 5 10 <210> 1180 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.197 HC CDR1 <400> 1180 Ser Tyr Ala Ile Ser 1 5 <210> 1181 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.197 HC CDR2 <400> 1181 Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1182 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.197 HC CDR3 <400> 1182 Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr 1 5 10 15 <210> 1183 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.198 LC CDR1 <400> 1183 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1184 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.198 LC CDR2 <400> 1184 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1185 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.198 LC CDR3 <400> 1185 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1186 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.198 HC CDR1 <400> 1186 Ser Tyr Ala Ile Ser 1 5 <210> 1187 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.198 HC CDR2 <400> 1187 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1188 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.198 HC CDR3 <400> 1188 Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr 1 5 10 15 <210> 1189 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.199 LC CDR1 <400> 1189 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1190 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.199 LC CDR2 <400> 1190 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1191 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.199 LC CDR3 <400> 1191 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Ile 1 5 10 <210> 1192 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.199 HC CDR1 <400> 1192 Ser Tyr Ala Ile Ser 1 5 <210> 1193 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.199 HC CDR2 <400> 1193 Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1194 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.199 HC CDR3 <400> 1194 Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr 1 5 10 15 <210> 1195 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.200 LC CDR1 <400> 1195 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1196 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.200 LC CDR2 <400> 1196 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1197 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.200 LC CDR3 <400> 1197 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1198 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.200 HC CDR1 <400> 1198 Ser Tyr Ala Ile Ser 1 5 <210> 1199 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.200 HC CDR2 <400> 1199 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1200 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.200 HC CDR3 <400> 1200 Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp Tyr 1 5 10 15 <210> 1201 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.201 LC CDR1 <400> 1201 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1202 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.201 LC CDR2 <400> 1202 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1203 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.201 LC CDR3 <400> 1203 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1204 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.201 HC CDR1 <400> 1204 Ser Tyr Ala Ile Ser 1 5 <210> 1205 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.201 HC CDR2 <400> 1205 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1206 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.201 HC CDR3 <400> 1206 Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Ser Asp Tyr 1 5 10 15 <210> 1207 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.202 LC CDR1 <400> 1207 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1208 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.202 LC CDR2 <400> 1208 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1209 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.202 LC CDR3 <400> 1209 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1210 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.202 HC CDR1 <400> 1210 Ser Tyr Ala Ile Ser 1 5 <210> 1211 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.202 HC CDR2 <400> 1211 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1212 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.202 HC CDR3 <400> 1212 Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Ser Asp Tyr 1 5 10 15 <210> 1213 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.203 LC CDR1 <400> 1213 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1214 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.203 LC CDR2 <400> 1214 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1215 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.203 LC CDR3 <400> 1215 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1216 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.203 HC CDR1 <400> 1216 Arg Phe Ala Met His 1 5 <210> 1217 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.203 HC CDR2 <400> 1217 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1218 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.203 HC CDR3 <400> 1218 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1219 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.204 LC CDR1 <400> 1219 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn 1 5 10 <210> 1220 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.204 LC CDR2 <400> 1220 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1221 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.204 LC CDR3 <400> 1221 Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1222 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.204 HC CDR1 <400> 1222 Arg Phe Ala Met His 1 5 <210> 1223 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.204 HC CDR2 <400> 1223 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1224 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.204 HC CDR3 <400> 1224 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1225 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.205 LC CDR1 <400> 1225 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1226 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.205 LC CDR2 <400> 1226 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1227 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.205 LC CDR3 <400> 1227 Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1228 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.205 HC CDR1 <400> 1228 Ser Phe Ala Met His 1 5 <210> 1229 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.205 HC CDR2 <400> 1229 Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1230 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.205 HC CDR3 <400> 1230 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1231 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.206 LC CDR1 <400> 1231 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1232 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.206 LC CDR2 <400> 1232 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1233 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.206 LC CDR3 <400> 1233 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1234 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.206 HC CDR1 <400> 1234 Asn Phe Ala Met His 1 5 <210> 1235 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.206 HC CDR2 <400> 1235 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1236 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.206 HC CDR3 <400> 1236 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1237 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.207 LC CDR1 <400> 1237 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1238 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.207 LC CDR2 <400> 1238 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1239 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.207 LC CDR3 <400> 1239 Ala Thr Trp Asp Asp Ala Leu Ser Gly Trp Val 1 5 10 <210> 1240 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.207 HC CDR1 <400> 1240 Arg Phe Ala Met His 1 5 <210> 1241 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.207 HC CDR2 <400> 1241 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1242 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.207 HC CDR3 <400> 1242 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1243 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.208 LC CDR1 <400> 1243 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1244 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.208 LC CDR2 <400> 1244 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1245 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.208 LC CDR3 <400> 1245 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1246 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.208 HC CDR1 <400> 1246 Arg Phe Ala Met His 1 5 <210> 1247 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.208 HC CDR2 <400> 1247 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1248 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.208 HC CDR3 <400> 1248 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1249 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.209 LC CDR1 <400> 1249 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Ala Val Asn 1 5 10 <210> 1250 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.209 LC CDR2 <400> 1250 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1251 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.209 LC CDR3 <400> 1251 Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1252 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.209 HC CDR1 <400> 1252 Ser Phe Ala Met His 1 5 <210> 1253 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.209 HC CDR2 <400> 1253 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1254 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.209 HC CDR3 <400> 1254 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1255 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.210 LC CDR1 <400> 1255 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1256 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.210 LC CDR2 <400> 1256 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1257 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.210 LC CDR3 <400> 1257 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1258 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.210 HC CDR1 <400> 1258 Arg Phe Ala Met His 1 5 <210> 1259 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.210 HC CDR2 <400> 1259 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1260 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.210 HC CDR3 <400> 1260 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1261 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.211 LC CDR1 <400> 1261 Ser Gly Ser Arg Ser Asn Ile Gly Gly Asn Thr Val Asn 1 5 10 <210> 1262 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.211 LC CDR2 <400> 1262 Gly Asp Asn Gln Arg Pro Ser 1 5 <210> 1263 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.211 LC CDR3 <400> 1263 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1264 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.211 HC CDR1 <400> 1264 Thr Tyr Ser Met His 1 5 <210> 1265 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.211 HC CDR2 <400> 1265 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1266 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.211 HC CDR3 <400> 1266 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1267 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.212 LC CDR1 <400> 1267 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1268 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.212 LC CDR2 <400> 1268 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1269 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.212 LC CDR3 <400> 1269 Ala Ala Trp Glu Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1270 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.212 HC CDR1 <400> 1270 Asn Phe Ala Met His 1 5 <210> 1271 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.212 HC CDR2 <400> 1271 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1272 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.212 HC CDR3 <400> 1272 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1273 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.213 LC CDR1 <400> 1273 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1274 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.213 LC CDR2 <400> 1274 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1275 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.213 LC CDR3 <400> 1275 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1276 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.213 HC CDR1 <400> 1276 Arg Phe Ala Met His 1 5 <210> 1277 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.213 HC CDR2 <400> 1277 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1278 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.213 HC CDR3 <400> 1278 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1279 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.214 LC CDR1 <400> 1279 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1280 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.214 LC CDR2 <400> 1280 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1281 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.214 LC CDR3 <400> 1281 Ala Thr Trp Asp Asp Thr Leu Asp Ser Trp Val 1 5 10 <210> 1282 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.214 HC CDR1 <400> 1282 Asn Phe Ala Met His 1 5 <210> 1283 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.214 HC CDR2 <400> 1283 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1284 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.214 HC CDR3 <400> 1284 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1285 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.215 LC CDR1 <400> 1285 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1286 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.215 LC CDR2 <400> 1286 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1287 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.215 LC CDR3 <400> 1287 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1288 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.215 HC CDR1 <400> 1288 Ser Phe Ala Met His 1 5 <210> 1289 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.215 HC CDR2 <400> 1289 Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1290 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.215 HC CDR3 <400> 1290 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1291 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.216 LC CDR1 <400> 1291 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1292 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.216 LC CDR2 <400> 1292 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1293 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.216 LC CDR3 <400> 1293 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1294 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.216 HC CDR1 <400> 1294 Ser Phe Ala Met His 1 5 <210> 1295 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.216 HC CDR2 <400> 1295 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1296 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.216 HC CDR3 <400> 1296 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1297 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.217 LC CDR1 <400> 1297 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1298 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.217 LC CDR2 <400> 1298 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1299 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.217 LC CDR3 <400> 1299 Ala Ala Trp Asp Asp Ser Leu Asn Val Trp Val 1 5 10 <210> 1300 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.217 HC CDR1 <400> 1300 Arg Phe Ala Met His 1 5 <210> 1301 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.217 HC CDR2 <400> 1301 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1302 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.217 HC CDR3 <400> 1302 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1303 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.218 LC CDR1 <400> 1303 Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn Pro Val Asn 1 5 10 <210> 1304 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.218 LC CDR2 <400> 1304 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1305 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.218 LC CDR3 <400> 1305 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1306 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.218 HC CDR1 <400> 1306 Ser Phe Ala Met His 1 5 <210> 1307 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.218 HC CDR2 <400> 1307 Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1308 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.218 HC CDR3 <400> 1308 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1309 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.219 LC CDR1 <400> 1309 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1310 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.219 LC CDR2 <400> 1310 Ser Asn Ser Gln Arg Pro Ser 1 5 <210> 1311 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.219 LC CDR3 <400> 1311 Ala Gly Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1312 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.219 HC CDR1 <400> 1312 Arg Phe Ala Met His 1 5 <210> 1313 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.219 HC CDR2 <400> 1313 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1314 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.219 HC CDR3 <400> 1314 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1315 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.220 LC CDR1 <400> 1315 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1316 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.220 LC CDR2 <400> 1316 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1317 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.220 LC CDR3 <400> 1317 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1318 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 220 HC CDR1 <400> 1318 Asn Phe Ala Met His 1 5 <210> 1319 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.220 HC CDR2 <400> 1319 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Phe Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1320 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 220 HC CDR3 <400> 1320 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1321 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.221 LC CDR1 <400> 1321 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1322 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.221 LC CDR2 <400> 1322 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1323 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.221 LC CDR3 <400> 1323 Ala Thr Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1324 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.221 HC CDR1 <400> 1324 Arg Phe Ala Met His 1 5 <210> 1325 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.221 HC CDR2 <400> 1325 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1326 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.221 HC CDR3 <400> 1326 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1327 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.222 LC CDR1 <400> 1327 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1328 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.222 LC CDR2 <400> 1328 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1329 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.222 LC CDR3 <400> 1329 Ala Thr Trp Asp Asp Ala Leu Ser Gly Trp Val 1 5 10 <210> 1330 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.222 HC CDR1 <400> 1330 Arg Phe Ala Met His 1 5 <210> 1331 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.222 HC CDR2 <400> 1331 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1332 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.222 HC CDR3 <400> 1332 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1333 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.223 LC CDR1 <400> 1333 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1334 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.223 LC CDR2 <400> 1334 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1335 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.223 LC CDR3 <400> 1335 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1336 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.223 HC CDR1 <400> 1336 Arg Phe Ala Met His 1 5 <210> 1337 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.223 HC CDR2 <400> 1337 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1338 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.223 HC CDR3 <400> 1338 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1339 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.224 LC CDR1 <400> 1339 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1340 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.224 LC CDR2 <400> 1340 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1341 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.224 LC CDR3 <400> 1341 Ala Thr Trp Asp Ser Ser Leu Ser Ala Trp Val 1 5 10 <210> 1342 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.224 HC CDR1 <400> 1342 Ser Tyr Ser Met His 1 5 <210> 1343 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.224 HC CDR2 <400> 1343 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1344 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.224 HC CDR3 <400> 1344 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1345 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.225 LC CDR1 <400> 1345 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1346 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.225 LC CDR2 <400> 1346 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1347 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.225 LC CDR3 <400> 1347 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1348 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.225 HC CDR1 <400> 1348 Thr Tyr Ser Met His 1 5 <210> 1349 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.225 HC CDR2 <400> 1349 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1350 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.225 HC CDR3 <400> 1350 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1351 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.226 LC CDR1 <400> 1351 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1352 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.226 LC CDR2 <400> 1352 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1353 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.226 LC CDR3 <400> 1353 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1354 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.226 HC CDR1 <400> 1354 Asn Phe Ala Met His 1 5 <210> 1355 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.226 HC CDR2 <400> 1355 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Phe Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1356 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.226 HC CDR3 <400> 1356 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1357 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.227 LC CDR1 <400> 1357 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1358 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.227 LC CDR2 <400> 1358 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1359 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.227 LC CDR3 <400> 1359 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1360 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.227 HC CDR1 <400> 1360 Asn Phe Ala Met His 1 5 <210> 1361 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.227 HC CDR2 <400> 1361 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1362 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.227 HC CDR3 <400> 1362 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1363 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.228 LC CDR1 <400> 1363 Ser Gly Ser Ser Ser Asn Val Gly Ser Asn Thr Val Asn 1 5 10 <210> 1364 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.228 LC CDR2 <400> 1364 Ser Asn Asp Gln Arg Pro Ser 1 5 <210> 1365 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.228 LC CDR3 <400> 1365 Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1366 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.228 HC CDR1 <400> 1366 Ser Phe Ala Met His 1 5 <210> 1367 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.228 HC CDR2 <400> 1367 Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1368 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.228 HC CDR3 <400> 1368 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1369 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.229 LC CDR1 <400> 1369 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1370 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.229 LC CDR2 <400> 1370 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1371 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.229 LC CDR3 <400> 1371 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1372 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.229 HC CDR1 <400> 1372 Arg Phe Ala Met His 1 5 <210> 1373 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.229 HC CDR2 <400> 1373 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1374 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.229 HC CDR3 <400> 1374 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1375 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.230 LC CDR1 <400> 1375 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1376 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.230 LC CDR2 <400> 1376 Ser Ser Asn Gln Arg Pro Ser 1 5 <210> 1377 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.230 LC CDR3 <400> 1377 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1378 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.230 HC CDR1 <400> 1378 Asn Phe Ala Met His 1 5 <210> 1379 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.230 HC CDR2 <400> 1379 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1380 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.230 HC CDR3 <400> 1380 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1381 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.231 LC CDR1 <400> 1381 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1382 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.231 LC CDR2 <400> 1382 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1383 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.231 LC CDR3 <400> 1383 Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1384 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.231 HC CDR1 <400> 1384 Ser Phe Ala Met His 1 5 <210> 1385 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.231 HC CDR2 <400> 1385 Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1386 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.231 HC CDR3 <400> 1386 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1387 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.232 LC CDR1 <400> 1387 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1388 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.232 LC CDR2 <400> 1388 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1389 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.232 LC CDR3 <400> 1389 Ala Ala Trp Asp Asp Ser Leu Asn Ala Trp Val 1 5 10 <210> 1390 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.232 HC CDR1 <400> 1390 Ser Tyr Ser Met His 1 5 <210> 1391 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.232 HC CDR2 <400> 1391 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1392 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.232 HC CDR3 <400> 1392 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1393 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 233 LC CDR1 <400> 1393 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1394 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 233 LC CDR2 <400> 1394 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1395 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 233 LC CDR3 <400> 1395 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1396 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 233 HC CDR1 <400> 1396 Arg Phe Ala Met His 1 5 <210> 1397 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 233 HC CDR2 <400> 1397 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1398 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 233 HC CDR3 <400> 1398 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1399 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.234 LC CDR1 <400> 1399 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1400 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.234 LC CDR2 <400> 1400 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1401 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.234 LC CDR3 <400> 1401 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1402 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.234 HC CDR1 <400> 1402 Arg Phe Ala Met His 1 5 <210> 1403 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.234 HC CDR2 <400> 1403 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1404 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.234 HC CDR3 <400> 1404 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1405 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.235 LC CDR1 <400> 1405 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1406 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.235 LC CDR2 <400> 1406 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1407 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.235 LC CDR3 <400> 1407 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1408 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.235 HC CDR1 <400> 1408 Ser Tyr Ala Met His 1 5 <210> 1409 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.235 HC CDR2 <400> 1409 Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1410 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.235 HC CDR3 <400> 1410 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1411 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.236 LC CDR1 <400> 1411 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1412 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.236 LC CDR2 <400> 1412 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1413 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.236 LC CDR3 <400> 1413 Gly Thr Trp Asp Ser Asn Ser Glu Thr Trp Val 1 5 10 <210> 1414 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.236 HC CDR1 <400> 1414 Thr Tyr Ser Met His 1 5 <210> 1415 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.236 HC CDR2 <400> 1415 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1416 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.236 HC CDR3 <400> 1416 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1417 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.237 LC CDR1 <400> 1417 Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1418 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.237 LC CDR2 <400> 1418 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1419 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.237 LC CDR3 <400> 1419 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1420 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.237 HC CDR1 <400> 1420 Ser Phe Ala Met His 1 5 <210> 1421 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.237 HC CDR2 <400> 1421 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1422 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.237 HC CDR3 <400> 1422 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1423 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.238 LC CDR1 <400> 1423 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1424 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.238 LC CDR2 <400> 1424 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1425 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.238 LC CDR3 <400> 1425 Ala Ala Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1426 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.238 HC CDR1 <400> 1426 Thr Tyr Ser Met His 1 5 <210> 1427 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.238 HC CDR2 <400> 1427 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1428 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.238 HC CDR3 <400> 1428 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1429 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.239 LC CDR1 <400> 1429 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn 1 5 10 <210> 1430 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.239 LC CDR2 <400> 1430 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1431 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.239 LC CDR3 <400> 1431 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1432 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.239 HC CDR1 <400> 1432 Asn Phe Ala Met His 1 5 <210> 1433 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.239 HC CDR2 <400> 1433 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1434 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.239 HC CDR3 <400> 1434 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1435 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.240 LC CDR1 <400> 1435 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1436 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.240 LC CDR2 <400> 1436 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1437 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.240 LC CDR3 <400> 1437 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1438 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.240 HC CDR1 <400> 1438 Asn Phe Ala Met His 1 5 <210> 1439 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.240 HC CDR2 <400> 1439 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1440 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.240 HC CDR3 <400> 1440 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1441 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 241 LC CDR1 <400> 1441 Ser Gly Ser Ser Ser Asn Ile Gly Ile Asn Ser Val Asn 1 5 10 <210> 1442 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 241 LC CDR2 <400> 1442 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1443 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 241 LC CDR3 <400> 1443 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1444 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 241 HC CDR1 <400> 1444 Ser Phe Ala Met His 1 5 <210> 1445 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 241 HC CDR2 <400> 1445 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1446 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 241 HC CDR3 <400> 1446 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1447 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 242 LC CDR1 <400> 1447 Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn 1 5 10 <210> 1448 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 242 LC CDR2 <400> 1448 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1449 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 242 LC CDR3 <400> 1449 Ala Thr Trp Asp Asp Ser Leu Asn Gly Trp Val 1 5 10 <210> 1450 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 242 HC CDR1 <400> 1450 Ser Phe Ala Met His 1 5 <210> 1451 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 242 HC CDR2 <400> 1451 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Glu Ser Val Lys 1 5 10 15 Gly <210> 1452 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 242 HC CDR3 <400> 1452 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1453 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 243 LC CDR1 <400> 1453 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1454 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 243 LC CDR2 <400> 1454 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1455 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 243 LC CDR3 <400> 1455 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1456 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 243 HC CDR1 <400> 1456 Ser Phe Ala Met His 1 5 <210> 1457 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No. 243 HC CDR2 <400> 1457 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1458 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No. 243 HC CDR3 <400> 1458 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1459 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.244 LC CDR1 <400> 1459 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1460 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.244 LC CDR2 <400> 1460 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1461 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.244 LC CDR3 <400> 1461 Ala Ala Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1462 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.244 HC CDR1 <400> 1462 Asn Phe Ala Met His 1 5 <210> 1463 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.244 HC CDR2 <400> 1463 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1464 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.244 HC CDR3 <400> 1464 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1465 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.245 LC CDR1 <400> 1465 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1466 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.245 LC CDR2 <400> 1466 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1467 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.245 LC CDR3 <400> 1467 Ala Thr Trp Asp Asp Ser Leu Asn Ala Trp Val 1 5 10 <210> 1468 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.245 HC CDR1 <400> 1468 Arg Phe Ala Met His 1 5 <210> 1469 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.245 HC CDR2 <400> 1469 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1470 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.245 HC CDR3 <400> 1470 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1471 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.246 LC CDR1 <400> 1471 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1472 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.246 LC CDR2 <400> 1472 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1473 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.246 LC CDR3 <400> 1473 Ala Thr Trp Asp Asp Ser Leu Asn Gly Tyr Val 1 5 10 <210> 1474 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.246 HC CDR1 <400> 1474 Arg Phe Ala Met His 1 5 <210> 1475 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.246 HC CDR2 <400> 1475 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1476 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.246 HC CDR3 <400> 1476 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1477 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.247 LC CDR1 <400> 1477 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1478 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> No.247 LC CDR2 <400> 1478 Ser Asn Gln Arg Pro Ser 1 5 <210> 1479 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.247 LC CDR3 <400> 1479 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1480 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.247 HC CDR1 <400> 1480 Arg Phe Ala Met His 1 5 <210> 1481 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.247 HC CDR2 <400> 1481 Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1482 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.247 HC CDR3 <400> 1482 Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro Phe Phe 1 5 10 15 Asp Tyr <210> 1483 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.248 LC CDR1 <400> 1483 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1484 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.248 LC CDR2 <400> 1484 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1485 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.248 LC CDR3 <400> 1485 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 1486 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.248 HC CDR1 <400> 1486 Thr Ser Gly Val Gly Val Gly 1 5 <210> 1487 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.248 HC CDR2 <400> 1487 Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser Leu Lys Thr 1 5 10 15 <210> 1488 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> No.248 HC CDR3 <400> 1488 Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr Tyr Gly Met 1 5 10 15 Asp Val <210> 1489 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.249 LC CDR1 <400> 1489 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 1490 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.249 LC CDR2 <400> 1490 Tyr Asp Ser Asp Arg Pro Ser 1 5 <210> 1491 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.249 LC CDR3 <400> 1491 Gln Val Trp Asp Gly Ser Ser Asp His Tyr Val 1 5 10 <210> 1492 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.249 HC CDR1 <400> 1492 Ser Tyr Ala Met Ser 1 5 <210> 1493 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.249 HC CDR2 <400> 1493 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1494 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.249 HC CDR3 <400> 1494 Leu Ser His Gly Val Val Gly Ala Gln Asp Ala Phe Asp Ile 1 5 10 <210> 1495 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.250 LC CDR1 <400> 1495 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1496 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.250 LC CDR2 <400> 1496 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1497 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.250 LC CDR3 <400> 1497 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1498 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.250 HC CDR1 <400> 1498 Ser Tyr Ala Ile Ser 1 5 <210> 1499 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.250 HC CDR2 <400> 1499 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1500 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.250 HC CDR3 <400> 1500 Glu Glu Ala Thr Thr Gly Ile Asn Thr Asn Trp Phe Asp Pro 1 5 10 <210> 1501 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.251 LC CDR1 <400> 1501 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1502 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.251 LC CDR2 <400> 1502 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1503 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.251 LC CDR3 <400> 1503 Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val 1 5 10 <210> 1504 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.251 HC CDR1 <400> 1504 Asp Tyr Ala Met His 1 5 <210> 1505 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.251 HC CDR2 <400> 1505 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1506 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.251 HC CDR3 <400> 1506 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1507 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.252 LC CDR1 <400> 1507 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1508 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.252 LC CDR2 <400> 1508 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1509 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.252 LC CDR3 <400> 1509 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 1510 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.252 HC CDR1 <400> 1510 Asp Tyr Ala Met His 1 5 <210> 1511 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.252 HC CDR2 <400> 1511 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1512 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.252 HC CDR3 <400> 1512 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1513 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.253 LC CDR1 <400> 1513 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1514 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.253 LC CDR2 <400> 1514 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1515 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.253 LC CDR3 <400> 1515 Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val 1 5 10 <210> 1516 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.253 HC CDR1 <400> 1516 Asp Tyr Ala Met His 1 5 <210> 1517 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.253 HC CDR2 <400> 1517 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1518 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.253 HC CDR3 <400> 1518 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1519 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.254 LC CDR1 <400> 1519 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 1520 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.254 LC CDR2 <400> 1520 Tyr Asp Ser Asp Arg Pro Ser 1 5 <210> 1521 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.254 LC CDR3 <400> 1521 Gln Val Trp Asp Ser Ser Ser Asp His Pro Val 1 5 10 <210> 1522 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.254 HC CDR1 <400> 1522 Asp Tyr Ala Met His 1 5 <210> 1523 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.254 HC CDR2 <400> 1523 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1524 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.254 HC CDR3 <400> 1524 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1525 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.255 LC CDR1 <400> 1525 Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln 1 5 10 <210> 1526 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.255 LC CDR2 <400> 1526 Glu Asp Asn Gln Arg Pro Ser 1 5 <210> 1527 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.255 LC CDR3 <400> 1527 Gln Ser Tyr Asp Ser Ser Asn His Ala Val 1 5 10 <210> 1528 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.255 HC CDR1 <400> 1528 Asp Tyr Ala Met His 1 5 <210> 1529 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.255 HC CDR2 <400> 1529 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1530 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.255 HC CDR3 <400> 1530 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1531 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.256 LC CDR1 <400> 1531 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1532 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.256 LC CDR2 <400> 1532 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1533 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.256 LC CDR3 <400> 1533 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1534 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.256 HC CDR1 <400> 1534 Asp Tyr Ala Met His 1 5 <210> 1535 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.256 HC CDR2 <400> 1535 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1536 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.256 HC CDR3 <400> 1536 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1537 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.257 LC CDR1 <400> 1537 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1538 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.257 LC CDR2 <400> 1538 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1539 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.257 LC CDR3 <400> 1539 Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val 1 5 10 <210> 1540 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.257 HC CDR1 <400> 1540 Asp Tyr Ala Met His 1 5 <210> 1541 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.257 HC CDR2 <400> 1541 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1542 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.257 HC CDR3 <400> 1542 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1543 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.258 LC CDR1 <400> 1543 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1544 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.258 LC CDR2 <400> 1544 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1545 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.258 LC CDR3 <400> 1545 Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val 1 5 10 <210> 1546 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.258 HC CDR1 <400> 1546 Asp Tyr Ala Met His 1 5 <210> 1547 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.258 HC CDR2 <400> 1547 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1548 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.258 HC CDR3 <400> 1548 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1549 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.259 LC CDR1 <400> 1549 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1550 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.259 LC CDR2 <400> 1550 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1551 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.259 LC CDR3 <400> 1551 Ala Ala Trp Asp Asp Ser Leu Asn Gly Val Val 1 5 10 <210> 1552 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.259 HC CDR1 <400> 1552 Asp Tyr Ala Met His 1 5 <210> 1553 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.259 HC CDR2 <400> 1553 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1554 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.259 HC CDR3 <400> 1554 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1555 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.260 LC CDR1 <400> 1555 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1556 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.260 LC CDR2 <400> 1556 Thr Asn Asn Gln Arg Pro Ser 1 5 <210> 1557 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.260 LC CDR3 <400> 1557 Ala Ala Trp Asp Asp Ser Leu Asn Gly Leu Val 1 5 10 <210> 1558 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.260 HC CDR1 <400> 1558 Asp Tyr Ala Met His 1 5 <210> 1559 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.260 HC CDR2 <400> 1559 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1560 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.260 HC CDR3 <400> 1560 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1561 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.261 LC CDR1 <400> 1561 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1562 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.261 LC CDR2 <400> 1562 Asp Asn Asp Lys Arg Pro Ser 1 5 <210> 1563 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.261 LC CDR3 <400> 1563 Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10 <210> 1564 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 261 HC CDR1 <400> 1564 Asp Tyr Ala Met His 1 5 <210> 1565 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.261 HC CDR2 <400> 1565 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1566 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No. 261 HC CDR3 <400> 1566 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1567 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.262 LC CDR1 <400> 1567 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1568 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.262 LC CDR2 <400> 1568 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1569 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.262 LC CDR3 <400> 1569 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Tyr Val 1 5 10 <210> 1570 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.262 HC CDR1 <400> 1570 Asp Tyr Ala Met His 1 5 <210> 1571 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.262 HC CDR2 <400> 1571 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1572 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.262 HC CDR3 <400> 1572 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1573 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.263 LC CDR1 <400> 1573 Ser Gly Ser Ser Pro Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1574 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.263 LC CDR2 <400> 1574 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1575 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.263 LC CDR3 <400> 1575 Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10 <210> 1576 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.263 HC CDR1 <400> 1576 Asp Tyr Ala Met His 1 5 <210> 1577 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.263 HC CDR2 <400> 1577 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1578 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.263 HC CDR3 <400> 1578 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1579 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.264 LC CDR1 <400> 1579 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1580 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.264 LC CDR2 <400> 1580 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1581 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.264 LC CDR3 <400> 1581 Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10 <210> 1582 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.264 HC CDR1 <400> 1582 Asp Tyr Ala Met His 1 5 <210> 1583 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.264 HC CDR2 <400> 1583 Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val Lys 1 5 10 15 Gly <210> 1584 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.264 HC CDR3 <400> 1584 Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val 1 5 10 <210> 1585 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.265 LC CDR1 <400> 1585 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1586 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.265 LC CDR2 <400> 1586 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1587 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.265 LC CDR3 <400> 1587 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val 1 5 10 <210> 1588 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.265 HC CDR1 <400> 1588 Ser Asn Tyr Met Thr 1 5 <210> 1589 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.265 HC CDR2 <400> 1589 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1590 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.265 HC CDR3 <400> 1590 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1591 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.266 LC CDR1 <400> 1591 Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 1 5 10 <210> 1592 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.266 LC CDR2 <400> 1592 Tyr Asp Ser Asp Arg Pro Ser 1 5 <210> 1593 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.266 LC CDR3 <400> 1593 Gln Val Arg Asp Ser Ser Ser Asp His Pro Val 1 5 10 <210> 1594 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.266 HC CDR1 <400> 1594 Ser Asn Tyr Met Thr 1 5 <210> 1595 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.266 HC CDR2 <400> 1595 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1596 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.266 HC CDR3 <400> 1596 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1597 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.267 LC CDR1 <400> 1597 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1598 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.267 LC CDR2 <400> 1598 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1599 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.267 LC CDR3 <400> 1599 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Val 1 5 10 <210> 1600 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.267 HC CDR1 <400> 1600 Ser Asn Tyr Met Thr 1 5 <210> 1601 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.267 HC CDR2 <400> 1601 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1602 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.267 HC CDR3 <400> 1602 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1603 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.268 LC CDR1 <400> 1603 Thr Gly Ser Asp Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1604 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.268 LC CDR2 <400> 1604 Asn Asn Asn Asn Arg Pro Ser 1 5 <210> 1605 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.268 LC CDR3 <400> 1605 Gln Ser Ser Asp Ser Gly Leu Thr Gly Trp Val 1 5 10 <210> 1606 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.268 HC CDR1 <400> 1606 Ser Asn Tyr Met Thr 1 5 <210> 1607 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.268 HC CDR2 <400> 1607 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1608 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.268 HC CDR3 <400> 1608 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1609 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.269 LC CDR1 <400> 1609 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1610 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.269 LC CDR2 <400> 1610 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1611 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.269 LC CDR3 <400> 1611 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1612 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.269 HC CDR1 <400> 1612 Ser Asn Tyr Met Thr 1 5 <210> 1613 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.269 HC CDR2 <400> 1613 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1614 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.269 HC CDR3 <400> 1614 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1615 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.270 LC CDR1 <400> 1615 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 1616 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.270 LC CDR2 <400> 1616 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 1617 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.270 LC CDR3 <400> 1617 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 1618 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.270 HC CDR1 <400> 1618 Ser Asn Tyr Met Thr 1 5 <210> 1619 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.270 HC CDR2 <400> 1619 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1620 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.270 HC CDR3 <400> 1620 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1621 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.271 LC CDR1 <400> 1621 Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1622 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.271 LC CDR2 <400> 1622 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1623 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.271 LC CDR3 <400> 1623 Ser Ser Tyr Ala Gly Ser Asn Asn Leu Val 1 5 10 <210> 1624 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.271 HC CDR1 <400> 1624 Ser Asn Tyr Met Thr 1 5 <210> 1625 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.271 HC CDR2 <400> 1625 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1626 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.271 HC CDR3 <400> 1626 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1627 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.272 LC CDR1 <400> 1627 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1628 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.272 LC CDR2 <400> 1628 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1629 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.272 LC CDR3 <400> 1629 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1630 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.272 HC CDR1 <400> 1630 Ser Asn Tyr Met Thr 1 5 <210> 1631 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.272 HC CDR2 <400> 1631 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1632 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.272 HC CDR3 <400> 1632 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1633 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.273 LC CDR1 <400> 1633 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 1634 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.273 LC CDR2 <400> 1634 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 1635 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.273 LC CDR3 <400> 1635 Gln Gln Tyr Gly Ser Ser Pro Leu Thr 1 5 <210> 1636 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.273 HC CDR1 <400> 1636 Ser Asn Tyr Met Thr 1 5 <210> 1637 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.273 HC CDR2 <400> 1637 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1638 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.273 HC CDR3 <400> 1638 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1639 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.274 LC CDR1 <400> 1639 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1640 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.274 LC CDR2 <400> 1640 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1641 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.274 LC CDR3 <400> 1641 Gln Ser Tyr Asp Ser Ser Leu Gly Val Val 1 5 10 <210> 1642 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.274 HC CDR1 <400> 1642 Ser Asn Tyr Met Thr 1 5 <210> 1643 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.274 HC CDR2 <400> 1643 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1644 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.274 HC CDR3 <400> 1644 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1645 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.275 LC CDR1 <400> 1645 Gly Gly Asn Asn Ile Gly Ser Asn Thr Val Asn 1 5 10 <210> 1646 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.275 LC CDR2 <400> 1646 Ser Asn Asn Leu Arg Pro Ser 1 5 <210> 1647 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.275 LC CDR3 <400> 1647 Ala Ala Trp Asp Asp Ser Leu Asn Gly Pro Val 1 5 10 <210> 1648 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.275 HC CDR1 <400> 1648 Ser Asn Tyr Met Thr 1 5 <210> 1649 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.275 HC CDR2 <400> 1649 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1650 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.275 HC CDR3 <400> 1650 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1651 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.276 LC CDR1 <400> 1651 Ser Gly Ser Ser Ser Asn Ile Gly Gly Ser Asp Val Gly 1 5 10 <210> 1652 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.276 LC CDR2 <400> 1652 Lys Ser Asn Gln Arg Pro Ser 1 5 <210> 1653 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.276 LC CDR3 <400> 1653 Ala Thr Trp Asp Asp Arg Leu Asn Trp Val 1 5 10 <210> 1654 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.276 HC CDR1 <400> 1654 Ser Asn Tyr Met Thr 1 5 <210> 1655 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.276 HC CDR2 <400> 1655 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1656 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.276 HC CDR3 <400> 1656 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1657 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.277 LC CDR1 <400> 1657 Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn 1 5 10 <210> 1658 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.277 LC CDR2 <400> 1658 Ala Ala Ser Ser Leu Gln Ser 1 5 <210> 1659 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.277 LC CDR3 <400> 1659 Gln Gln Ser Tyr Ser Thr Pro Phe Thr 1 5 <210> 1660 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.277 HC CDR1 <400> 1660 Asn Tyr Tyr Met His 1 5 <210> 1661 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.277 HC CDR2 <400> 1661 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1662 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.277 HC CDR3 <400> 1662 Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr 1 5 10 <210> 1663 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.278 LC CDR1 <400> 1663 Gln Ala Gly Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 1664 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.278 LC CDR2 <400> 1664 Lys Ala Ser Ser Leu Glu Ser 1 5 <210> 1665 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.278 LC CDR3 <400> 1665 Gln Gln Ala His Ser Phe Pro Phe Thr 1 5 <210> 1666 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.278 HC CDR1 <400> 1666 Ser Tyr Tyr Met His 1 5 <210> 1667 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.278 HC CDR2 <400> 1667 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1668 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.278 HC CDR3 <400> 1668 Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr 1 5 10 <210> 1669 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.279 LC CDR1 <400> 1669 Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10 <210> 1670 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.279 LC CDR2 <400> 1670 Asp Ala Ser Asn Leu Glu Thr 1 5 <210> 1671 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.279 LC CDR3 <400> 1671 Gln Gln Ser Tyr Ser Thr Leu Pro Thr 1 5 <210> 1672 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.279 HC CDR1 <400> 1672 Ser Tyr Tyr Met His 1 5 <210> 1673 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.279 HC CDR2 <400> 1673 Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1674 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.279 HC CDR3 <400> 1674 Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr 1 5 10 <210> 1675 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.280 LC CDR1 <400> 1675 Thr Gly Ser Ser Ser Asn Thr Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1676 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.280 LC CDR2 <400> 1676 Ser Asn Asn Gln Arg Pro Ser 1 5 <210> 1677 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.280 LC CDR3 <400> 1677 Ala Ala Trp Asp Asp Ser Leu Asn Gly Gly Val 1 5 10 <210> 1678 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.280 HC CDR1 <400> 1678 Ser Asn Tyr Met Ser 1 5 <210> 1679 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.280 HC CDR2 <400> 1679 Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1680 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.280 HC CDR3 <400> 1680 Asp Leu Ile Val Tyr Gly Met Asp Val 1 5 <210> 1681 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No. 281 LC CDR1 <400> 1681 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1682 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No. 281 LC CDR2 <400> 1682 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1683 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No. 281 LC CDR3 <400> 1683 Ala Ala Trp Asp Asp Ser Leu Ser Gly Trp Val 1 5 10 <210> 1684 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No. 281 HC CDR1 <400> 1684 Ser Asn Tyr Met Ser 1 5 <210> 1685 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.281 HC CDR2 <400> 1685 Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1686 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No. 281 HC CDR3 <400> 1686 Asp Leu Ile Val Tyr Gly Met Asp Val 1 5 <210> 1687 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.282 LC CDR1 <400> 1687 Ser Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1688 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.282 LC CDR2 <400> 1688 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1689 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.282 LC CDR3 <400> 1689 Ala Ala Trp Asp Asp Ser Leu Asn Gly Gly Val 1 5 10 <210> 1690 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.282 HC CDR1 <400> 1690 Ser Asn Tyr Met Ser 1 5 <210> 1691 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.282 HC CDR2 <400> 1691 Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1692 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.282 HC CDR3 <400> 1692 Asp Leu Ile Val Tyr Gly Met Asp Val 1 5 <210> 1693 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.283 LC CDR1 <400> 1693 Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 1 5 10 <210> 1694 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.283 LC CDR2 <400> 1694 Asp Ala Ser Asn Arg Ala Thr 1 5 <210> 1695 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.283 LC CDR3 <400> 1695 Gln Gln Tyr Gly Ser Ser Pro Pro Tyr Thr 1 5 10 <210> 1696 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.283 HC CDR1 <400> 1696 Ser Asn Tyr Met Ser 1 5 <210> 1697 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.283 HC CDR2 <400> 1697 Val Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1698 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> No.283 HC CDR3 <400> 1698 Asp Leu Arg Gly Val Leu Asp Tyr 1 5 <210> 1699 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.284 LC CDR1 <400> 1699 Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1700 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.284 LC CDR2 <400> 1700 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1701 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.284 LC CDR3 <400> 1701 Gly Thr Trp Asp Ser Ser Leu Ser Ala Gly Val 1 5 10 <210> 1702 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.284 HC CDR1 <400> 1702 Ser Asn Tyr Met Ser 1 5 <210> 1703 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.284 HC CDR2 <400> 1703 Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1704 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.284 HC CDR3 <400> 1704 Gly His Val Asp Ile Pro Tyr Gly Met Asp Val 1 5 10 <210> 1705 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.285 LC CDR1 <400> 1705 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1706 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.285 LC CDR2 <400> 1706 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1707 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.285 LC CDR3 <400> 1707 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1708 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.285 HC CDR1 <400> 1708 Ser Tyr Ala Ile Ser 1 5 <210> 1709 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.285 HC CDR2 <400> 1709 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1710 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.285 HC CDR3 <400> 1710 Glu Lys Gly Tyr Ser Gly Ser Gly Ser Val Asn Trp Phe Asp Pro 1 5 10 15 <210> 1711 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.286 LC CDR1 <400> 1711 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1712 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.286 LC CDR2 <400> 1712 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1713 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.286 LC CDR3 <400> 1713 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1714 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.286 HC CDR1 <400> 1714 Ser Tyr Ala Ile Ser 1 5 <210> 1715 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.286 HC CDR2 <400> 1715 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1716 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> No.286 HC CDR3 <400> 1716 Glu Lys Gly Tyr Ser Gly Ser Gly Ser Val Asn Trp Phe Asp Pro 1 5 10 15 <210> 1717 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.287 LC CDR1 <400> 1717 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1718 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.287 LC CDR2 <400> 1718 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1719 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.287 LC CDR3 <400> 1719 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1720 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.287 HC CDR1 <400> 1720 Ser Tyr Ala Ile Ser 1 5 <210> 1721 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.287 HC CDR2 <400> 1721 Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln 1 5 10 15 Gly <210> 1722 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.287 HC CDR3 <400> 1722 Glu Glu Ala Thr Thr Gly Ile Asn Thr Asn Trp Phe Asp Pro 1 5 10 <210> 1723 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.288 LC CDR1 <400> 1723 Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn Tyr Val Gln 1 5 10 <210> 1724 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.288 LC CDR2 <400> 1724 Glu Asp Asn Gln Arg Pro Ser 1 5 <210> 1725 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> No.288 LC CDR3 <400> 1725 Gln Ser Tyr Asp Ser Ser Asn His Trp Val 1 5 10 <210> 1726 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.288 HC CDR1 <400> 1726 Ser Tyr Ala Met His 1 5 <210> 1727 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.288 HC CDR2 <400> 1727 Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1728 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.288 HC CDR3 <400> 1728 Ala Asn Leu Gly Tyr Cys Thr Asn Gly Val Cys Ala Pro Ser Gly Gly 1 5 10 15 <210> 1729 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> No.289 LC CDR1 <400> 1729 Ser Gly Gly Ser Ser Asn Ile Gly Asn Asn Tyr Val Ser 1 5 10 <210> 1730 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.289 LC CDR2 <400> 1730 Asp Asn Asn Lys Arg Pro Ser 1 5 <210> 1731 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.289 LC CDR3 <400> 1731 Gly Thr Trp Asp Ser Ser Leu Ser Ala Trp Val 1 5 10 <210> 1732 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.289 HC CDR1 <400> 1732 Asp Tyr Ala Met His 1 5 <210> 1733 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> No.289 HC CDR2 <400> 1733 Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val Lys 1 5 10 15 Gly <210> 1734 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.289 HC CDR3 <400> 1734 Asn Leu Arg Tyr Phe Asp Trp Leu Leu Gly Asp Asp Ala Phe Asp Ile 1 5 10 15 <210> 1735 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> No.290 LC CDR1 <400> 1735 Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His 1 5 10 <210> 1736 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> No.290 LC CDR2 <400> 1736 Gly Asn Ser Asn Arg Pro Ser 1 5 <210> 1737 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> No.290 LC CDR3 <400> 1737 Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val 1 5 10 <210> 1738 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> No.290 HC CDR1 <400> 1738 Ser Asn Tyr Met Thr 1 5 <210> 1739 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> No.290 HC CDR2 <400> 1739 Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys Gly 1 5 10 15 <210> 1740 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> No.290 HC CDR3 <400> 1740 Asp Leu Val Val Tyr Gly Met Asp Val 1 5 <210> 1741 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.1 LC variable region <400> 1741 Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1742 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.1 HC variable region <400> 1742 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Lys Gly Asp Cys Gly Gly Asp Cys Tyr Ser Phe Leu Leu Gly Glu 100 105 110 Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 1743 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.2 LC variable region <400> 1743 Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Thr Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Val Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Arg Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ile Pro His 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1744 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.2 HC variable region <400> 1744 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Lys Gly Asp Cys Gly Gly Asp Cys Tyr Ser Phe Leu Leu Gly Glu 100 105 110 Asp Ala Phe Asp Ile Trp Gly Gly Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 1745 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.3 LC variable region <400> 1745 Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile 85 90 95 Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1746 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.3 HC variable region <400> 1746 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr 100 105 110 Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 1747 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.4 LC variable region <400> 1747 Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asp Leu Pro Ile 85 90 95 Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1748 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.4 HC variable region <400> 1748 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr 100 105 110 Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 1749 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.5 LC variable region <400> 1749 Glu Leu Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asp Asn Leu Pro Ile 85 90 95 Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1750 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.5 HC variable region <400> 1750 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Ser Leu Val Ser Gly Arg Tyr Cys Ser Gly Val Thr Cys Tyr 100 105 110 Ser Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 1751 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.6 LC variable region <400> 1751 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1752 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.6 HC variable region <400> 1752 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1753 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.7 LC variable region <400> 1753 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Pro Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1754 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.7 HC variable region <400> 1754 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1755 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.8 LC variable region <400> 1755 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1756 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.8 HC variable region <400> 1756 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1757 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.9 LC variable region <400> 1757 Glu Leu Glu Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1758 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.9 HC variable region <400> 1758 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1759 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.10 LC variable region <400> 1759 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1760 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.10 HC variable region <400> 1760 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Glu Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1761 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.11 LC variable region <400> 1761 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1762 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.11 HC variable region <400> 1762 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Glu Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1763 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.12 LC variable region <400> 1763 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1764 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.12 HC variable region <400> 1764 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1765 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.13 LC variable region <400> 1765 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Gly Asn Tyr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1766 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.13 HC variable region <400> 1766 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1767 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.14 LC variable region <400> 1767 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn 20 25 30 Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Arg Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 1768 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.14 HC variable region <400> 1768 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1769 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.15 LC variable region <400> 1769 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Pro Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1770 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.15 HC variable region <400> 1770 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1771 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.16 LC variable region <400> 1771 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1772 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.16 HC variable region <400> 1772 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1773 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.17 LC variable region <400> 1773 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1774 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.17 HC variable region <400> 1774 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1775 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.18 LC variable region <400> 1775 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1776 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.18 HC variable region <400> 1776 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1777 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.19 LC variable region <400> 1777 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1778 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.19 HC variable region <400> 1778 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1779 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.20 LC variable region <400> 1779 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1780 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.20 HC variable region <400> 1780 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1781 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.21 LC variable region <400> 1781 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1782 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.21 HC variable region <400> 1782 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1783 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.22 LC variable region <400> 1783 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1784 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.22 HC variable region <400> 1784 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1785 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.23 LC variable region <400> 1785 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1786 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.23 HC variable region <400> 1786 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1787 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.24 LC variable region <400> 1787 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Pro Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1788 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.24 HC variable region <400> 1788 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1789 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.25 LC variable region <400> 1789 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1790 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.25 HC variable region <400> 1790 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1791 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.26 LC variable region <400> 1791 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1792 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.26 HC variable region <400> 1792 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1793 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.27 LC variable region <400> 1793 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1794 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.27 HC variable region <400> 1794 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1795 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.28 LC variable region <400> 1795 Glu Leu Glu Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1796 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.28 HC variable region <400> 1796 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1797 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.29 LC variable region <400> 1797 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1798 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.29 HC variable region <400> 1798 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1799 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.30 LC variable region <400> 1799 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1800 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.30 HC variable region <400> 1800 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1801 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.31 LC variable region <400> 1801 Glu Leu Gly Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Asn 20 25 30 Tyr Val His Trp Tyr Gln Gln Leu Pro Gly Ala Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1802 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.31 HC variable region <400> 1802 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Arg Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1803 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.32 LC variable region <400> 1803 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1804 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.32 HC variable region <400> 1804 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1805 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.33 LC variable region <400> 1805 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1806 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.33 HC variable region <400> 1806 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1807 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.34 LC variable region <400> 1807 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1808 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.34 HC variable region <400> 1808 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Thr Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1809 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.35 LC variable region <400> 1809 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1810 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.35 HC variable region <400> 1810 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1811 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.36 LC variable region <400> 1811 Glu Leu Val Val Thr Gln Pro Ser Ala Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Gly Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1812 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.36 HC variable region <400> 1812 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1813 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.37 LC variable region <400> 1813 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Pro Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1814 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.37 HC variable region <400> 1814 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1815 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.38 LC variable region <400> 1815 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1816 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.38 HC variable region <400> 1816 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1817 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.39 LC variable region <400> 1817 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1818 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.39 HC variable region <400> 1818 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1819 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.40 LC variable region <400> 1819 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1820 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.40 HC variable region <400> 1820 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1821 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.41 LC variable region <400> 1821 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1822 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.41 HC variable region <400> 1822 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1823 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.42 LC variable region <400> 1823 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Lys Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1824 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.42 HC variable region <400> 1824 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Asp Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1825 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.43 LC variable region <400> 1825 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Arg Asn Asn Gln Arg Pro Pro Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Arg Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1826 <211> 131 <212> PRT <213> Artificial Sequence <220> <223> No.43 HC variable region <400> 1826 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Gly Val Val Val Pro Ala Val Met Tyr Asp Thr Thr Asp 100 105 110 Pro Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> 1827 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.44 LC variable region <400> 1827 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Val Thr Thr Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1828 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.44 HC variable region <400> 1828 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Arg Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Pro Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1829 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.45 LC variable region <400> 1829 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1830 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.45 HC variable region <400> 1830 Gln Val Gln Leu Gln Glu Ser Asp Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1831 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.46 LC variable region <400> 1831 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1832 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.46 HC variable region <400> 1832 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1833 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.47 LC variable region <400> 1833 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Phe Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1834 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.47 HC variable region <400> 1834 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1835 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.48 LC variable region <400> 1835 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1836 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.48 HC variable region <400> 1836 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Val Ser Gly Gly Ser Ile Ser His Tyr 20 25 30 Phe Trp Ser Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Asn Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys 50 55 60 Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 65 70 75 80 Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser Thr Gly 100 105 110 Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 1837 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.49 LC variable region <400> 1837 Glu Leu Ala Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Thr Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1838 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.49 HC variable region <400> 1838 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1839 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.50 LC variable region <400> 1839 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1840 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.50 HC variable region <400> 1840 Gln Val Gln Leu Gln Glu Ser Asp Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1841 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.51 LC variable region <400> 1841 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1842 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.51 HC variable region <400> 1842 Gln Val Gln Leu Gln Glu Ser Asp Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1843 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.52 LC variable region <400> 1843 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Phe Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1844 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.52 HC variable region <400> 1844 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1845 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.53 LC variable region <400> 1845 Glu Leu Gln Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Gly Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Ala Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1846 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.53 HC variable region <400> 1846 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1847 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.54 LC variable region <400> 1847 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Ala Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Thr His Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1848 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.54 HC variable region <400> 1848 Arg Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1849 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.55 LC variable region <400> 1849 Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Thr Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser 85 90 95 Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1850 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.55 HC variable region <400> 1850 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1851 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.56 LC variable region <400> 1851 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro 85 90 95 Gly Arg Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 1852 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.56 HC variable region <400> 1852 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1853 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.57 LC variable region <400> 1853 Glu Leu Val Met Thr Gln Ser Pro Gly Ile Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1854 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.57 HC variable region <400> 1854 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1855 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.58 LC variable region <400> 1855 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1856 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.58 HC variable region <400> 1856 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1857 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.59 LC variable region <400> 1857 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1858 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.59 HC variable region <400> 1858 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1859 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.60 LC variable region <400> 1859 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Pro Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1860 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.60 HC variable region <400> 1860 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1861 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.61 LC variable region <400> 1861 Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Ser 85 90 95 Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1862 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.61 HC variable region <400> 1862 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1863 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.62 LC variable region <400> 1863 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Phe Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1864 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.62 HC variable region <400> 1864 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1865 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.63 LC variable region <400> 1865 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1866 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.63 HC variable region <400> 1866 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Val Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1867 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.64 LC variable region <400> 1867 Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1868 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.64 HC variable region <400> 1868 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1869 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.65 LC variable region <400> 1869 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Ser Ala Thr Leu Ala Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro 85 90 95 Gly Arg Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 1870 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.65 HC variable region <400> 1870 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1871 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.66 LC variable region <400> 1871 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1872 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.66 HC variable region <400> 1872 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1873 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.67 LC variable region <400> 1873 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1874 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.67 HC variable region <400> 1874 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1875 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.68 LC variable region <400> 1875 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Pro Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro 85 90 95 Gly Arg Val Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 1876 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.68 HC variable region <400> 1876 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Val Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1877 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> No.69 LC variable region <400> 1877 Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Arg Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile His Ala Ala Ser Thr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Val Glu 65 70 75 80 Pro Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Asp Ser Leu 85 90 95 Ser Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1878 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.69 HC variable region <400> 1878 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1879 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.70 LC variable region <400> 1879 Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser 85 90 95 Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1880 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.70 HC variable region <400> 1880 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1881 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.71 LC variable region <400> 1881 Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1882 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.71 HC variable region <400> 1882 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1883 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> No.72 LC variable region <400> 1883 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met 35 40 45 Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln 65 70 75 80 Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser Ser 85 90 95 Thr Leu Pro Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 <210> 1884 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.72 HC variable region <400> 1884 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1885 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.73 LC variable region <400> 1885 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Ser Ala Thr Leu Ala Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Phe Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Glu Tyr Gly Ser Ser Pro 85 90 95 Gly Arg Val Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 110 <210> 1886 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.73 HC variable region <400> 1886 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Pro Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1887 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.74 LC variable region <400> 1887 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1888 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.74 HC variable region <400> 1888 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1889 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.75 LC variable region <400> 1889 Glu Leu Thr Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1890 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.75 HC variable region <400> 1890 Glu Val Gln Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1891 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.76 LC variable region <400> 1891 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Phe Phe Cys Arg Ala Ser Gln Ser Val Ser Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1892 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.76 HC variable region <400> 1892 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1893 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.77 LC variable region <400> 1893 Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Gly Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln His Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 1894 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.77 HC variable region <400> 1894 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1895 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.78 LC variable region <400> 1895 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Phe Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser 50 55 60 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu 65 70 75 80 Pro Glu Asp Phe Ala Leu Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95 Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1896 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.78 HC variable region <400> 1896 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Ala Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1897 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.79 LC variable region <400> 1897 Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser Thr Pro Ser 85 90 95 Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1898 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.79 HC variable region <400> 1898 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1899 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.80 LC variable region <400> 1899 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1900 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.80 HC variable region <400> 1900 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1901 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.81 LC variable region <400> 1901 Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1902 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.81 HC variable region <400> 1902 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1903 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.82 LC variable region <400> 1903 Glu Leu Thr Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105 <210> 1904 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.82 HC variable region <400> 1904 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1905 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.83 LC variable region <400> 1905 Glu Leu Gln Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1906 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.83 HC variable region <400> 1906 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Gly Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Met Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1907 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.84 LC variable region <400> 1907 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 20 25 30 Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu 35 40 45 Met Ile Tyr Asp Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ser Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1908 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.84 HC variable region <400> 1908 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Val Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1909 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.85 LC variable region <400> 1909 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1910 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.85 HC variable region <400> 1910 Gln Val Gln Leu Gln Glu Ser Asp Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1911 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.86 LC variable region <400> 1911 Glu Leu Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Arg Ala Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 1912 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.86 HC variable region <400> 1912 Glu Val Gln Leu Val Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1913 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.87 LC variable region <400> 1913 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1914 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.87 HC variable region <400> 1914 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Asn Ile Phe Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Ile Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser 115 120 125 Ser <210> 1915 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.88 LC variable region <400> 1915 Glu Leu Val Met Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Ser 85 90 95 Ile Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 1916 <211> 129 <212> PRT <213> Artificial Sequence <220> <223> No.88 HC variable region <400> 1916 Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 1 5 10 15 Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Asp Ser Ile Ser Ser Ser 20 25 30 Ser Tyr Tyr Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 35 40 45 Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 65 70 75 80 Ser Leu Asn Leu Ser Ser Ala Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95 Cys Ala Arg Gly Ser Arg Gly Tyr Tyr Asp Phe Leu Thr Gly Tyr Ser 100 105 110 Thr Gly Gly Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Ala Val Ser 115 120 125 Ser <210> 1917 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.89 LC variable region <400> 1917 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Arg Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 1918 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.89 HC variable region <400> 1918 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1919 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.90 LC variable region <400> 1919 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1920 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.90 HC variable region <400> 1920 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1921 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.91 LC variable region <400> 1921 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1922 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.91 HC variable region <400> 1922 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ala Gln 1 5 10 15 Thr Leu Arg Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Phe Ser 115 120 125 <210> 1923 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.92 LC variable region <400> 1923 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1924 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.92 HC variable region <400> 1924 Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1925 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.93 LC variable region <400> 1925 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Arg Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1926 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.93 HC variable region <400> 1926 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Val Asp Val Trp Gly Gin Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1927 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.94 LC variable region <400> 1927 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1928 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.94 HC variable region <400> 1928 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1929 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.95 LC variable region <400> 1929 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1930 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.95 HC variable region <400> 1930 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1931 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.96 LC variable region <400> 1931 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1932 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.96 HC variable region <400> 1932 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1933 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.97 LC variable region <400> 1933 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1934 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.97 HC variable region <400> 1934 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Ser Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1935 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.98 LC variable region <400> 1935 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1936 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.98 HC variable region <400> 1936 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1937 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.99 LC variable region <400> 1937 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1938 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.99 HC variable region <400> 1938 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1939 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.100 LC variable region <400> 1939 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1940 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.100 HC variable region <400> 1940 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1941 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.101 LC variable region <400> 1941 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1942 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.101 HC variable region <400> 1942 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1943 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.102 LC variable region <400> 1943 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1944 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.102 HC variable region <400> 1944 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1945 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.103 LC variable region <400> 1945 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1946 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.103 HC variable region <400> 1946 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1947 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.104 LC variable region <400> 1947 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Gly Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1948 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.104 HC variable region <400> 1948 Gln Val Gln Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1949 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.105 LC variable region <400> 1949 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 1950 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.105 HC variable region <400> 1950 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1951 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.106 LC variable region <400> 1951 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1952 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.106 HC variable region <400> 1952 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1953 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.107 LC variable region <400> 1953 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1954 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.107 HC variable region <400> 1954 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1955 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.108 LC variable region <400> 1955 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1956 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.108 HC variable region <400> 1956 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1957 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.109 LC variable region <400> 1957 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1958 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.109 HC variable region <400> 1958 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1959 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.110 LC variable region <400> 1959 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1960 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.110 HC variable region <400> 1960 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1961 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.111 LC variable region <400> 1961 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1962 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.111 HC variable region <400> 1962 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1963 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.112 LC variable region <400> 1963 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1964 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.112 HC variable region <400> 1964 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1965 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.113 LC variable region <400> 1965 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Ile Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1966 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.113 HC variable region <400> 1966 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1967 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.114 LC variable region <400> 1967 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1968 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.114 HC variable region <400> 1968 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1969 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.115 LC variable region <400> 1969 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1970 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.115 HC variable region <400> 1970 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1971 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.116 LC variable region <400> 1971 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1972 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.116 HC variable region <400> 1972 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1973 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.117 LC variable region <400> 1973 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1974 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.117 HC variable region <400> 1974 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1975 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.118 LC variable region <400> 1975 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1976 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.118 HC variable region <400> 1976 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1977 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.119 LC variable region <400> 1977 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1978 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.119 HC variable region <400> 1978 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1979 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.120 LC variable region <400> 1979 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 1980 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.120 HC variable region <400> 1980 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Thr Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1981 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.121 LC variable region <400> 1981 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 1982 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.121 HC variable region <400> 1982 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1983 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.122 LC variable region <400> 1983 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1984 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.122 HC variable region <400> 1984 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1985 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.123 LC variable region <400> 1985 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1986 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.123 HC variable region <400> 1986 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1987 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.124 LC variable region <400> 1987 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1988 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.124 HC variable region <400> 1988 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ala Gln 1 5 10 15 Thr Leu Arg Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Phe Ser 115 120 125 <210> 1989 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.125 LC variable region <400> 1989 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1990 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.125 HC variable region <400> 1990 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1991 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.126 LC variable region <400> 1991 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1992 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.126 HC variable region <400> 1992 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1993 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.127 LC variable region <400> 1993 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1994 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.127 HC variable region <400> 1994 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ala Gln 1 5 10 15 Thr Leu Arg Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Phe Ser 115 120 125 <210> 1995 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.128 LC variable region <400> 1995 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn 20 25 30 Phe Val Ser Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 1996 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.128 HC variable region <400> 1996 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1997 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.129 LC variable region <400> 1997 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Ser Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Asn Asn Leu 85 90 95 Ser Ala Gly Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 1998 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.129 HC variable region <400> 1998 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 1999 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.130 LC variable region <400> 1999 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2000 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.130 HC variable region <400> 2000 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2001 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.131 LC variable region <400> 2001 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2002 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.131 HC variable region <400> 2002 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2003 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.132 LC variable region <400> 2003 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2004 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.132 HC variable region <400> 2004 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2005 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.133 LC variable region <400> 2005 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2006 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.133 HC variable region <400> 2006 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2007 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.134 LC variable region <400> 2007 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2008 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.134 HC variable region <400> 2008 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2009 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.135 LC variable region <400> 2009 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2010 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.135 HC variable region <400> 2010 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2011 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.136 LC variable region <400> 2011 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2012 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.136 HC variable region <400> 2012 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2013 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.137 LC variable region <400> 2013 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2014 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.137 HC variable region <400> 2014 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2015 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.138 LC variable region <400> 2015 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2016 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.138 HC variable region <400> 2016 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2017 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.139 LC variable region <400> 2017 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2018 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.139 HC variable region <400> 2018 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr His Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2019 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.140 LC variable region <400> 2019 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2020 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.140 HC variable region <400> 2020 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Ser Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2021 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.141 LC variable region <400> 2021 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2022 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.141 HC variable region <400> 2022 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2023 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.142 LC variable region <400> 2023 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2024 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.142 HC variable region <400> 2024 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2025 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.143 LC variable region <400> 2025 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2026 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.143 HC variable region <400> 2026 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2027 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.144 LC variable region <400> 2027 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2028 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.144 HC variable region <400> 2028 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2029 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.145 LC variable region <400> 2029 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2030 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.145 HC variable region <400> 2030 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2031 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.146 LC variable region <400> 2031 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2032 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.146 HC variable region <400> 2032 Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2033 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.147 LC variable region <400> 2033 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Gly Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2034 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.147 HC variable region <400> 2034 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Phe Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2035 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.148 LC variable region <400> 2035 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2036 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.148 HC variable region <400> 2036 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2037 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.149 LC variable region <400> 2037 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2038 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.149 HC variable region <400> 2038 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2039 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.150 LC variable region <400> 2039 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2040 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.150 HC variable region <400> 2040 Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2041 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.151 LC variable region <400> 2041 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2042 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.151 HC variable region <400> 2042 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2043 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.152 LC variable region <400> 2043 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2044 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.152 HC variable region <400> 2044 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2045 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.153 LC variable region <400> 2045 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2046 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.153 HC variable region <400> 2046 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2047 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.154 LC variable region <400> 2047 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2048 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.154 HC variable region <400> 2048 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2049 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.155 LC variable region <400> 2049 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2050 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.155 HC variable region <400> 2050 Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2051 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.156 LC variable region <400> 2051 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2052 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.156 HC variable region <400> 2052 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2053 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.157 LC variable region <400> 2053 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2054 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.157 HC variable region <400> 2054 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2055 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.158 LC variable region <400> 2055 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2056 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.158 HC variable region <400> 2056 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2057 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.159 LC variable region <400> 2057 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2058 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.159 HC variable region <400> 2058 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2059 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.160 LC variable region <400> 2059 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2060 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.160 HC variable region <400> 2060 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2061 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.161 LC variable region <400> 2061 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2062 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.161 HC variable region <400> 2062 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2063 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.162 LC variable region <400> 2063 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2064 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.162 HC variable region <400> 2064 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2065 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.163 LC variable region <400> 2065 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2066 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.163 HC variable region <400> 2066 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2067 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.164 LC variable region <400> 2067 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2068 <211> 133 <212> PRT <213> Artificial Sequence <220> <223> No.164 HC variable region <400> 2068 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Pro Arg Asp His Gly His Arg Leu Leu 115 120 125 Ser Phe His Gln Gly 130 <210> 2069 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.165 LC variable region <400> 2069 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2070 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.165 HC variable region <400> 2070 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2071 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.166 LC variable region <400> 2071 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2072 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.166 HC variable region <400> 2072 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2073 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.167 LC variable region <400> 2073 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2074 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.167 HC variable region <400> 2074 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2075 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.168 LC variable region <400> 2075 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2076 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.168 HC variable region <400> 2076 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2077 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.169 LC variable region <400> 2077 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Lys Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2078 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.169 HC variable region <400> 2078 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2079 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.170 LC variable region <400> 2079 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2080 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.170 HC variable region <400> 2080 Glu Val Gln Leu Leu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2081 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.171 LC variable region <400> 2081 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2082 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.171 HC variable region <400> 2082 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2083 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.172 LC variable region <400> 2083 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Ala Leu 100 105 110 <210> 2084 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.172 HC variable region <400> 2084 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Pro Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2085 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.173 LC variable region <400> 2085 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2086 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.173 HC variable region <400> 2086 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2087 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.174 LC variable region <400> 2087 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2088 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.174 HC variable region <400> 2088 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2089 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.175 LC variable region <400> 2089 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2090 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.175 HC variable region <400> 2090 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2091 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.176 LC variable region <400> 2091 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2092 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.176 HC variable region <400> 2092 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2093 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.177 LC variable region <400> 2093 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2094 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.177 HC variable region <400> 2094 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2095 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.178 LC variable region <400> 2095 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2096 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.178 HC variable region <400> 2096 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2097 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.179 LC variable region <400> 2097 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2098 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.179 HC variable region <400> 2098 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2099 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.180 LC variable region <400> 2099 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2100 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.180 HC variable region <400> 2100 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2101 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.181 LC variable region <400> 2101 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2102 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.181 HC variable region <400> 2102 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2103 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.182 LC variable region <400> 2103 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2104 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.182 HC variable region <400> 2104 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2105 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.183 LC variable region <400> 2105 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2106 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.183 HC variable region <400> 2106 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2107 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.184 LC variable region <400> 2107 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Arg Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asp Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2108 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.184 HC variable region <400> 2108 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2109 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.185 LC variable region <400> 2109 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2110 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.185 HC variable region <400> 2110 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2111 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.186 LC variable region <400> 2111 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2112 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.186 HC variable region <400> 2112 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2113 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.187 LC variable region <400> 2113 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2114 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.187 HC variable region <400> 2114 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2115 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.188 LC variable region <400> 2115 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2116 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.188 HC variable region <400> 2116 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2117 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.189 LC variable region <400> 2117 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Arg Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2118 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.189 HC variable region <400> 2118 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2119 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.190 LC variable region <400> 2119 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2120 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.190 HC variable region <400> 2120 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2121 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.191 LC variable region <400> 2121 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Arg 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2122 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.191 HC variable region <400> 2122 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2123 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.192 LC variable region <400> 2123 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2124 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.192 HC variable region <400> 2124 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Ser Phe Ala Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2125 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.193 LC variable region <400> 2125 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2126 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.193 HC variable region <400> 2126 Gln Ile Thr Leu Lys Glu Ser Gly Pro Ser Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2127 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.194 LC variable region <400> 2127 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2128 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.194 HC variable region <400> 2128 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Ser Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Gly Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2129 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.195 LC variable region <400> 2129 Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Gly Ser Pro Gly Lys 1 5 10 15 Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 35 40 45 Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 65 70 75 80 Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 85 90 95 Ser Asp Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2130 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> No.195 HC variable region <400> 2130 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Asn Phe Thr Arg Tyr 20 25 30 Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu 50 55 60 Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr 65 70 75 80 Leu Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Leu Gly Ile Ala Val Ala Gly Thr Pro Ile Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2131 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.196 LC variable region <400> 2131 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2132 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.196 HC variable region <400> 2132 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser 115 120 <210> 2133 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.197 LC variable region <400> 2133 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2134 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.197 HC variable region <400> 2134 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser 115 120 <210> 2135 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.198 LC variable region <400> 2135 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Ala Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2136 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.198 HC variable region <400> 2136 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2137 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.199 LC variable region <400> 2137 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2138 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.199 HC variable region <400> 2138 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Glu Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser 115 120 <210> 2139 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.200 LC variable region <400> 2139 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2140 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.200 HC variable region <400> 2140 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Phe Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser 115 120 <210> 2141 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.201 LC variable region <400> 2141 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2142 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.201 HC variable region <400> 2142 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Ser Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser 115 120 <210> 2143 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.202 LC variable region <400> 2143 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2144 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.202 HC variable region <400> 2144 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Val Arg Gly Tyr Ser Gly Tyr Gly Ser Thr Tyr Tyr Ser Asp 100 105 110 Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser Ser Ser 115 120 <210> 2145 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.203 LC variable region <400> 2145 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2146 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.203 HC variable region <400> 2146 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2147 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.204 LC variable region <400> 2147 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Thr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2148 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.204 HC variable region <400> 2148 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2149 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.205 LC variable region <400> 2149 Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2150 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.205 HC variable region <400> 2150 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Ala Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2151 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.206 LC variable region <400> 2151 Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2152 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.206 HC variable region <400> 2152 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2153 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.207 LC variable region <400> 2153 Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Arg Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ala Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2154 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.207 HC variable region <400> 2154 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2155 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.208 LC variable region <400> 2155 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2156 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.208 HC variable region <400> 2156 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2157 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.209 LC variable region <400> 2157 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Ala Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2158 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.209 HC variable region <400> 2158 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2159 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.210 LC variable region <400> 2159 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2160 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.210 HC variable region <400> 2160 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asp Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2161 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.211 LC variable region <400> 2161 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Arg Ser Asn Ile Gly Gly Asn 20 25 30 Thr Val Asn Trp Phe Gln Gln Leu Pro Gly Ala Val Pro Lys Leu Leu 35 40 45 Val Tyr Gly Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2162 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.211 HC variable region <400> 2162 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2163 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.212 LC variable region <400> 2163 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Glu Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2164 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.212 HC variable region <400> 2164 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Arg Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2165 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.213 LC variable region <400> 2165 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2166 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.213 HC variable region <400> 2166 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2167 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.214 LC variable region <400> 2167 Glu Leu Met Leu Thr Gln Pro His Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Thr Leu 85 90 95 Asp Ser Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2168 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.214 HC variable region <400> 2168 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Pro Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2169 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.215 LC variable region <400> 2169 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2170 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.215 HC variable region <400> 2170 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2171 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.216 LC variable region <400> 2171 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2172 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.216 HC variable region <400> 2172 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2173 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.217 LC variable region <400> 2173 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Val Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2174 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.217 HC variable region <400> 2174 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2175 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.218 LC variable region <400> 2175 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Ser Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Ser Asn 20 25 30 Pro Val Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asn Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2176 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.218 HC variable region <400> 2176 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2177 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.219 LC variable region <400> 2177 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Ala Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Ser Gln Arg Pro Ser Gly Val Pro Asp Arg Val Ser 50 55 60 Ala Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Gly Asp Tyr Tyr Cys Ala Gly Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2178 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.219 HC variable region <400> 2178 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2179 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.220 LC variable region <400> 2179 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2180 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.220 HC variable region <400> 2180 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Pro Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Phe Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2181 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.221 LC variable region <400> 2181 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2182 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.221 HC variable region <400> 2182 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2183 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.222 LC variable region <400> 2183 Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Arg Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ala Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2184 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.222 HC variable region <400> 2184 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2185 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.223 LC variable region <400> 2185 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2186 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.223 HC variable region <400> 2186 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2187 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.224 LC variable region <400> 2187 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2188 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.224 HC variable region <400> 2188 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2189 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.225 LC variable region <400> 2189 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2190 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.225 HC variable region <400> 2190 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Met His Trp Ile Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2191 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.226 LC variable region <400> 2191 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2192 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.226 HC variable region <400> 2192 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Phe Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2193 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.227 LC variable region <400> 2193 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2194 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.227 HC variable region <400> 2194 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2195 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.228 LC variable region <400> 2195 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Leu Ser Cys Ser Gly Ser Ser Ser Asn Val Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asp Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Gly Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2196 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.228 HC variable region <400> 2196 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2197 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.229 LC variable region <400> 2197 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2198 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.229 HC variable region <400> 2198 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2199 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.230 LC variable region <400> 2199 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2200 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.230 HC variable region <400> 2200 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Phe Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2201 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.231 LC variable region <400> 2201 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2202 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.231 HC variable region <400> 2202 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2203 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.232 LC variable region <400> 2203 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2204 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.232 HC variable region <400> 2204 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2205 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.233 LC variable region <400> 2205 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2206 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.233 HC variable region <400> 2206 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2207 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.234 LC variable region <400> 2207 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2208 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.234 HC variable region <400> 2208 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2209 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.235 LC variable region <400> 2209 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2210 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.235 HC variable region <400> 2210 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Gln Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2211 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.236 LC variable region <400> 2211 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Pro Glu Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Asn Ser 85 90 95 Glu Thr Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2212 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.236 HC variable region <400> 2212 Glu Val Gln Leu Leu Glu Ser Arg Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2213 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.237 LC variable region <400> 2213 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2214 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.237 HC variable region <400> 2214 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2215 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.238 LC variable region <400> 2215 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2216 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.238 HC variable region <400> 2216 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Ser Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2217 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.239 LC variable region <400> 2217 Asp Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Met Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2218 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.239 HC variable region <400> 2218 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2219 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.240 LC variable region <400> 2219 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2220 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.240 HC variable region <400> 2220 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Pro Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2221 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.241 LC variable region <400> 2221 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ile Asn 20 25 30 Ser Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Leu Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2222 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.241 HC variable region <400> 2222 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2223 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.242 LC variable region <400> 2223 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys 20 25 30 Thr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2224 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.242 HC variable region <400> 2224 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Glu Ser Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2225 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.243 LC variable region <400> 2225 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2226 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.243 HC variable region <400> 2226 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2227 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.244 LC variable region <400> 2227 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2228 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.244 HC variable region <400> 2228 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2229 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.245 LC variable region <400> 2229 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2230 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.245 HC variable region <400> 2230 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2231 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.246 LC variable region <400> 2231 Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu 85 90 95 Asn Gly Tyr Val Phe Gly Pro Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2232 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.246 HC variable region <400> 2232 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2233 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> No.247 LC variable region <400> 2233 Glu Leu Val Leu Thr Gln Ser Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser 65 70 75 80 Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser 85 90 95 Gly Trp Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 <210> 2234 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.247 HC variable region <400> 2234 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2235 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.248 LC variable region <400> 2235 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2236 <211> 128 <212> PRT <213> Artificial Sequence <220> <223> No.248 HC variable region <400> 2236 Gln Ile Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Val Gly Val Gly Trp Ile Arg Gln Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Thr Leu Ile Asp Trp Asp Asp Asn Lys Tyr Tyr Thr Thr Ser 50 55 60 Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Ile Pro Gly Phe Leu Arg Tyr Arg Asn Arg Tyr Tyr Tyr 100 105 110 Tyr Gly Met Asp Val Trp Gly Gly Gly Thr Thr Val Thr Val Ser Ser 115 120 125 <210> 2237 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.249 LC variable region <400> 2237 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ala Pro Gly Lys 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Gly Ser Ser Asp His 85 90 95 Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 <210> 2238 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.249 HC variable region <400> 2238 Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 1 5 10 15 Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala 20 25 30 Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 35 40 45 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Lys Leu Ser His Gly Val Val Gly Ala Gln Asp Ala Phe Asp Ile Trp 100 105 110 Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 <210> 2239 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.250 LC variable region <400> 2239 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2240 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> No.250 HC variable region <400> 2240 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Glu Ala Thr Thr Gly Ile Asn Thr Asn Trp Phe Asp Pro 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2241 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.251 LC variable region <400> 2241 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2242 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.251 HC variable region <400> 2242 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2243 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.252 LC variable region <400> 2243 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2244 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.252 HC variable region <400> 2244 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2245 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.253 LC variable region <400> 2245 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln His Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2246 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.253 HC variable region <400> 2246 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2247 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.254 LC variable region <400> 2247 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ala Pro Gly Lys 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His 85 90 95 Pro Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 <210> 2248 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.254 HC variable region <400> 2248 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2249 <211> 112 <212> PRT <213> Artificial Sequence <220> <223> No.255 LC variable region <400> 2249 Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 1 5 10 15 Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ser Pro Thr Thr Val 35 40 45 Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 65 70 75 80 Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 85 90 95 Ser Asn His Ala Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly 100 105 110 <210> 2250 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.255 HC variable region <400> 2250 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2251 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.256 LC variable region <400> 2251 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2252 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.256 HC variable region <400> 2252 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2253 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.257 LC variable region <400> 2253 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2254 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.257 HC variable region <400> 2254 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2255 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.258 LC variable region <400> 2255 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Val Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2256 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.258 HC variable region <400> 2256 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2257 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.259 LC variable region <400> 2257 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2258 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.259 HC variable region <400> 2258 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2259 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.260 LC variable region <400> 2259 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Thr Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu 85 90 95 Asn Gly Leu Val Phe Gly Gly Gly Thr Glu Leu Thr Val Leu 100 105 110 <210> 2260 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.260 HC variable region <400> 2260 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Ile Val Ser Ser 115 120 <210> 2261 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.261 LC variable region <400> 2261 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asp Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2262 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.261 HC variable region <400> 2262 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2263 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.262 LC variable region <400> 2263 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser Leu 85 90 95 Ser Gly Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2264 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.262 HC variable region <400> 2264 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2265 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.263 LC variable region <400> 2265 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Pro Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2266 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.263 HC variable region <400> 2266 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2267 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.264 LC variable region <400> 2267 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2268 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.264 HC variable region <400> 2268 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Thr Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Asp Trp Asn Ser Gly Leu Ile Gly Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Leu Ser Arg Asp Asn Ala Lys Asn Ser Ile Phe 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Val Lys Asp Met Gly Ser Thr Gly Gly Tyr Tyr Gly Met Asp Val Trp 100 105 110 Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2269 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.265 LC variable region <400> 2269 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2270 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.265 HC variable region <400> 2270 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2271 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.266 LC variable region <400> 2271 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Val Ala Pro Gly Lys 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr 35 40 45 Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Val Arg Asp Ser Ser Ser Asp His 85 90 95 Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 2272 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.266 HC variable region <400> 2272 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2273 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.267 LC variable region <400> 2273 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2274 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.267 HC variable region <400> 2274 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2275 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.268 LC variable region <400> 2275 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Asp Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Asn Asn Asn Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Gln Ser Ser Asp Ser Gly 85 90 95 Leu Thr Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2276 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.268 HC variable region <400> 2276 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2277 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.269 LC variable region <400> 2277 Glu Leu Val Val Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Arg Gly Leu Arg 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ala Leu 85 90 95 Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2278 <211> 127 <212> PRT <213> Artificial Sequence <220> <223> No.269 HC variable region <400> 2278 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Phe 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Val Ser Tyr Asp Gly Ser Asn Asn Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Asp Tyr Tyr Gly Ser Gly Ser Tyr Tyr Asn Pro Ser Pro 100 105 110 Phe Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2279 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.270 LC variable region <400> 2279 Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 2280 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.270 HC variable region <400> 2280 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2281 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> No.271 LC variable region <400> 2281 Glu Leu Glu Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Ala Gly Ser Asn 85 90 95 Asn Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 <210> 2282 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.271 HC variable region <400> 2282 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2283 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.272 LC variable region <400> 2283 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2284 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.272 HC variable region <400> 2284 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2285 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.273 LC variable region <400> 2285 Glu Leu Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Leu 85 90 95 Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 100 105 <210> 2286 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.273 HC variable region <400> 2286 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2287 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.274 LC variable region <400> 2287 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Gly Val Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2288 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.274 HC variable region <400> 2288 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2289 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.275 LC variable region <400> 2289 Glu Leu Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys 1 5 10 15 Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Asn Thr Val 20 25 30 Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr 35 40 45 Ser Asn Asn Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser 50 55 60 Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu Asn Gly 85 90 95 Pro Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 2290 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.275 HC variable region <400> 2290 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2291 <211> 109 <212> PRT <213> Artificial Sequence <220> <223> No.276 LC variable region <400> 2291 Glu Leu Glu Leu Thr Gln Pro Ser Ala Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Gly Ser 20 25 30 Asp Val Gly Trp Tyr Gln His Leu Pro Gly Met Ala Pro Arg Leu Leu 35 40 45 Ile Tyr Lys Ser Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Ala Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Gly Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Arg Leu 85 90 95 Asn Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 <210> 2292 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.276 HC variable region <400> 2292 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2293 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.277 LC variable region <400> 2293 Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 2294 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.277 HC variable region <400> 2294 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2295 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.278 LC variable region <400> 2295 Glu Leu Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Gly Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Lys Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ala His Ser Phe Pro Phe 85 90 95 Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105 <210> 2296 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.278 HC variable region <400> 2296 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2297 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> No.279 LC variable region <400> 2297 Glu Leu Thr Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Leu Pro 85 90 95 Thr Phe Gly Gin Gly Thr Arg Leu Glu Ile Lys 100 105 <210> 2298 <211> 122 <212> PRT <213> Artificial Sequence <220> <223> No.279 HC variable region <400> 2298 Glu Val Gln Leu Leu Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Asn Pro Ser Gly Gly Ser Thr Ser Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Ile Ala Pro Tyr Thr Arg Gly Ala Phe Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2299 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.280 LC variable region <400> 2299 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Thr Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu 65 70 75 80 Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser 85 90 95 Leu Asn Gly Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2300 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.280 HC variable region <400> 2300 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Ile Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2301 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.281 LC variable region <400> 2301 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser 85 90 95 Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2302 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.281 HC variable region <400> 2302 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Ile Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2303 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.282 LC variable region <400> 2303 Glu Leu Val Leu Thr Gln Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu 65 70 75 80 Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser 85 90 95 Leu Asn Gly Gly Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2304 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.282 HC variable region <400> 2304 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ile Thr Val Ser Ser Asn 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Ile Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 2305 <211> 108 <212> PRT <213> Artificial Sequence <220> <223> No.283 LC variable region <400> 2305 Glu Leu Val Met Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro Pro 85 90 95 Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100 105 <210> 2306 <211> 116 <212> PRT <213> Artificial Sequence <220> <223> No.283 HC variable region <400> 2306 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Pro Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Arg Gly Val Leu Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <210> 2307 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.284 LC variable region <400> 2307 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Gly Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2308 <211> 119 <212> PRT <213> Artificial Sequence <220> <223> No.284 HC variable region <400> 2308 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Val Thr Val Ser Ser Asn 20 25 30 Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg His Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Gly His Val Asp Ile Pro Tyr Gly Met Asp Val Trp Gly Gln Gly 100 105 110 Thr Thr Val Thr Val Ser Ser 115 <210> 2309 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.285 LC variable region <400> 2309 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2310 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.285 HC variable region <400> 2310 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Lys Gly Tyr Ser Gly Ser Gly Ser Val Asn Trp Phe Asp 100 105 110 Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2311 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.286 LC variable region <400> 2311 Glu Leu Val Val Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2312 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> No.286 HC variable region <400> 2312 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Lys Gly Tyr Ser Gly Ser Gly Ser Val Asn Trp Phe Asp 100 105 110 Pro Trp Gly Gln Gly Thr Leu Val Thr Val Pro Ser 115 120 <210> 2313 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.287 LC variable region <400> 2313 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu 100 105 110 <210> 2314 <211> 123 <212> PRT <213> Artificial Sequence <220> <223> No.287 HC variable region <400> 2314 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Glu Glu Ala Thr Thr Gly Ile Asn Thr Asn Trp Phe Asp Pro 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 2315 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.288 LC variable region <400> 2315 Glu Leu Met Leu Thr Gln Pro His Ser Val Ser Glu Ser Pro Gly Lys 1 5 10 15 Thr Val Thr Ile Ser Cys Thr Arg Ser Ser Gly Ser Ile Ala Ser Asn 20 25 30 Tyr Val Gln Trp Tyr Gln Gln Arg Pro Gly Ser Ala Pro Thr Thr Val 35 40 45 Ile Tyr Glu Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Ile Asp Ser Ser Ser Asn Ser Ala Ser Leu Thr Ile Ser Gly 65 70 75 80 Leu Lys Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser 85 90 95 Ser Asn His Trp Val Phe Gly Gly Gly Thr Lys Val Thr Val Leu 100 105 110 <210> 2316 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> No.288 HC variable region <400> 2316 Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ala Asn Leu Gly Tyr Cys Thr Asn Gly Val Cys Ala Pro Ser 100 105 110 Gly Gly Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 125 <210> 2317 <211> 110 <212> PRT <213> Artificial Sequence <220> <223> No.289 LC variable region <400> 2317 Glu Leu Val Leu Thr Gln Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15 Lys Val Thr Ile Ser Cys Ser Gly Gly Ser Ser Asn Ile Gly Asn Asn 20 25 30 Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80 Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95 Ser Ala Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2318 <211> 125 <212> PRT <213> Artificial Sequence <220> <223> No.289 HC variable region <400> 2318 Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Gly Asp Tyr 20 25 30 Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Gly Ile Ser Trp Asn Ser Gly Arg Ile Gly Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys 85 90 95 Ala Lys Asn Leu Arg Tyr Phe Asp Trp Leu Leu Gly Asp Asp Ala Phe 100 105 110 Asp Ile Trp Gly Gin Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 2319 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> No.290 LC variable region <400> 2319 Glu Leu Glu Leu Thr Gln Pro Ser Val Ser Gly Ala Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly 20 25 30 Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu 35 40 45 Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu 65 70 75 80 Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser 85 90 95 Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110 <210> 2320 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> No.290 HC variable region <400> 2320 Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser Asn 20 25 30 Tyr Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Val Ile Tyr Ser Gly Gly Ser Thr Phe Tyr Ala Asp Ser Val Lys 50 55 60 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu 65 70 75 80 Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95 Arg Asp Leu Val Val Tyr Gly Met Asp Val Trp Gly Gin Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115

Claims (23)

A method of preventing or treating SARS-coronavirus infection (COVID-19), comprising administering to a patient a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof,
A method of administering to a patient a composition comprising said antibody or antigen-binding fragment thereof at a dose of 1 to 120 mg/kg.
According to claim 1,
A method of administering to a patient a composition comprising the antibody or antigen-binding fragment thereof at a dose of 5 to 100 mg/kg.
3. The method of claim 2,
A method of administering to a patient a composition comprising said antibody or antigen-binding fragment thereof at a dose of 10-80 mg/kg.
4. The method of claim 3,
A composition comprising said antibody or antigen-binding fragment thereof at a dose of 20 to 80 mg/kg, 40 to 80 mg/kg, 20 to 40 mg/kg, 10 to 40 mg/kg, or 10 to 20 mg/kg to a patient dosing, method.
4. The method of claim 3,
A method of administering to a patient a composition comprising said antibody or antigen-binding fragment thereof at a dose of 10 mg/kg, 20 mg/kg, 40 mg/kg, or 80 mg/kg.
According to claim 1,
A method of administering a composition comprising the antibody or antigen-binding fragment thereof one or more times.
According to claim 1,
A method of administering a composition comprising the antibody or antigen-binding fragment thereof intravenously or subcutaneously.
According to claim 1,
The method, wherein the antibody or antigen-binding fragment thereof is any one selected from the group consisting of the antibody or antigen-binding fragment thereof of Table 1.
According to claim 1,
The method, wherein the antibody or antigen-binding fragment thereof is any one selected from the group consisting of the antibody or antigen-binding fragment thereof of Table 2.
According to claim 1,
The antibody or antigen-binding fragment thereof
a light chain variable region comprising a CDR1 region of SEQ ID NO: 829, a CDR2 region of SEQ ID NO: 830, and a CDR3 region of SEQ ID NO: 831; and
An antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising a CDR1 region of SEQ ID NO: 832, a CDR2 region of SEQ ID NO: 833, and a CDR3 region of SEQ ID NO: 834
Including method.
According to claim 1,
The antibody or antigen-binding fragment thereof
light chain variable region of the polypeptide sequence of SEQ ID NO: 2017; and
Heavy chain variable region of the polypeptide sequence of SEQ ID NO: 2018
A method comprising
According to claim 1,
SARS-coronavirus-2 activity inhibitory drug, antiviral agent, plasma of a person recovering from SARS-coronavirus-2 infection, anti-TNFα (tumor necrosis factor-α) antibody or a mixture of any one or more thereof.
13. The method of claim 12,
The SARS-coronavirus-2 activity inhibitory drug is a binding molecule that binds to a spike protein (S protein) on the surface of the SARS-coronavirus-2 surface.
14. The method of claim 13,
The SARS-binding molecule binding to the spike protein (S protein) on the surface of the coronavirus-2 is
a) an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof different from the antibody or antigen-binding fragment thereof of claim 1;
b) a recombinant protein of angiotensin-converting enzyme 2 (ACE2), a fragment thereof, or a variant thereof; and
c) a recombinant, protein, fragment thereof, or variant thereof of neuropilin-1
Any one or more selected from the group consisting of, the method.
15. The method of claim 14,
The b) angiotensin-converting enzyme inhibitor 2 (Angiotensin-converting enzyme 2, ACE2) recombinant protein, a fragment thereof, or a variant thereof; or
The c) neuropilin-1 recombinant, protein, fragment thereof, or variant thereof is a fusion protein fused to the Fc region of an antibody, the method.
13. The method of claim 12,
The antiviral agent is remdesivir (remdesivir), chloroquine (chloroquine), hydroxychloroquine (hydroxychloroquine), or a mixture of any one or more thereof, the method.
13. The method of claim 12,
The method of claim 1, wherein the anti-TNFα antibody is infliximab, adalimumab, cetorizumab pegol, golimumab, or a mixture of any one or more thereof.
According to claim 1,
The method, wherein the patient is a SARS-coronavirus infection (COVID-19) mild, moderate or severe patient.
According to claim 1,
The SARS-coronavirus infection (COVID-19) is caused by SARS-coronavirus-2
a) hot flashes;
b) cough;
b) shortness of breath or shortness of breath;
c) sore throat;
d) body aches or myalgias;
e) fatigue;
f) headache;
g) chills;
h) respiratory disorders or nasal congestion;
i) loss of taste or smell;
j) nausea or vomiting; and
k) diarrhea
At least one symptom selected from the group consisting of is caused, the method.
According to claim 1,
A method in which the patient remains free of or good for all of the following symptoms for at least 24 hours after administering the composition comprising the anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof to a patient:
a) hot flashes;
b) cough;
b) shortness of breath;
c) sore throat;
d) body aches or myalgias;
e) fatigue; and
f) Headache.
As a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof,
A pharmaceutical composition for preventing or treating coronavirus infection (COVID-19), wherein the composition comprising the antibody or antigen-binding fragment thereof is administered at a dose of 1 to 120 mg/kg.
(a) a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof; and
(b) instructions to administer the composition at a dose of 1 to 120 mg/kg for the treatment of patients with coronavirus infection (COVID-19)
kit containing.
In the manufacture of a pharmaceutical composition for preventing or treating coronavirus infection (COVID-19) administered to a patient, the use of a composition comprising an anti-SARS-coronavirus-2 antibody or antigen-binding fragment thereof,
A use in which a composition comprising said antibody or antigen-binding fragment thereof in a dose of 1 to 120 mg/kg is administered.

Images